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Abstract
Beta-site APP Cleaving Enzyme 1 (BACE1) is a key enzyme in the 
generation o f P-amyloid, the major component of senile plaques in the brains o f 
Alzheimer's Disease patients. Transgenic mice carrying human BACE1 cDNA and 
knockout mice with endogenous murine BACE1 removed were tested for 
behavioural, neurochemical and physiological changes with respect to appropriate 
wild type control mice. BACE1 transgenic mice exhibited a bold, exploratory 
behaviour, showed elevated 5-HT turnover and had unimpaired cognition. BACE1 
knockout mice showed a contrasting behaviour, being timid and less exploratory 
with sex-dependent memory impairment as measured in the fear conditioning test. 
Unexpectedly these mouse lines did show alterations in their ability to put on weight 
suggesting an intriguing link between BACE1 and fat metabolism. Despite these 
clear differences both mouse lines were viable and fertile with no changes in 
morbidity.
The behaviour o f a mouse line with both BACE1 and BACE2, a homologue 
o f BACE1, endogenous genes knocked out was also investigated. The added deletion 
o f endogenous BACE2 had no additional effect beyond that seen in BACE1 
knockout mice. Compound transgenic mice carrying human BACE1 and Swedish 
mutant Amyloid Precursor Protein (APPkm 67o/67inl) transgenes or human mutant 
Presenilin 1 ( P S 1m i46v )  and A PPkm 67o/67inl transgenes were tested for cognitive 
deficits. In combination with A PPkm 67o/67inl, the presence o f the BACE1 transgene 
had no effect on cognition but the presence of the P S 1m i46v  transgene did result in 
impaired learning and memory.
The results presented in this thesis suggest an unexpected role for BACE1 in 
neurotransmission and fat metabolism, perhaps through changes in APP processing 
and P-amyloid levels although these effects may be unrelated to the role of BACE1 
as p-secretase. As BACE1 inhibition is a target for Alzheimer’s Disease 
modification, the potential effect o f BACE1 therapeutic agents on anxiety and 
cognition should be considered.
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1.1 Historical Perspective
Alois Alzheimer first described the disease that was subsequently named after 
him in 1906 (1), publishing the description in 1907 (2;3). Bom in 1864 in the small 
Bavarian town of Marktbreit, Alzheimer studied at the universities of Aschaffenburg, 
Tubingen, Berlin and Wurzburg and in 1887 was granted his medical degree, 
defending his doctoral thesis on the wax producing glands of the ear in the same 
year. Initially he worked in Frankfurt am Main at the Stadtische Irrenanstalt (mental 
asylum) where he became interested in neuropathology and met the neurologist, 
Franz Nissl. Alzheimer and Nissl worked together on the pathology of the nervous 
system, in particular the cerebral cortex. Their work was published in 6 volumes 
between 1906 and 1918 collectively entitled ‘Histologische und Histopatologische 
Arbeiten fiber die Grosshimrinde’ (Histologic and Histopathologic Studies o f the 
Cerebral Cortex).
In 1895, aged 31, Alzheimer became director of the Irrenanstalt and for 7
years continued to work on a wide range 
of subjects. In 1902 he was offered a post 
in Heidelberg University Psychiatric 
Clinic working for ‘The Linnaeus of 
Psychiatry’ Emil Kraepelin. Nissl had 
already moved to Heidelberg and so the 
two worked together again. In 1903 
Alzheimer moved with Kraepelin to 
Munich university psychiatric clinic and 
in 1908 he joined the staff o f the 
Psychiatric Institute as Ausserordentlicher 
(associate) professor and director o f the 
clinic's anatomical laboratory. The 
laboratory soon gained an international 
reputation and became a meeting place for 
several important researchers, among 
them Ugo Cerletti, Hans Gerhardt Creutzfeldt, Alfons Maria Jakob, Fritz H. Lewy, F. 
Lotmar and Gaetano Perusini.
Alois Alzheimer
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Almost one century before Alzheimer’s work, in 1817, James Parkinson 
published ‘An Essay on the Shaking Palsy’ and stated that he believed cognitive 
decline was not part of Parkinsonism (4) thus establishing a differentiation between 
mental and physical affliction. In the early 1900s many researchers were working in 
the field o f psychiatry and there was little distinction between the different 
diagnoses. The ability of researchers to differentiate between types of mental 
affliction was made easier with improvements made in histology and to the high 
powered achromatic lenses used in microscopy (5). Post mortem tissue sections from 
patients were examined for clues to the cause of the illness. This was the type of 
work that Alzheimer carried out and which proved so useful in finding pathological 
differences as the basis of disease symptoms.
It was while working in Munich university that Alzheimer gave a 
presentation at a meeting of the South-West German Society o f Alienists in 
November 1906 entitled "Eine Eigenartige Erkrankung der Himrinde" (A Peculiar 
Disease o f the Cerebral Cortex) (1). The presentation described the clinical and 
neuropathological features of a woman aged 51 years who had died in the Munich 
mental asylum. The woman, named only as August D, began having various 
disparate symptoms 5 years previously.
Initially she had fits of jealousy towards 
her husband and subsequently suffered 
from memory loss, hallucinations and 
became unable to care for herself while 
rejecting offers of help. Eventually her 
family was no longer able to cope and she 
was admitted to hospital. On 
hospitalisation her symptoms included 
disorientation, impaired memory, 
dyscalculia and dyslexia.
At the autopsy of August D,
Alzheimer described three key 
observations previously unseen together.
The cerebral cortex was thinner than 
normal; there were senile plaques and
August D.
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neurofibrillary tangles which were positive for Bodian’s silver stain. The presence of 
these structures together was novel and defined the new disease.
The word amyloid is a derivative of amylum and comes from the Greek 
amulon (meaning fine meal or starch). The term amyloid refers to the atypical 
staining properties of autopsy specimens with iodine sulphuric acid as described by 
Virchow (6). Subsequently Alzheimer used this terminology to describe the plaque 
deposits he saw in the brain of August D.
Alzheimer made a preliminary report o f his findings in 1906 and Perusini 
published 4 more cases in 1910 emphasising the differences between this condition 
and senility. Alzheimer published a full description of work on the disease to bear his 
name in 1911 which included a description of a second patient, Johann F (7;8). In 
this paper Alzheimer made reference to Kraepelin’s 8th edition o f his textbook on 
psychiatry (9) in which Kraepelin had described various aspects o f specific types of 
senile dementia and had called them after Alzheimer. Thus the peculiar combination 
of altered behaviour, amyloid plaques and neurofibrillary tangles were classed 
together as a specific new illness called Alzheimer’s Disease.
Historically the term dementia referred to any number of ailments where 
individuals were seen to be not in control of their faculties. Gradually, around the 
time Alzheimer was carrying out his studies, a distinction came to be made between 
mental defects that were pre-existing -  termed amentia -  and those that developed 
over a period of time -  termed dementia (10). In his paper on the history of the use of 
the term dementia published in the American Journal of Insanity, Blumer outlines 
the thinking of the day and makes extensive reference to the 7th edition of 
Kraepelin’s book on psychiatry (11). It was clear that while attempts were being 
made to classify different forms of dementia by behaviour, it took the scientific 
investigative research of Alzheimer and his peers to identify accurately the
Amyloid Plaques Neurofibrillary Tangles
14
histological lesions that came to be recognised as the hallmarks of AD. Subsequent 
classification o f different types o f dementia using histology in combination with 
behaviour enabled a more rigorous diagnosis of the disease to be performed, albeit 
post mortem.
1.2 Alzheimer’s Disease in the Post-genomic Era
During the following 8 decades AD research focussed mainly on genetics and 
the discrimination of the disease from other dementias, leading to the realisation that 
the symptoms o f AD, including memory loss, were not part o f aging but were 
actually disease related. In the early part o f the last century a number of papers 
showed that dementia had a familial component (12-14). AD patients were shown to 
have amyloid plaques containing degenerating nerve endings and their plaque count 
far exceeded that found in normal aging (15; 16). Terry and Davies (17) indicated that 
the presenile form of dementia (with onset before age 65) is identical to the most 
common form of senile dementia, recommending the condition be designated as 
senile dementia of the Alzheimer type (SDAT). Application o f the modem biological 
technologies used in molecular and cell biology allowed a more detailed 
understanding o f AD biology. Masters and colleagues eliminated the probability o f a 
viral component of AD when they published a study of 52 families with AD affected 
members comparing them to familial Creutzfeldt-Jakob disease (18). A key 
breakthrough was the identification of a novel amyloid protein in the plaques of AD 
patients, called beta protein (19). Analysis o f the beta protein cDNA suggested it was 
derived from a larger precursor protein with distribution in a large number o f tissues 
(20). Key papers followed including those which described the cloning o f the APP 
gene (21) and the molecular genetic approach to finding genes associated with the 
disease (22). With the improved antibody reagents available a clearer understanding 
o f proteins involved in the formation of neurofibrillary tangle was possible (23) and 
the microtubule associated protein Tau (MAPT or simply x) was identified as a key 
component of the Neurofibrillary tangles (24;25). However a unifying hypothesis of 
how the different proteins interacted to produce the disease was not published until 
1991 with the Amyloid Cascade Hypothesis (26;27). Even now this hypothesis is not 
wholly accepted by all with various researchers falling into the ‘Baptist’ or ‘Tauist’ 
camps. Each camp has differing opinions as to the correct aetiology of the disease
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though some common themes are present and one unified hypothesis may be 
possible (28;29). Strong evidence in support of the amyloid cascade hypothesis was 
presented when, in a triple transgenic mouse model expressing 3 mutant transgenes 
(A P P sw e, P S 1Mi46v  and Tp3oil) was found to develop plaque pathology prior to tangle 
pathology (30).
Disease Etiology Regions most Characteristic Disease proteins
affected pathology deposited
Huntington's disease Huntingtin
(dominant)
Striatum, other basal 
ganglia, cortex, other 
regions
Intranuclear inclusions 
and cytoplasmic 
aggregates
Huntingtin with 
polyglutamine expansion
Other polyglutamine 
diseases (DRPLA, 
SCA1-3, etc., SBMA)
Atrophin-1, ataxin-1- 
3, etc.; androgen 
receptor (AR) 
(dominant)
Basal ganglia, brain 
stem cerebellum, and 
spinal cord
Intranuclear inclusions Atrophin-1, ataxins or AR
Alzheimer's disease 
(AD)
Sporadic (ApoE risk 
factor)
Cortex, hippocampus, 
basal forebrain, brain 
stem
Neuritic plaques and 
neurofibrillary tangles
A0 peptide (from APP) 
and hyper- 
phosphorylated tau
Amyloid precursor 
protein (APP) 
(dominant)
Same as sporadic Same as sporadic Same as sporadic
Presenilin 1,2 
(dominant)
Same as sporadic Same as sporadic Same as sporadic
Fronto-temporal 
dementia with 
Parkinsonism
Tau mutations 
(dominant)
Frontal and temporal 
cortex, hippocampus
Pick bodies Hyper-phosphorylated tau 
protein
Parkinson's disease 
(PD)
Sporadic Substantia nigra, cortex, 
locus ceruleus, raphe, 
etc.
Lewy bodies and Lewy 
neurites
a-Synudein
a-Synudein
(dominant)
Similar to sporadic, but 
more widespread
Similar to sporadic a-Synudein
Parkin (also DJ-1, 
PINK1) recessive 
(some dominant)
Substantia nigra Lewy bodies absent (or 
much less frequent)
a-Synudein (when 
present)
Amyotrophic lateral 
sclerosis (ALS)
Sporadic Spinal motor neurons 
and motor cortex
Bonina bodies and 
axonal spheroids
Unknown
(neurofilaments)
Superoxide
dismutase-1
(dominant)
Same as sporadic Same Unknown
Prion diseases (kuru, 
CJD, GSS disease, fatal 
familial insomnia, new 
variant CJD)
Sporadic, genetic 
and infectious
Cortex, thalamus, brain 
stem, cerebellum, other 
areas
Spongiform 
degeneration, amyloid, 
other aggregates
Prion protein
ApoE, apoipoprotein E; APP, amyloid precursor protein; CJD, Creutzfeldt-Jakob disease; DRPLA, dentato-rubral and pallido-Luysian atrophy; GSS, 
Gerstmann-Straussler-Scheinker; SBMA, spinal and bulbar muscular atrophy; SCA, spino-cerebellar ataxia.
Table 1.1 Diagnostic characteristics of a range of neurodegenerative diseases.
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The term Neurodegeneration refers to the death o f neurons and when this 
occurs in neurons of the Central Nervous System it leads to a progressive shrinking 
o f the brain. This condition is known as dementia and, as many of the patients in this 
condition are elderly, the term senile dementia has been used to describe the chronic 
neurodegenerative process (31). The causes of dementia are many but a relatively 
small range o f disease syndromes account for the majority o f neurodegenerative 
processes in the brain. Each disease has numerous sub-divisions and classifications 
but they can broadly be split according to the type o f lesion found in the brain. These 
diseases are; Alzheimer’s Disease, which is characterised by neuronal plaque with 
tangles; Parkinson’s Disease, which is characterised by Lewy bodies and Frontal 
Temporal Dementia which is characterised by tangles alone. These diseases do have 
overlapping pathology and symptoms and as more is discovered about the biology of 
these diseases more common features may be found. Table 1 lists various 
neurodegenerative diseases and the characteristics which define each disease (32). 
AD along with Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS) 
are unusual in as much that they have sporadic forms where the disease occurs in the 
absence of genetic linkage and familial forms where mutations in specific proteins 
pre-dispose an individual to the disease. This genetic component to the diseases has 
proved very valuable for researchers attempting to model the disease.
AD is the most prevalent o f all adult onset neurodegenerative disorders and is 
characterised by a progressive memory loss that may also be associated with other 
neuropsychiatric and behavioural impairments. The principle neuropathological 
features o f this disease are overt neuronal and synaptic loss, extra-cellular 
accumulation o f amyloid plaques composed primarily o f P-amyloid peptide and 
intra-cellular neurofibrillary tangles composed of hyperphosphorylated x (33). These 
defining hallmarks o f AD neuropathology have been the focus o f intense research 
over the past two decades and have led to the identification a key enzyme involved in 
P-amyloid production, as well as to the identification of a variety o f kinases that can 
potentially hyperphosphorylate x in vivo. While the Amyloid Precursor Protein 
(APP) promoter may be important in the progression o f AD pathogenesis (34) a 
number o f mutations o f the APP protein have been identified that are associated with 
the prevalence of AD (see table below).
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Mutation Phenotype Age of Onset References
Glu665Asp AD, but may not be pathogenic * Approx 86 (35)
Lys/Met670/Asn/Leu (Swedish) AD 52 (44-59) (36)
Ala673Thr Normal N/A (37)
His677Arg AD 55 (55-56) (38)
D678N FAD 60 (39)
Ala692Gly (Flemish) Large dense core plaques linked to CAA 40-60 but variable (40-43)
Glu693Gly (Artie)
AD, but may not be pathogenic *
'A' plasma A04O & 42, high protofibril levels
58?
N/A
(44)
(45)
Glu693Gln (Dutch) HCHWA-D (a stroke syndrome) Typically -50 but variable (46)
Glu693Lys (Italian) Cerebral Haemorrhage ? (47)
Asp694Asn (Iowa) AD or Cerebral Haemorrhage 69 (48)
Ala713Thr AD, but may not be pathogenic * 59 (49)
Ala713Val Schizophrenia: probably not pathogenic * 7 (50)
Thr714Ile (Austrian)
Affects y-secretase cleavage directly, 1IX 4" 
A£(42:40) ratio in vitro. In brain, abundant and 
predominant non-fibrillar pre-amyloid plaques made 
of N-truncated AJJ(42) in absence of A(i(40).
(51)
Thr714Ala (Iranian) AD 52 (40-60) (52)
Val715Met (French) AD 52 (40-60) (53)
Val715Ala (German) AD 47 (54;55)
Ile716Val (Florida) AD 55 (56)
Val717Phe AD 47 (42-52) (57)
Val717Gly AD 55 (45-62) (58)
Val717Ile (London) AD 55 (50-60) (59)
Val717Leu (Indiana) CSF tau and A-P consistent with AD; earlier onset than other 717 mutations 38 (60)
Leu723Pro (Australian) AD 56(45-60) (61)
Table 1.2 Pathogenic mutations in APP
Adapted from http://www.alzforum.org/. * Mutation found in AD patient but 
is rare and may be a normal polymorphism and not directly disease related.
The Amyloid Cascade Hypothesis places the P-amyloid protein central to AD 
pathology. The hypothesis states that either genetic or sporadic factors lead to an 
increase in the production o f Ap42 (one o f the peptides derived from the action o f 
two key secretase enzymes on APP, namely P- & y-secretase) which aggregates and 
accumulates in the limbic and association cortices o f AD patients, p-amyloid
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oligomers exert subtle effects on synaptic plasticity and a gradual deposition of A042 
oligomers as diffuse plaques follow, stimulating microglial and astrocytic activation 
with altered neuronal ionic homeostasis and oxidative injury. Subsequent to P- 
amyloid production the hypothesis states that the other major feature o f AD, 
neurofibrillary tangles (NFTs), are generated with altered kinase / phosphatase 
activity leading to hyperphosphorylated x and NFT tangle formation. The presence of 
plaques and tangles is thought to lead to widespread neuronal and synaptic 
dysfunction and some neuronal loss with neurotransmitter defects. These cellular 
changes manifest as the clinical symptoms of onset o f dementia.
The amyloid cascade hypothesis has been updated from the original 
publication in 1991 to include new discoveries (33). A number o f variations o f this 
dogma in AD research have been published which among others include aluminium 
(62), inflammation (63), mitochondria (64) or cholesterol (65) as more or less 
important in the cascade. Others have challenged the hypothesis arguing that p- 
amyloid functions as a protective adaptation to AD (66) or that x is the central 
initiator of disease since neurofibrillary tangles alone can cause neurodegeneration 
(67). Interestingly a recent report has shown that persistence o f NFTs in a mouse 
model o f transient mutant x expression (xp3oil) was insufficient to cause cognitive 
decline or neuronal death when the transgene expression was turned off, even though 
these features were seen when the transgene expression was switched on (68).
Prior to the formation o f the amyloid cascade hypothesis, the cholinergic 
hypothesis o f geriatric memory dysfunction was put forward in 1982 (69). The 
hypothesis states that the loss o f cholinergic function in the CNS contributes 
significantly to the cognitive symptoms associated with AD and advanced age. The 
paper written by Bartus and colleagues generated considerable interest, ranking 4th 
among all neuroscience papers cited in the last 15 years. The hypothesis has proved 
to be of value as the only currently marketed treatments for AD do not modify the 
disease but use cholinesterase inhibitors to alleviate the symptoms. A more recent 
review of the cholinergic hypothesis describes the progress made with models and 
treatment strategies for neurodegenerative diseases (70). In his review Bartus points 
out that while disease modification based on the amyloid cascade hypothesis may 
yield a treatment in the future, the current symptomatic treatments are vital to 
continue treating those for whom disease modification will be o f little use.
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As already described AD can occur sporadically or shows a familial 
component. Four genes have been identified that account for approximately half o f 
the genetic risk for inheriting AD. These genes are Presenilin 1 (PS1), Presenilin 2 
(PS2), amyloid precursor protein (APP) and apolipoprotein E (ApoE) (71). Studies 
on the effects o f mutations or polymorphisms in these genes have demonstrated that 
they alter the processing o f APP and the sequellae outlined in the amyloid cascade 
hypothesis.
In addition to these genes, a number of others have been implicated in the 
disease progression of both sporadic and familial AD. A major component o f AD 
pathology is the NFTs present in the brains of AD patients as well as a range o f other 
related neurodegenerative disorders, x is the primary component of these tangle 
structures and several mutations have been found in this protein but there appears to 
be little correlation between the mutations and clinical presentation of the disease 
(72). Many other genes have now been discovered that have a variety o f effects in 
the pathogenesis o f AD. Genes that promote p-amyloid degradation such as 
Neprilysin (73) and Prolyl Isomerase (74) have been described as well as Receptor 
for Advanced Glycosylation Endproducts (RAGE) and LDL Receptor Protein (LRP) 
which regulate P-amyloid homeostasis in the CNS (75). The genetics of AD remains 
the subject o f intense ongoing research with the role o f genes directly involved in P- 
amyloid and x modulation as well as neuroinflammation and cell death still to be 
clearly defined and new genes to be discovered.
1.3 Molecular Biology o f Alzheimer’s Disease
The main constituent protein found in the cerebral plaques o f AD patients 
was found to be an aggregated form of a novel 4 kDa protein named beta protein 
which was derived from a larger amyloid precursor protein (APP). At least three 
enzymes, a -, p- and y-secretase cleave APP. a -  plus y-secretase cleavage leads to 
non-pathogenic processing o f APP and the cleaved protein fragments are cleared 
from the brain. P- plus y-secretase cleavage o f APP generate the P-amyloid fragment 
which subsequently accumulates in the brains o f AD patients to produce amyloid 
plaques that are one o f the hallmarks o f this disease. While P-amyloid is the core 
component o f the amyloidogenic process contributing to AD, it is generated by all 
cells during normal metabolism (76). P-amyloid has toxic and neurotrophic (77)
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properties and yet the role of this protein in peripheral tissues is not clear. Proposed 
functions for P-amyloid include a role as a sealant for the blood-brain barrier (78), as 
an essential synaptic protein (79) and serving as an anti-oxidant in the aging brain 
(80). In addition the P-amyloid channel hypothesis (81) has been proposed in which 
hydrophobic polymerised P-amyloid protein can infiltrate the lipid membrane bi­
layer and form channels through which calcium ions can pass leading to the 
disruption o f neuronal cells and mitochondria homeostasis.
AD is postulated to be a disease resulting from protein mis-folding (82) 
where the normal production and clearance of P-amyloid and x is somehow impaired 
and the proteins accumulate into respective plaques and tangles with associated 
neuronal cell damage. A number key proteins and structures in the pathogenesis o f 
AD have been identified. These are discussed below along with current hypotheses 
for the disease progression.
1.3.1 Amyloid Precursor Protein
APP is a trans-membrane protein with a large extra-cellular N-terminus and a 
small intra-cellular C-terminus (Figure 1.1). The genomic locus o f APP is localised 
to chromosome 21q21 spanning 170 kb. The promoter region has been shown to 
have two blocks o f regulatory sequences. One block extends from -600 to -460 bp 
and acts as a positive regulator. A second block o f sequences extending from -450 to 
-150 bp acts in the same way as a negative regulator. A 38-mer synthetic 
oligonucleotide encompassing the region -489 to -452 of the APP promoter may also 
act as part o f an enhancer-like element (83).
The APP gene comprises 19 exons which generate a protein of up to 770 
amino acids. APP is expressed throughout the body with 3 main isoforms. These 
include APP695 (exons 1-6, 9-18, not 13a), APP751 (exons 1-7, 9-18, not 13a), 
APP770 (exons 1-18, not 13a). APP695 is the predominant neuronal isoform with 
APP751 most prominent throughout the rest o f the body (84). They differ in that 
APP751 and APP770 contain exon 7, which encodes a serine protease inhibitor 
domain, p-amyloid is derived from that part o f the protein encoded by parts o f exons 
16 and 17 (see below). Quantitative mRNA analyses o f human brain samples showed 
that APP695 and APP751 expression levels were variable but were not changed in 
AD patients whereas APP770 was significantly elevated (85).
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Figure 1.1 Diagrammatical representation of APP Protein.
Figure includes secretase cleavage sites, intron/exon boundaries and identified 
mutations. The p-amyloid sequence is shown in red. Mutations in the APP sequence 
are labelled showing the cluster o f mutations around the C-terminus o f the p-amyloid 
sequence. Adapted from the Alzheimer’s Disease Forum Website: 
http://www.alzforum.org/res/com/mut/app/diagram 1 .asp
The biological function of APP is unclear though a number of studies have 
pointed out its role at the synapse. In their review Sisodia and Gallagher described 
several lines of evidence that APP is involved in synaptic formation and guidance 
(86). Kamal and colleagues concluded that APP functions as a Kinesin-1 membrane 
receptor, mediating the axonal transport of P-secretase and Presenilin-1, and that
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processing o f APP to P-amyloid by secretases can occur in an axonal membrane 
compartment transported by kinesin-1 (87).
1.3.2 p-secretase
P-secretase was first cloned and published in 1999 by four independent 
groups (88-91). Each o f these used different methods to identify the enzyme. Hussain 
et al (88) showed that point mutations in P-secretase (which they called Asp2) at 
both o f its active sites (asp—ser/thr—gly sequence) resulted in a protein that could no 
longer process APP to p-amyloid. The publication from Sinha et al (89) described a 
protein fractionation approach to purify P-secretase (which they named p501). 
Several substrate analogue inhibitor variants o f the APP sequence spanning the beta 
site, including transition-state analogues, were designed and used to pull out their 
candidate protease from human brain extracts, with a 300,000-fold enrichment. They 
described a membrane-bound enzyme activity that cleaved full-length APP at the P- 
secretase cleavage site, and found it to be the predominant beta-cleavage activity in 
human brain. Vasser et al (90) used an expression cloning strategy to clone a human 
trans-membrane aspartic protease with all the known characteristics o f p-secretase 
and they named this protein BACE1 (Beta site APP Cleaving Enzyme 1). Yan et al 
(91) deduced that p-secretase has aspartyl -  protease - like characteristics from 
pharmacological data. They demonstrated that solublised P-secretase protein (which 
they called ASP2) cleaved a synthetic APP peptide substrate at the P-secretase site. 
Although p-secretase has been published using a variety of names including ASP2 
and Memapsin 2, the name settled on is BACE1. Hereinafter the term BACE1 will 
be used for P-secretase.
BACE1 maps to chromosome region Ilq23.2-q23.3 (92). BACE1 protein 
comprises 501 amino acids containing a 21-amino acid signal peptide followed by a 
23-amino acid pro-protein domain and the sequence is shown diagrammatically in 
figure 1.2 overleaf. BACE1 is a type 1 trans-membrane protein with a single catalytic 
domain formed from two active sites on the luminal domain encompassing amino 
acids 93-95 [DTG] and 289-291 [DSG]. The luminal domain o f the mature protein is 
followed by a trans-membrane domain (amino acids 461-477) and a short cytosolic 
C-terminal tail o f 24 amino acids. On folding the protease is activated to allow the 
cleavage o f APP at the P-secretase site.
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Figure 1.2 Diagrammatical representation of BACE1 protein.
The Pre- & Pro- BACE peptide sequences are shown in blue and pink respectively 
and the intra-membrane region in red. Adapted from the AD Forum Website: 
http://www.alzforum.org/res/com/mut/app/diagram 1 .asp
Northern blot analysis o f human BACE1 mRNA in adult peripheral tissues 
and various sub-regions of the brain detected 3 transcripts of approximately 7.0, 4.4, 
and 2.6 kb. By in situ hybridization, expression of BACE mRNA in rat brain was 
observed at higher levels in neurons than in glia (90) supporting the idea that neurons 
are the primary source of the extra-cellular A(3 deposited in amyloid plaques. Vassar 
and colleagues (90) ascribed the difference between the apparent and calculated 
molecular weight (approximately 70 and 51 kD, respectively) of the BACE protein to 
N-linked glycosylation. Immunostaining demonstrated intra-cellular localization of 
BACE1 to the Golgi and endosomes.
P-secretase expression is distributed throughout the body at low levels (76) 
with a high level of expression in neuronal cells (90;93). In addition to neuronal 
expression even higher levels of BACE1 mRNA are detected in the pancreas (94). 
Splice variants o f BACE1 mRNA have been identified in rat and human brain, all 
resulting from alternate splicing o f the RNA at an internal donor in exon 3 and/or an 
internal acceptor in exon 4 as shown below in figure 1.3.
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Figure 13 Alternate Splice Variants of BACE1
Alternate splicing leads to 25 (BACE 1-476), 44 (BACE 1-457) or 69 (BACE 1-432) 
amino acid deletions of the full length BACE1 (BACE 1-501). Tentative exon 
numbers are shown as the authors did not identify the transcription start site of 
BACE1. The translation initiation site, 5' nucleotide sequence o f each exon, end of 
the coding sequence & internal splice site in exons 3 and 4 are numbered. SP = signal 
peptide, PRO = pro-protein sequence, TM = transmembrane domain, A =  protease 
aspartic active sites, * = V-glycosylation sites. After Tanahashi & Tabira (95).
Pulse-chase experiments by the authors o f figure 1.3 indicate that BACE1- 
476 and BACE 1-457 are not processed in the cell Golgi. Characterisation o f BACE 1 
RNA expression in neuronal tissue has shown that human frontal cortex has 3 times 
the level of BACE1 expression as human cerebellum and 4 times the level in rat 
frontal cortex. Neither o f these latter regions develops p-amyloid plaques. Most 
human and rat brain regions express all 4 splice variants o f BACE 1, though BACE1- 
457 is absent from human cerebellum (96). These species specific differences in 
BACE1 transcripts may indicate differences in the evolutionary conservation o f the 
gene.
BACE1 is an important target for therapeutic intervention in AD. 
Consequently the protein, represented diagrammatically in Figure 1.2, has been well 
characterised as part of target validation efforts by various different groups. BACE1
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is a pepsin family member with unusual properties and thus represents a novel class 
of aspartyl proteases (97). The newly synthesised BACE1 propeptide is processed in 
the secretary pathway by furin or a furin-like propeptide convertase (98). Although 
APP cleavage by BACE1 has been reported to be in the endoplasmic reticulum and 
Golgi, endosomes are likely to be the major site for BACE1 activity owing to the 
acidic pH optimum of the enzyme (99). Micro-domains may exist within the cell 
where BACE1 may cleave APP at or near its pH optimum though these domains 
have yet to be found. BACE1 contains a cytoplasmic dileucine motif and the 
mutation of this dileucine to dialanine (100) increases the levels of BACE1 on the 
cell surface and decreases BACE1 internalisation. This is consistent with a role for 
the cytoplasmic tail of BACE 1 in trafficking and localisation. He et al (101) showed 
that the Asp496, Leu499 and Leu500 residues in BACE1 were essential for successful 
binding to GGA (Golgi-localised y-ear-containing ARE binding), a protein involved 
in the regulation of intra-cellular transport (102). In addition to data on cellular 
trafficking, all of the Reticulon family members, RTN1, RTN2, RTN3 and RTN4 
(the last of which is also known as Nogo) have been shown to be binding partners for 
BACE1. Increase in the expression of any of these reticulon family members has 
been claimed to cause a reduction in P-amyloid production by blocking the access of 
BACE1 to APP (103).
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Figure 1.4 Key features of the BACE1 polypeptide
The Pre-, Pro- and Trans-membrane regions are indicated as are the Extra- and Intra­
cellular regions. A=Active sites, N=N-glycosylation sites, C=Cysteine resides with 
appropriate intramolecular disulphide linkages, L=Leucine. Adapted from (97).
The C-terminal cytoplasmic tail of BACE1 interacts with the copper 
chaperone for SOD1 (CCS) and this interaction remains stable enough for both of 
these proteins to be co-transported through axons. Additionally a peptide 
encompassing the BACE1 cytoplasmic domain binds a single Cu (I) atom with high
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affinity. These data point towards the role BACE1 may play in copper metabolism 
and P-amyloid generation. These properties would also be evident in inactive 
BACE1 suggesting a non-proteolytic role for BACE1 linked to metal homeostasis 
(104).
The extra-cellular domain of BACE1 is shed, a process that has been shown 
to be controlled by a metalloproteinase. ADAM 10 is a strong candidate for BACE1 
sheddase (105). Recently two papers have suggested a mechanism for BACE1 
activation whereby BACE1 dimerises to generate an active enzyme as long as it is 
still attached to the membrane whereas the monomeric soluble ectodomain has 
reduced aspartyl protease activity (106; 107). To date no mutations have been found 
in BACE1 which are linked to AD incidence (108) although BACE1 polymorphisms 
play a role in AD (109).
While the primary function o f BACE1 appears to be the processing of APP 
alternative roles for the protein may yet be discovered. Alternative substrates for 
BACE1 are P-selectin glycoprotein ligand-1 (110), the sialyl-transferase ST6Gall 
(111), Amyloid precursor like protein 2 (APLP2) (112), a voltage gated sodium 
channel P-subunit (VGSCP) (113) and the lipoprotein-related receptor protein (LRP) 
(114). P-selectin glycoprotein ligand-1 is expressed as a homodimer and mediates 
leukocyte adhesion to endothelial cells and is critically involved in the inflammatory 
response both in brain and in peripheral tissues. ST6Gall is a Golgi resident sialyl- 
transferase cleaved by BACE1 to generate sialyl- a-2,6-galatose residue. The results 
o f Kitazume et al (115) indicate that BACE1 deficiency may interfere with ST6Gall 
metabolism and a-2,6-sialylation, and BACE1 knockout mice may have abnormal B 
cells through aberrant ST6Gall processing. APLP2 is a type 1 membrane-inserted 
protein belonging to the APP-superfamily (116) and can be cleaved by y-secretase 
(117). Like APP, APLP2 can be processed to generate a large extra-cellular soluble 
ectodomain (118). APLP2 can not contribute to the p-amyloid peptide as it does not 
contain the P-amyloid sequence however APLP2 processing is modulated by BACE1 
in vivo (119).
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1.3.3 BA CE2
BACE2 was cloned by a number of groups and the first papers were 
published around the same time as BACE1 (92;99; 120-122). BACE2 has 52% 
homology to BACE1 and contains the same two DTGS & DSGT motifs 
characteristic of aspartyl proteases (123). Both enzymes are type 1 trans-membrane 
proteins with a short cytoplasmic tail, a single trans-membrane region and a large 
extra-cellular domain containing the active site (Figure 1.5). BACE2 has been shown 
to cleave APP at the p-secretase site as well as other sites within the P-amyloid
fragment (124) though the enzyme cleaves at greater efficiency at 2 sites within the
P-amyloid domain of APP (Phe +19 and Phe +20) near the a-secretase cleavage site. 
BACE2 is thought to operate more as an a-secretase enzyme with processing of APP 
by BACE2 leading to reduced P-amyloid production (125).
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Figure 1.5 Comparative amino acid sequences of BACE1 & BACE2
Dark shading indicates identical amino acid sequences and light shading represents 
similar sequences. Adapted from Sun et al (126).
BACE2 is distributed throughout the body with low mRNA levels detected in 
most human organs and higher expression in colon, kidney, pancreas, placenta, 
prostate, stomach and trachea. Interestingly BACE2 mRNA is found in low levels in 
the CNS (121). Both BACE1 and BACE2 have been reported to participate in the 
normal and abnormal processes in human muscle suggesting a broader function 
beyond that of a P-secretase (127).
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1.3.4 y -secretase
y-secretase is a complex of proteins including Presenilin 1 (PS1) (128) in 
addition to Nicastrin, anterior pharynx (APH1) and presenilin enhancer 2 (PEN2) 
(129). When co-expressed in yeast, an organism that lacks endogenous y-secretase 
activity, these four proteins were sufficient to reconstitute y-secretase activity (130).
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Table 1.3 y- secretase substrates and their proposed biological functions
* Transmembrane domain sequences are shown in bold. X Major middle transmembrane cleavage 
sites. §A|342-producing site (increasingly used in Alzheimer’s disease). || Cleavage sites that release 
intracellular domains. ^ Determined by overexpression assays. # Determined using y-secretase
inhibitors. ** Determined using in vivo genetic models. A PI, activator protein-1; APLP, amyloid- 
precursor-like protein; APP, amyloid precursor protein; CASK, calmodulin-dependent serine kinase; 
CBP, CREB (cAMP responsive- element-binding protein)-binding protein; CSF1, colony-stimulating 
factor-1; DCC, deleted in colorectal cancer; ICD, intracellular domain; LPS, lipopolysaccharides; 
LRP, low-density-lipoprotein receptor protein; ND, not determined; NM DA, N-methyl-D-actetate; 
PMA, phorbol-12-myristate- 13-acetate; STS, staurosporine; TP A, 12-O-tetradecanoylphorbol- 13- 
acetate; TRE, TPA-responsive element. Adapted from (131).
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The y-secretase enzyme complex has several substrates other than APP 
including the notch receptor 1 (NOTCH 1), the notch ligands delta-like protein 
(DSELTA1) and Jagged2 (JAG2), v-erg-a erythroblastic leukaemia viral oncogene 
homologue 4 (ERBB4) and others listed in Table 1.3 (129; 131). PS1 and PS2 have 
also been shown to interact with MOCA (modifier of cellular adhesion), P-catenin 
and proteins involved in cell death, calcium metabolism and cell adhesion (132). 
Mutations in PS 1 have been closely associated with familial AD.
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Figure 1.6 Schematic diagram  of Presenilin 1
(a) Presenilin 1 (PS1), which contains 467 amino acids, has eight transmembrane 
domains, with a large cytoplasmic loop between the sixth and seventh 
transmembrane domains. PS2 has a similar structure, but contains 448 amino acids.
(b) The large cytoplasmic loop of PS1 comprises residues 265-381 (residues given in 
single-letter code). The endoproteolytic cleavage site (which generates the two stable 
fragments) and a putative caspase cleavage site are shown, (c) The binding site for p- 
catenin has been mapped to residues 331-351, within the large cytoplasmic loop, 
whereas the MOCA-binding site spans the junctional region between the loop and 
transmembrane domain 7 (residues 375-396). MOCA, ‘modifier of cellular 
adhesion’. After (132).
The PS1 protein is represented in Figure 1.6 (132). The 8 trans-membrane 
spanning regions are shown with key residues including the endoproteolytic, caspase,
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p-catenin binding and MOCA binding sites. While PS1 is not the sole protein of the 
Y-secretase complex, mutations in PS1 are closely associated with AD incidence 
(133).
PS1 knockout mice have an embryonic lethal phenotype (134) similar to that 
seen in NOTCH 1 knockout mice (135) indicating that y-secretase cleavage of 
NOTCH 1 is essential in development. PS2 and PS1 are 67% identical (136), are 
membrane bound proteins with eight predicted transmembrane (TM) regions and a 
hydrophilic loop of approximately 120 amino acids between the 6th and 7th TM 
domains (Figure 1.6). The majority o f early onset Familial Alzheimer’s Disease 
(FAD) linked mutations occur as autosomal dominant mutations within PS1. Two in- 
frame deletions, two splicing mutations and over 70 missense mutations have been 
found distributed throughout the PS1 protein compared to only 6 missense mutations 
for PS2. Whilst there is a clear understanding of the genetics o f the presenilins their 
biological function in normal neuronal cells remains unclear though the interaction of 
PS 1 and PS2 with several proteins indicates a diversified function for these proteins 
and for the y-secretase complex.
1.3.5 a-secretase
The identity of the a-secretase has not yet been confirmed but three members 
o f the ADAM (A Disintegrin And Metalloproteinase Domain) family of proteases, 
ADAM-10, ADAM-17 (TACE or Tumour Necrosis Factor-Alpha Converting 
Enzyme) and ADAM-9, have been proposed as a-secretases (137). In particular 
ADAM 10 has been shown to have a-secretase activity in vivo where the expression 
o f a catalytically inactive ADAM-10 mutant led to increased plaque size and number 
in double transgenic mice (138). In addition APP, BACE1 and ADAM 10 have been 
shown to co-localise in human cortical neurones (139).
ADAM9 mRNA is ubiquitously expressed in human tissues (140) while 
ADAM 10 mRNA expression is restricted in humans to kidney, spleen, lymph node, 
thymus, liver, bone marrow, and brain (141; 142). ADAM 17 mRNA expression is 
found to be highest in macrophages (143). The ADAM9 mRNA expression in human 
brain is higher than ADAM 10 and ADAM 17 mRNAs suggesting that ADAM9 
mainly plays a role as "constitutive" and/or "regulated" a-secretase (144). ADAM9 
also has a splicing variant, which lacks the carboxyl-terminus, and the secreted short
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form of ADAM9 also has an a-secretase-like activity toward APP (145). Both 
ADAM 10 (146) and ADAM 17 (147) knockout mice exhibit embryonic and 
perinatal lethality respectively. This lethality precludes the examination of the 
function o f these proteins in older mice when amyloid plaques are forming however, 
when a dominant negative ADAM 10 mutant transgenic mouse was crossed with an 
APP transgenic mouse, the resulting offspring had a reduced amyloid burden 
compared to the parental APP mouse line indicating the ADAM 10 at least is anti- 
amyloidogenic in vivo (138). The evidence seems to point to a functional overlap 
between these 3 zinc metalloproteinases with some redundancy in a-secretase 
activity depending on cell type.
1.3.6 A PP  Processing P athw ay
The APP processing pathway explains the way in which the APP protein is 
acted upon by the secretase enzymes and either enters an amyloidogenic or non- 
amyloidogenic processing pathway (Figure 1.7). These processing events are crucial 
to the development of AD.
L u m e n
C y t o s o l
Figure 1.7 APP Processing pathway
APP = Amyloid Precursor Protein, sAPPa = soluble APPa, sAPPp = soluble APPp, 
CTFa = c-terminal a , CTFp = c-terminal p, P3 = P3 fragment, Ap = P-amyloid 
fragment, AICD = APP Intracellular Domain, Green = non-amyloidogenic pathway, 
red = amyloidogenic pathway.
s A P P a
P - c l e a v a g e
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Initially APP is cleaved by p- or a-secretase in the extra-cellular region. 
Subsequently the residual C-terminal stub is cleaved by y-secretase. An additional, 
novel 8-secretase cleavage has been proposed located 12 residues from the N- 
terminus of the P-amyloid domain (148). a-secretase cleavage is the initial event in 
the non-amyloidogenic processing o f APP leading to the formation of the P3 
fragment which is degraded within the cell. However cleavage by P-secretase 
initiates the amyloidogenic processing of APP leading to the formation of a 4 kD 
protein called P-amyloid. These form amyloid plaques which are one of the classic 
lesions definitive of AD.
1.3.7 Protein Mis-folding
Subsequent to translation most proteins undergo tertiary processing before 
they adopt their quaternary structure and are able to perform the function for which 
they were transcribed. Protein folding and unfolding are crucial ways in which 
protein biological activity and targeting to cellular compartments can be regulated. 
Aggregation o f the mis-folded proteins that escape the cellular quality control 
mechanisms is a common feature of many diseases (149). The recognition and 
selective degradation o f mis-folded polypeptides serves as a quality control 
mechanism for intra-cellular proteins. In the human brain this function occurs via a 
large ATP-dependent proteolytic machine, the 26S proteasome. This intra-cellular 
machinery prevents the accumulation of non-functional, potentially toxic proteins. 
The selective degradation o f intra-cellular proteins is given clear insight by Goldberg 
in his review (150). While the vast majority o f mis-folded proteins are degraded 
successfully some escape the degradation process. It is possible that unfolded or mis- 
folded proteins aggregate before they can be degraded and hence circumvent the 
normal cellular degradation pathways. When mis-folded proteins accumulate within 
the cell the cell responds by producing more proteasome, a process that finally 
results in cell death. Caspase-4 appears to act upstream of the p-amyloid induced 
endoplasmic reticulum stress (ER stress) response to unfolded proteins. Thus 
Caspase-4 activation may mediate neuronal cell death in AD (151). Selkoe (82) gives 
an insight to systemic, organ restricted and intra-cellular amyloidoses. He states that
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time, rather than old age, is the primary determinant for many amyloidoses. This is 
exemplified in a striking manner by Down Syndrome suffers who, carrying an 
additional copy o f the amyloid precursor protein due to a trisomy o f chromosome 21, 
may form Ap aggregates in the brain as early as aged 10. In familial AD, patients 
with mis-sense mutations in APP or y-secretase may also accumulate P-amyloid in a 
reduced timescale. However the time needed for intra-cellular mis-folded proteins to 
overcome the proteasome is clearly reflected by the prevalence of AD in the aged 
population.
Recent research has pointed very strongly to the cytotoxicity in AD being due 
to the metastable intermediates of the fibrillogenic process rather than the stable 
deposits found in the plaques themselves. The concentration of oligomer species of 
Ap rather than amyloid plaque number gives a better correlate with decreases in 
synaptic terminal number in APP mouse models (152). Reassuringly, this correlation 
is also seen in humans where the memory and cognitive deficits of patients with Mild 
Cognitive Impairment is strongly linked to increased soluble cerebral Ap 
concentrations (153; 154).
1.3.8 Plaques
Amyloid plaques are the extra-cellular deposits of the fibrillar form of P* 
amyloid protein. Circulating p-amyloid in the blood can diffuse across the blood- 
brain barrier and aggregate into fibrillar forms which become deposited as amyloid 
plaques in the brain. Plaque deposition is initiated by extracellular accumulation of 
the longer Ap42 peptide. This form of p-amyloid readily aggregates and is deposited 
as discrete amyloid plaques as it precipitates out of solution. The shorter Ap40 
peptide also accumulates in amyloid plaques after the initial seeding by Ap42. While 
the plaques themselves are extra-cellular and non-toxic, the P-amyloid peptide is 
neuro-toxic (155) and hence amyloid plaques are surrounded by neuritic cells and 
dead cell bodies. The formation and maturation of plaques and neurofibrillary tangles 
contribute to the neuronal cell loss and brain shrinkage seen with the terminal decline 
o f demented AD patients.
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1.3.9 Tangles
Neurofibrillary tangles (NFTs) are formed from the pathogenic deposition o f 
polymeric forms of the micro-tubule associated protein tau (MAPT or simply x). The 
protein x is essential in the shaping and reshaping o f cells. The normal function o f x 
is to stabilise microtubule assembly and allows for new units of tubulin to be 
assembled on cell spindle fibres (156). Studies have shown that the x found in AD 
brains is highly phosphorylated and is a found in the paired helical filaments (PHFs) 
(157) that are a major component of NFTs (158). Mutations in x can lead to 
hyperphosphorylation of the protein by kinases which dramatically alters its function 
and results in the formation o f PHFs (159). Mutations in the x gene can also alter the 
stability o f the mature protein by the inclusion or exclusion o f exon 10 and the 
microtubule binding domains that it encodes thus affecting microtubule assembly 
and filament formation (72). In addition a recent report by Alonso et al (160) 
suggests that mutations in x may cause the molecule to be more susceptible to 
hyperphosphorylation leading to neurodegeneration by becoming ‘toxic’ to the 
microtubule system as it sequesters normal x.
While amyloid plaques are found during the post mortem of brains from non­
demented patients, NFTs are a stronger correlate o f memory impairment and disease 
progression in AD than are plaques and the development of NFT lesions allows the 
delineation of 6 stages of disease progression (161). The first two stages are present 
in clinically silent cases and NFTs are limited to trans-entorhinal regions. In stages 3 
and 4 NFT lesions are seen in limbic regions and are presented as incipient AD. 
Finally fully developed AD defines stages 5 and 6 and NFT lesions extend to 
neocortical regions.
Mutations in x have been identified with fronto-temporal dementia (162) and 
NFTs are also present in a spectrum of diseases collectively called tauopathies (163) 
in which tangles are associated with neurodegeneration in the absence o f plaques 
(164). These findings suggest that tangles are the main neurodegenerative factor in 
AD and not plaques. Whether AD is a type of tauopathy that includes plaques or is 
an amyloidopathy that includes tangles is the subject of much discussion. An 
understanding of the interaction between plaques and tangles in AD may be revealed 
by studying the activity o f kinases on APP and x. An interesting hypothesis that may 
provide a unifying mechanism for tangle and plaque deposition has been proposed to
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include the Notch and Wnt signalling pathways (165). Essentially PS1, a component 
of the y-secretase complex that contributes to P-amyloid formation, cleaves a protein 
involved in cell fate determination, Notch, to generate a Notch intracellular domain 
(NICD) fragment. NICD may regulate GSK3P activity (a kinase that phosphorylates 
t)  via the dishevelled protein possibly involving protein kinase C. Dishevelled is 
known to be the target o f Wnt-1, the Drosophila homologue o f which, wingless, is 
involved in cell fate decisions and pattern formation in flies. Thus PS1 activity can 
contribute to P-amyloid production and plaque formation via APP processing and to 
x phosphorylation and tangle formation via a number of cellular kinases.
Contained within the genomic x locus is a discrete gene named Saitathin 
(STH) (166). STH is located in the intron between exons 9 and 10 of the human x 
gene. It is intronless and encodes a 128 amino acid protein with no clear 
homologues. STH tissue expression is similar to that o f x and a Q7R polymorphism 
in the protein is over-represented in the homozygous state in late onset AD subjects. 
No clear function has been assigned for STH though it does contain putative 
phosphorylation sites that suggest a possible role in x phosphorylation and AD.
1.4 Clinical Interventions in Alzheimer ys Disease
Not only does Alzheimer’s Disease afflict those who develop the disease, it 
also has a major impact on the people who care for affected individuals (167-169). It 
is estimated that 50% of those over 80 years of age and 10% of those over 65 years 
o f age will develop the disease (170; 171). These figures translate the estimated 
incidence of new cases to be 4.6 million for AD and 25 million for dementia 
worldwide in 2000. With the increase in the elderly worldwide population the 
estimate o f dementia prevalence increases to 63 million in 2030 and 114 million in 
2050 (172). The current incidence of AD places an enormous emotional burden on 
caregivers as well as a financial burden on state and private health care 
arrangements. The predicted increase in AD prevalence will only exacerbate these 
burdens and makes the search for an effective therapy more imperative.
In order to diagnose accurately the disease several methods of assessing 
people suspected of having a neurodegenerative disorder have been developed. These 
can be divided into assessments of behaviour including the cognitive state o f the
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person, their functional abilities and their general overall condition as well as 
biochemical and imaging assessments o f clinical markers o f disease state. In addition 
an index to assess the condition of the affected individual’s caregivers has been 
developed. An examination o f the methods o f assessment has been valuable in order 
to better convey the impact that this disease has on AD patients and those that love 
them. The following descriptions of assessment methods are not comprehensive but 
they do serve to illustrate the effects of the disease.
1.4.1 Prediction and Assessment of Alzheimer’s Disease
A definitive diagnosis of AD can only be given post mortem using current 
technologies. The presence o f amyloid plaques, neurofibrillary tangles and 
neurodegeneration in the brains o f patients post mortem are the hallmarks of the 
disease. AD is often diagnosed in primary care when concerned relatives approach 
practitioners for help with elderly relatives who appear to have changed personality 
and have begun to lose their memory. Generally the initial assessments o f AD in 
subjects that present with memory impairment are behavioural. While individual 
tests of cognition have their own merit no one test has been shown to be better than 
the other. One of the tests devised is the Alzheimer's Disease Assessment Scale, 
Cognitive Subsection method (ADAS-Cog) (173), which tests memory, orientation, 
praxis and language to assess cognitive function. A scoring scale o f 0 to 70 is used 
and most normal patients score 5 to 10 while severely demented patients score 70. 
Another method is the Blessed Information-Memory Concentration Test (174) which 
examines short term memory, concentration, spatial ability (orientation) and verbal 
responses. The Cambridge Neuropsychological Test Automated Battery (CANTAB) 
test (175) is a computer automated battery of neuropsychological tests, for use in 
accurate, sensitive cognitive assessment. The Clinical Dementia Rating Scale (CDR) 
(176) is used to gauge AD progression in clinical and longitudinal dementia studies. 
A widespread method is the Mini-Mental State Examination (MMSE) (177; 178). The 
MMSE is a brief, quantitative measure which is used to test the cognitive state of 
adults. It can be used to screen for cognitive impairment, estimate the level of 
impairment at a specific time and to follow the course of mental decline over time.
In addition to cognitive testing, the function of AD patients is used to assess 
disease state. These include the Functional Assessment Questionnaire (FAQ) (179),
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which is designed for community studies of normal aging and mild senile dementia, 
the Instrumental Activities O f Daily Living (IADL) and the Physical Self 
Maintenance Scale (PSMS) (180), both of which assess the ability of a patient to 
carry out normal daily activities such as going outside, paying bills, feeding, bathing, 
etc. and finally the Progressive Deterioration Scale (PDS) (181) looks at the quality 
o f life experience and is assessed by the caregiver. Besides cognitive and functional 
assessments various global assessments of the patient have been devised. These are 
the Clinical Global Impression O f Change (CGIC) (182); the Clinician Interview- 
Based Impression (CIBI) (183) and the Global Deterioration Scale (CDS) (184). 
Finally there are 2 caregiver based assessments. These are the Behavioural Pathology 
In Alzheimer's Disease Rating Scale (BEHAVE-AD) (185) and the Neuropsychiatric 
Inventory (NPI) (186). The assessments provide an indication of the impact that the 
patient has on those that look after the individual. An excellent overview o f these and 
many more rating scales used in dementia research is given by Lon Schneider 
(Alzheimer Insights Online 2(3) Oct 1996). The plethora of test scales used to assess 
AD patients and caregivers is a clear indication of the devastating nature o f this 
disease and the widespread collateral burden of care that it places on loved ones 
(187).
A number o f tests are used to diagnose the disease including volumetric 
analysis o f the brain ventricles with MRI (188) which can also be predictive o f AD 
(189), imaging amyloid pathological lesions in the brain with Positron Emission 
Tomography (PET) scanning (190; 191), biomarkers o f AD (192) and harvesting 
cerebrospinal fluid to test for the presence of brain specific proteins diagnostic of 
neurodegenerative disease (193; 194).
Peripheral indicators such as elevated cortisol levels have also been linked to 
cognitive decline (195). Studies have shown that the function of the hypothalamus 
and Hypothalimc-Pituatary-Axis (HPA) is impaired in AD patients and HPA over 
activity may be responsible for the non cognitive behavioural disturbances seen in 
demented patients (196). Indeed the detrimental effects of chronic glucocorticoid 
hypersecretion occurring through over-activation of the HPA have been seen in 
obesity, AIDS dementia and depression as well as in AD (197).
In the century following Alois Alzheimer’s publication extensive research has 
been carried out on all aspects of the disease. An effective cure or comprehensive 
symptomatic relief still remain elusive despite the many millions o f pounds spent on
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research and development into a therapy for AD. Individuals that increase mental 
stimulation during youth and midlife tend to be protected from AD in later years
(198). While inactivity may be a risk factor for AD or may be reflective of a very 
early sub clinical feature of the disease, these data suggest that daily recreational 
activities such as playing bingo or completing crosswords may be effective in 
reducing the chances of developing AD. An interesting corroboration to this report is 
the finding that when mice with elevated p-amyloid protein and plaques were 
exposed to an enriched environment including coloured tunnels, toys and chewing 
material over a 5 month period the P-amyloid load and plaque number was reduced
(199). Calorie restriction has been shown to attenuate P-amyloid deposition in APP 
transgenic mice (200) hinting at an simple protective treatment against AD by 
reduction of calorie intake, however starvation in mice has been shown to increase x 
hyperphosphorylation at sites predominantly hyperphosphorylated in AD (201) 
hence promoting the development of NFTs. Finally animals that were allowed access 
to a running wheel in their cage for 1 month showed a decrease in P-amyloid load 
pointing to voluntary exercise as a prophylactic in AD (202). While these reports 
indicate potential lifestyle changes that may help to treat or prevent AD, current 
therapies are directed at alleviating the symptoms of the disease (symptomatic 
treatments) or altering the underlying disease pathology (disease modifying 
treatment).
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Figure 1.8 Predicted change in MMSE score in response to treatm ent
After Gauther et al (203).
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The goal of symptomatic therapies is to alleviate the symptoms of the disease 
and slow cognitive decline. While this strategy may be easier to achieve and indeed 
is the only proven method of treating AD, it does not alter the disease progression. 
Symptomatic treatment is represented by the red line in Figure 1.8. Disease 
modifying therapies seek to interfere with the underlying disease pathology, halting 
disease progression and hence stop the cognitive decline. This strategy is represented 
by the yellow line in Figure 1.8. Disease modification can be further split into 
therapeutic agents that seek to prevent the formation of the pathogenic proteins, 
namely P-amyloid and hyperphosphorylated x; seek to prevent the deposition of the 
pathogenic lesions that develop in AD, namely plaques and tangles; and those that 
treat the many other components of disease pathology that arise from the presence of 
these lesions in the brain.
1.4.2 Symptomatic Treatments for Alzheimer’s Disease
The ways in which current symptomatic treatments work have been 
extensively studied. Aricept™ is marketed by Lilly and is the current market leader 
for the treatment of Alzheimer’s Disease (204). Aricept™ is one of a class of 
treatments called acetyl cholinesterase inhibitors. These compounds act by inhibiting 
the enzyme acetyl cholinesterase which catalyses the breakdown of the 
neurotransmitter acetylcholine. Clear dysfunction is seen in the acetylcholine system 
in the forebrain o f AD patients and reducing the rate of breakdown o f this 
neurotransmitter may restore the normal function of the acetylcholine system in 
affected individuals. Cholinesterase inhibition may also have an effect on AD 
pathogenesis as recent studies indicate that these agents can attenuate neuronal 
damage and death from cytotoxic insults (205).
Symptomatic therapies that are less well understood include those targeted at 
the 5-Hydroxytryptamine system and Histamine 3 receptors. 5-Hydroxytryptamine 
(5HT) receptor density decreases in the brains o f aged animals and humans including 
the hippocampus and neocortex of patients with AD (206). 5- Hydroxytryptophane 
treatment o f aged rats increases cognitive performance in a test o f spatial learning 
and memory (207) pointing to the 5HT system as an avenue therapeutic intervention 
in AD. Receptor agonists have been developed for 5-HT1A (208;209), 5-HT4 (210)
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and 5-HT6 (211 ;212). In addition selective histamine H3 receptor antagonists have 
been shown to be effective in treating cognitive disorders (213).
1.4.3 Disease Modification Treatments for Alzheimer’s Disease
Disease modifying therapies for AD have been the subject of intense research 
by academic and industrial laboratories. However a limited understanding of the 
disease biology has hampered progress towards an effective treatment. Even when a 
disease modifying therapy is identified, the very long time course of the disease 
makes a total treatment strategy difficult to plan. Nevertheless a number of potential 
leads have been followed in the search for a way of modifying AD progression (214).
Preventing the formation of the neurotoxic P-amyloid peptide is an active 
topic for researchers as it provides a treatment that interferes with the disease 
progression. The major targets for preventing the formation of P-amyloid are the 
agonism of a-secretase and the inhibition of y- or P-secretases. Increasing the 
activity of a-secretase with an agonist is problematic as normal physiological 
processing ensures that the bulk o f APP enters the non-amyloidogenic a-secretase 
cleavage pathway so that only small changes may be brought about. This pathway 
can be stimulated via M l muscarinic receptor agonists which may function as 
cognitive enhancers and may influence disease progression if they impact on p- 
amyloid production (215). While a number o f enzymes have been identified at 
candidates for a-secretase (see 1.3.5), the full effect o f increasing the activity of 
these proteins, unrelated to APP cleavage, needs to be investigated as part o f a 
screening cascade for compound development.
Inhibition of y- and P-secretase is an attractive strategy as precedent exists for 
this target class with the marketing of successful inhibitors of HIV protease. 
As stated earlier, PS1 is a component of the y-secretase complex, y-secretase has 
been shown to cleave NOTCH 1 and both NOTCH 1 and PS1 knockout mice are 
embryonic lethal (see 1.3.4). Hence when efforts at developing y-secretase inhibitors 
led to dose dependant toxic effects, probably Notch related (216), y-secretase 
inhibition did not look to be a viable target. An alternative approach to y-secretase 
inhibition was indicated when very high doses of non-steroidal anti-inflammatory 
drugs (NSAIDs) were found to be able to modulate y-secretase activity such that the
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longer, more aggregation prone species of P-amyloid, Ap42, was reduced. This result 
was seen in conjunction with an increase in the less aggregating Ap38 species o f P- 
amyloid and no effect on NOTCH 1 cleavage (217). These results paved the way for 
y-secretase inhibition as a therapy with more potent y-secretase modulators that are 
selective against Notch 1 cleavage. Recent reports indicated that a potent y-secretase 
inhibitor, LY-411575, was able to lower CSF and brain P-amyloid, but elevated 
plasma p-amyloid at low doses (218). The use o f NSAIDs a potential y-secretase 
inhibition therapy for AD must be viewed with some caution however as a number of 
compounds have been found to increase Ap42 production (219).
The finding that BACE1 is an aspartyl protease allowed the prospect o f P- 
secretase inhibition as a viable disease modification strategy for AD (see 1.3.2). 
BACE1 knockout mice are viable and fertile (see paragraph 1.5) though they have 
subtle changes in anxiety and cognition (see chapters 2 and 3 of this thesis). These 
finding indicate that BACE1 is a viable target for inhibition and several BACE1 
inhibitors have been described (220;221) BACE2 is a homologue of BACE1 and 
deleting BACE2 in addition to BACE1 in mice does not appear to alter the 
phenotype beyond that seen in BACE1 mice alone (see chapter 4 of this thesis). 
Consequently BACE2 inhibition is not actively pursued as a drugable target for AD 
(222). While inhibition of BACE 1 appears to be very attractive as a target, the active 
site of the enzyme is unusually large and thus represents a challenge to medicinal 
chemists to develop small molecules that cross the blood brain barrier and inhibit 
enzyme activity, though progress has been made (223). A novel strategy for BACE1 
inhibition was recently suggested with the effective development o f antibodies that 
inhibit the interaction between BACE1 and APP (224). This P-amyloid 
immunotherapy approach is attractive and several groups have demonstrated the 
efficacy of this approach as a P-amyloid lowering therapy (225). In addition data 
showing altered anxiety and cognition suggest a role for BACE1 independent o f that 
o f a p-secretase. Further work is required to define any other potential roles for 
BACE1 in humans and appropriate screening cascades designed to screen out any 
potential deleterious effects of BACE 1 inhibition as a therapeutic strategy.
The P-amyloid fragment of APP has a propensity to aggregate into oligomers 
and can undergo further aggregation to create the fibrils that are found in amyloid 
plaques. One suggested method of a therapeutic intervention in AD is to interfere
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with the mechanism by which the pathogenic proteins fold and become aggregated. 
Potential events that are initiated by mis-folded and aggregated proteins include 
excitotoxicity, increased cellular oxidative stress, impaired cellular antioxidation 
functioning and/or impaired molecular chaperone and protein folding mechanisms 
(226). Anti-fibrillisation therapies have met with limited success. The search for a 
fibrillisation inhibitor has focussed on inhibition o f P-amyloid fibrillisation in vitro 
using compounds identified from screening compound banks. Data suggest that these 
inhibitor compounds do not all bind to a common single site on p-amyloid. (227). In 
addition the mechanism by which these protein-protein interactions occur is not 
clearly understood. In the absence of a clear mechanism of action the design of small 
molecule inhibitors o f fibrillisation using structural activity relationship modelling is 
extremely difficult. In order to develop an effective anti-fibrillisation therapy, a small 
molecule would need to interfere with the specific protein-protein interaction o f P- 
amyloid peptide binding to P-amyloid peptide, a strategy that has a track record of 
failure in the industry (228). A vital component of P-amyloid aggregation is zinc. 
The antibiotic Clioquinol has been reported to lower P-amyloid burden in APP 
transgenic mice by copper and zinc chelation (229). This strategy for anti- 
fibrillisation o f P-amyloid was progressed to the clinic with subtle positive effects in 
a subset of patients warranting further studies (230).
An alternative therapeutic approach to the treatment of AD is to try and clear 
the p-amyloid peptide from the brain and blood of patients. Vaccination of APP 
overexpressing mice with aggregated Ap42 resulted in  a surprising improvement in 
plaque load, neuritic dystrophy and gliosis in the m ice with no apparent ill effects 
(231). Inoculation with fragments o f P-amyloid elicits an antibody response in the 
body and levels of circulating amyloid are reduced. T h is  effect is thought to occur 
via one o f two mechanisms. Either P-amyloid vaccination stimulates microglia 
activation and plaques are cleared via Fc mediated phagocytosis (232;233), or P- 
amyloid antibodies induce a change in the P-amyloid equilibrium between the CNS 
and plasma acting as a peripheral sink for p-amyloid (234;235). Human clinical trials 
o f amyloid vaccination have resulted in the reduction o f CNS amyloid plaques. 
While this technique has proved efficacious as a d isease modifying therapy for AD 
side effects, including neuroinflammation, have lead, to a cessation o f the clinical 
trial and a return to the basic research into the m echanism s thought to underlie the
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process (236;237). New hopes for this approach have been raised with the finding 
that AD patients with serum antibodies against P-amyloid plaques show improved 
cognition and slowed disease progression (238;239).
Therapeutic interventions aimed at preventing the formation of the 
pathogenic forms o f x include stopping x hyperphosphorylation, promoting x 
dephosphorylation, preventing PHF formation and aggregation, promoting PHF 
disaggregation, clearing PHF from the CNS and ameliorating the consequences of 
PHF formation in neuronal cells. As x is phosphoylated by multiple phosphatases and 
kinases (240;241) an effective x specific therapy that targets x phosphorylation may 
prove to be problematic. However recent reports indicate that stabilising 
microtubules may be an effective treatment, x transgenic mice that were dosed with a 
microtubule binding drug showed an improvement in the impaired fast axonal 
transport and motor function seen in untreated mice (242).
Additional strategies have been suggested as potential avenues by which AD 
may be treated. Miller et al (243) have employed strand interference RNA (siRNA) 
technology to develop short hairpin RNA (shRNA) plasmids that can interfere with 
the production of x and APP in vitro. This technology has been shown to silence the 
expression o f genes in vivo (244) and has obvious application for the inhibition of 
pathogenic protein production in AD patients. In particular the size of the BACE1 
enzyme active site has proved difficult to inhibit with small molecule compounds 
and siRNA technology may yield an effective therapeutic agent (245). The main 
caveats to this technology are efficient delivery, sustained cell specific silencing of 
targeted genes and the possible side effects that such silencing may have on normal 
cell function (246).
Epidemiological studies have shown that people taking cholesterol 
biosynthesis inhibitors (statins) have a reduced risk of developing AD. While this 
mechanism is not fully understood, Sidera et al (247) showed that a cholesterol 
transport inhibitor, U 18666A, produced a change in the glycosylation state of 
BACE1, possibly by interfering with the trafficking and recycling o f lipid rafts. Lipid 
rafts are a cellular compartment where BACE1, APP, Presenilin and P-amyloid have 
been shown to co-localise. Interestingly there is epidemiological evidence that 
increased dietary intake o f the omega 3 (n-3) polyunsaturated fatty acid (PUFA) 
decosahexanoic acid (DHA) is associated with a reduced risk o f AD (248;249).
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When fed with a DHA enriched diet, the P-amyloid burden in aged APP transgenic 
mice was decreased (250) suggesting utility for increased dietary DHA as a 
protective therapy for AD.
Medicinal use of the Ginkgo Biloba tree (Maidenhair tree in English) has 
been traced back to 1280 AD during the Chinese Yuan dynasty. An extract from the 
tree, EGb 761, has been shown to improve cognitive performance in aged animals 
possibly acting via mitochondrial stimulation (251). This demonstrates a natural 
product approach to finding an effective treatment for AD.
1.5 Transgenic and Knockout Mouse Models
Transgenic models are those in which a protein from the gene o f interest is 
over-expressed. This over-expression can be controlled in a temporal or spatial 
manner with appropriate use of DNA regulatory sequences. Knockout models are 
generated by removing the endogenous protein expression from a gene of interest.
Several amyloid depositing mouse models have been generated using 
different promoters, gene constructs and APP mutations linked to familial forms of 
AD (252-254). In all o f these models there is an age dependent increase in brain p- 
amyloid levels and concomitant amyloid plaque deposition associated with 
astrogliosis, microgliosis and the appearance of dystrophic neurites (252;253;255). 
There are also reports o f reduced synaptophysin staining in some of these models, 
notably the PDAPP mouse model (152;256) and some neuronal loss in the APP23 
mouse model (257), although none o f these mouse lines demonstrate a convincing 
level o f neuronal degeneration. Behaviourally, several of the APP transgenic lines 
exhibit deficits in learning and memory (258-262) lending support to the notion that 
elevated p-amyloid levels and plaque deposition can cause behavioural changes 
despite a lack of neuronal loss (263).
The molecular, enzymatic and cell biological characterisation of BACE 1 has 
significantly increased our understanding of the role o f this enzyme in P-amyloid 
generation and presented the scientific community with a new therapeutic target for 
the treatment o f AD. Further validation of BACE 1 as a key enzyme in the generation 
o f P-amyloid has been made possible using mice lacking BACE1. In such animals 
there is a complete inhibition o f P-amyloid production, either from murine APP or in 
animals which are crossed with mice over-expressing APP (264). Furthermore
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removal of endogenous BACE1 by interbreeding BACE1 KO mice with a transgenic 
mouse line carrying mutant human APP (Tg2576) rescues the cognitive deficit seen 
in the APP mouse line alone demonstrating that it is the P-amyloid peptide rather 
than APP overexpression itself that leads to cognitive deficits (263). BACE1 knock­
out (KO) mice are viable and fertile, with an absence of any deleterious or adverse 
findings (264-266). This is in sharp contrast to mice lacking presenilin-1, one of the 
components of the y-secretase enzyme complex (130;267), which have an embryonic 
lethal phenotype (134). These observations, coupled with the clear correlation 
between p-amyloid burden and cognitive decline (268), provide good evidence that 
inhibition o f BACE1 could be of benefit to AD patients and potentially be less 
deleterious than approaches targeting inhibition of y-secretase.
In addition to the neuropathological features described above, the brains of 
AD patients are deficient in a multitude of neurotransmitter systems. These include 
acetylcholine and glutamate, upon which current symptomatic therapies such as 
cholinesterase inhibitors and NMDA antagonists are based, as well as noradrenalin, 
serotonin, and neuropeptides such as somatostatin and neuropeptide Y (269-271). 
The evaluation o f neurotransmitter deficits in transgenic mouse models of AD has 
only recently been undertaken. Several reports have suggested the existence o f 
cholinergic deficits in APP transgenic mice (272;273). In addition, elevated levels o f 
neuropeptides such as galanin, neuropeptide Y, cholecystokinin and enkephalin have 
been reported in aged brains of PDAPP mice (274). However the extent to which 
these changes are common to all mouse models of AD and their direct relevance to 
changes observed in AD patients remain to be investigated.
1.6 The need for a new model
The BACE1 mouse models described in this thesis have been generated in 
order to examine the effect of increasing or eliminating BACE1 expression in vivo. 
While it is clear that BACE 1 is the key enzyme in the development o f the P-amyloid 
plaques found in Alzheimer’s Disease, other functions may yet be revealed. Research 
investigating the numerous models o f human APP overexpression has not yielded an 
effective treatment for AD and a comprehensive examination of BACE 1 transgenic 
and knockout mouse models may increase the likelihood o f the discovery of such a
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treatment as well as point towards any potential problems associated with BACE1 
therapeutic agents. By combining these BACE1 models with other transgenic and 
knockout mice, o f both single and compound gene targets, the altered BACE1 
protein expression can be put into context alongside existing models.
The mouse models described in this thesis are those in which altered BACE1 
gene expression is a primary feature o f the mouse model, as with endogenous 
BACE1 expression removed in a so called knockout mouse (BACE1 KO) or where 
an expression cassette has been introduced to express human BACE1 protein in a 
normal mouse genetic background in a so called transgenic mouse (BACE1 Tg). In 
addition to these mouse lines the BACE1 KO mouse line has been crossed with a 
BACE2 KO mouse line to generate a BACE 1/2 double KO mouse line and the 
BACE1 Tg mouse line has been crossed to an APP Tg mouse line, named TAS10 
(275), to form a double transgenic line named B ACT AS. In order to make a 
comparison of increased expression of key enzymes involved in plaque formation, a 
second double transgenic line carrying human APP and PS1 transgenes, named 
TASTPM (276), was included the tests.
1.7 Objectives of Thesis
This thesis sets out to investigate the biology of BACE 1 using in vivo mouse 
models. Therapies that interfere with the activity o f p-secretase may have unknown 
consequences in vivo as the lull extent of the functions o f this enzyme are not clearly 
defined. The focus o f this thesis is on the analyses o f those behavioural phenotypes 
which are most obvious in human AD patients. Investigating the consequence of 
removing or increasing the protein on behaviour in a living organism will enable a 
deeper understanding o f the other functions of BACE 1 and any potential side effects 
of p-secretase therapy may be identified and screened out during the preclinical 
development o f the therapeutic agent.
47
Chapter 2 - <BJLCE1 transgenic 
mice are 6otd and hnochgut 
mice are timid
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2.1 Introduction
Genetically modified mouse lines were generated in which (i) endogenous 
BACE1 was removed to produce a BACE1 knockout (KO) mouse line and (ii) 
human BACE1 was inserted to produce BACE1 transgenic (Tg) mouse lines. In 
addition BACE1 Tg mice were crossed with APP Tg mice to produce the B ACT AS 
double Tg mouse line (dTg). These KO, Tg and respective wild type (wt) control 
mice were subjected to a screening battery of tests designed to examine basic 
differences in their anatomy and behaviour. Consistent with other reports the BACE1 
KO and single Tg mouse lines were viable, fertile and healthy. However some subtle 
differences were seen in basic measures o f physiology and in exploratory behaviour 
in these lines.
Both the Tg and KO mouse lines described in this thesis were generated by 
incorporating a LacZ reporter gene such that endogenous gene expression and 
inserted transgene expression could be easily followed by staining for P- 
galactosidase expression. Once generated the different lines of BACE1 Tg and KO 
mice were bred in numbers sufficient to produce enough animals for the studies. In 
order to investigate the effects o f increasing or removing expression of BACE1 in 
mice the different lines were tested in the SHIRPA protocol. SHIRPA is an acronym 
standing for SmithKline Beecham, Harwell, Imperial College of St. Mary’s, Royal 
Holloway College Phenotype Assessment and was developed by Rogers et al (277). 
This test was selected as it is sensitive to both gross and subtle behavioural deficits in 
mice and has been used routinely to discover novel phenotypes in mice generated 
from random (278) and targeted (279) mutant mouse research programmes.
The SHIRPA protocol includes three levels of behavioural assessment known 
as primary, secondary and tertiary screens. Behavioural data from the primary and 
secondary SHIRPA screens are presented in this chapter and tertiary SHIRPA 
screening behavioural data is presented in chapter 3. The primary SHIRPA screen 
comprises 39 basic measures to provide a behavioural, neurological and anatomic 
profile o f each mouse. The secondary SHIRPA screen consists o f four, more 
complex, tests which are; the Rotarod Assessment o f Sensorimotor Deficits in which 
balance and co-ordination are tested; the Spontaneous Locomotor Activity (LMA) 
test which records the movement o f each mouse in a home cage; the Holeboard Test 
o f Exploratory Behaviour which records the number o f times each mouse places its
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head in one of 12 holes and the Hotplate Test of Thermal Nociception in which 
sensitivity to thermal pain is recorded.
2.2 Materials & Methods
2.2.1 Generation of mouse models
Manipulations o f the BACE1 gene to generate the mouse models are detailed 
in appendix 7.1. In brief BACE1 KO mice were generated by replacing Exon 1 of the 
endogenous BACE1 locus with a LacZ reporter gene in a DNA targeting vector. This 
vector was then introduced into 129Sv Embryonic Stem (ES) cells by 
electroporation. The cloned DNA integrated with the ES cell genome by homologous 
recombination and positive recombination events were selected for with positive 
selectable markers. ES cells carrying the correctly integrated engineered murine 
genomic DNA were introduced into the blastocoel of 3.5 day old C57B1/6J host 
mouse embryos by micro-injection. Those embryos surviving the procedure were 
returned to the uterus of pseudopregnant foster mice and allowed to develop to term. 
The relative contribution o f the genetically engineered ES cell genome to the genome 
of the resultant [C57B1/6 x 12901aSv]hybrid pups was assessed by the proportion of 
light (ES Cell) and dark (host embryo) coat colour. Male offspring with 
approximately a 50:50 split o f coat colour were selected to breed with wt females to 
generate subsequent generations. Mice with a heterozygous deletion of BACE1 were 
bred to wt mice on a C57B1/6 background sub-strain over 5 generation o f breeding to 
generate a KO mouse line on an isogenic C57B1/6J background sub-strain. Finally 
these N6 mice were interbred to generate mice used in subsequent experiments.
BACE1 Tg mice were generated by constructing an expression cassette in 
which human BACE1 cDNA expression is under the control of a calmodulin kinase 
2 promoter (280). An Internal Ribosomal Entry Site (IRES) element was introduced 
down stream of the BACE1 cDNA followed by a LacZ reporter gene. The IRES 
element enabled the generation o f a bicistronic mRNA which is translated to give 2 
protein products (281). Thus the expression of human BACE1 protein in vivo is 
indicated by the blue stain produced when the BACE1 Tg mouse tissue is stained for 
P-galactosidase activity. This expression cassette was micro-injected into the male 
pronucleus of a single-celled C57B1/6 mouse embryo. Embryos surviving the
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procedure were placed into the oviduct coils o f a pseudo-pregnant female mouse via 
the infundibulum and allowed to develop to term. As C57B1/6J donor embryos were 
used the offspring from the recipient host female were all isogenic for the C57B1/6J 
sub-strain. 5 mice carrying the transgene were selected for breeding the N1F1 
generation of mice produced from this breeding were analysed for BACE1 transgene 
expression. Mice with high and low expression levels were selected for further 
breeding to generate the heterozygous BACE1 Tg mice used for experimentation.
2.2.2 BACE1 compound mouse lines
The B ACT AS dTg mice were generated by inter-breeding BACE1 Tg mice 
with an APP Tg mouse line previously established in the laboratory (275). The APP 
mouse used employed the Thyl promoter to drive expression the 695 amino acid 
isoform o f APP carrying the Swedish (A P P k m 67o/67in l )  mutation, hence the 
abbreviation Thyl-APP-Swedish (TAS). Both o f these mouse lines were isogenic for 
the C57B1/6J mouse sub-strain.
TASTPM dTg mice were obtained from a colony previously established 
within GSK (276). These mice were generated by interbreeding the TAS mice with a 
Tg line carrying a M l46V mutant Presenilin 1 gene under the control of the human 
Thyl promoter. The abbreviation is derived from the first transgene components, 
Thyl-Presenilin-Mutant (TPM).
2.23  Behavioural analysis
The SHIRPA screen (277) was used to assess the behavioural phenotype of 
the heterozygous Tg mouse line expressing the human BACE1 transgene on an 
inbred C57B1/6 background and a homozygous BACE1 KO line on a mixed genetic 
background. Each study cohort consisted of 10 male and 10 female Tg or KO 
animals and 10 male and 10 female wild-type littermates. Mice were housed 
individually and maintained under a standard 12-hr light: dark cycle with food and 
water available ad libitum. Testing began when the mice were between 6 and 7 
weeks of age. Similarly the B ACT AS mice were tested in the primary SHIRPA 
screen though the age o f testing was approximately 25 months.
The primary SHIRPA screen recorded 39 basic measurements starting with 
unobtrusive observation of the mice in a viewing jar (Table 2.1) through observation 
in an arena (Table 2.2), above the arena (Table 2.3) and ending with supine restraint
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(Table 2.4). In addition, Rotarod, 30-minute locomotor activity, holeboard 
exploration and the thermal analgesia hotplate tests were included in the secondary 
SHIRPA screen.
SHIRPA -  Primary screen protocol
A full description of the test is detailed by Rogers et al (277) however a brief 
description o f the scoring scales used is provided here to facilitate an overall 
impression of the phenotypes observed. The equipment used and a description of the 
protocol is listed in Appendix 7.2.
Behaviour Recorded in the Viewing Jar.
The animal was placed in the viewing jar for 5 min. This was located on top 
o f a grid which was suspended above a piece of white paper. The following 
behaviours were recorded without disturbing the animal. Incidents o f atypical or 
stereotyped behaviour and convulsions were recorded separately
Table 2.1 Primary SHIPRA Scoring in viewing jar
Score O bserved Behaviour
Body position 0 Completely flat
l Lying on side
2 Lying prone
3 Sitting or standing
4 Rearing on hind legs
5 Repeated vertical leaping
Spontaneous activity 0 None
1 Casual scratch, groom, slow movement
2 Vigorous scratch, groom, moderate movement
3 Vigorous, rapid/dart movement
4 Extremely vigorous, rapid/dart movement
Respiration 0 Gasping, irregular
1 Slow, shallow
2 Normal
3 Hyperventilation
Tremor 0 None
1 Mild
2 Marked
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Behaviour Recorded in the Arena.
A metal plate was inserted under the viewing jar and the animal transferred 
and briskly dropped onto the centre of the floor of the arena without being handled. 
The stop watch was started and the immediate reaction to the new environment was 
recorded.
Table 2.2 Primary SHIRPA Scoring in Arena
Score Observed Behaviour
Transfer arousal 0 Coma
l Prolonged freeze, then slight movement
2 Extended freeze, then moderate movement
3 Brief freeze (few sec), then active movement
4 Momentary freeze, then swift movement
5 No freeze, immediate movement
6 Extremely excited ("manic")
Locomotor activity n Number of squares crossed in 30 seconds
Palprebral closure 0 Eyes wide open
1 1/2 closed
2 Closed
Piloerection 0 None
1 Coat stood on end
Startle response 0 None
(90dB sound from clickbox 1 Preyer reflex (backwards flick of pinnae)
30 cm above arena) 2 Jump <lcm
3 Jump >lcm
Gait 0 Normal
1 Fluid but abnormal
2 Limited movement only
3 Incapacity
Pelvic elevation 0 Markedly flattened
1 Barely touches floor
2 Normal (3mm elevation)
3 Elevated (>3mm elevation)
Tail elevation 0 Dragging
(during forward motion) I Horizontally extended
2 Elevated / Straub tail
Touch-escape 0 No response
(Finger stroke from above) 1 Mild (escape response to firm stroke)
2 Moderate (rapid response to light stroke)
3 Vigorous (escape response to approach)
Positional passivity 0 Struggles when held by tail
(struggle response to 1 Struggles when held by neck (finger grip, not scruffed)
sequential handling) 2 Struggles when laid supine (on back)
3 Struggles when held by hind leg
4 No struggle
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Behaviour Recorded above the Arena
The mice were held above or on the arena either by scruffing or tail 
suspension and the following behaviours recorded.
Table 2.3 Primary SHIRPA Scores on or above the Arena
Score Observed Behaviour
Trunk Curl 0 Absent
l Present
Limb grasping 0 Absent
1 Present
Other (see comments) 0 Absent
1 Present
Visual placing 0 None
(extension o f  forelimbs 1 Upon nose contact
when lowered to wire grid) 2 Upon vibrissae contact
3 Before vibrissae contact (18mm)
4 Early vigorous extension (25mm)
Mouse removed from arena and tail gripped between thumb and forefinger. Mouse was lowered
and allowed to grip the grid then a gentle backwards pull was applied
Grip strength 0 None
(horizontal pull applied 1 Slight grip, semi-effective
To animal on wire grid) 2 Moderate grip, effective
3 Active grip, effective
4 Unusually effective
Body tone 0 Flaccid, no return of cavity to normal
(compress sides o f 1 Slight resistance
animal between thumb 
and index finger)
2 Extreme resistance, board-like
The proximal part o f  the inner canthus was lightly touched with the tip o f  the fine wire probe.
Pinna reflex 0 None
(ear retraction upon 1 Active retraction, moderately brisk flick
light tactile stimulation) 2 Hyperactive, repetitive flick
The cornea was lightly touched with the side o f  the fine wire probe.
Comeal reflex 0 None
(eye-blink response to 1 Active single eye-blink
light tactile stimulation 
with stylet)
2 Multiple eye-blink
Hind limb lifted clear o f  grid and mid digit o f  hind foot gently compressed with fine forceps
Toe pinch 0 None
(gentle compression o f 1 Slight withdrawal
mid- digit o f  hind foot) 2 Moderate withdrawal, not brisk
3 Brisk, rapid withdrawal
4 Very brisk with repeated extension and flexion
Animal held above the wire by tail suspension and lowered to allow the forelimbs to grip the wire
Wire manoeuvre 0 Active grip with hind legs
(animal allowed to hang 1 Difficulty of grasp with hind legs
by forelegs from wire) 2 Unable to grasp with hind legs
3 Unable to lift hind legs, falls within 10 sec
4 Falls immediately
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The mice are scruffed firmly and the following are observed during supine restraint 
Table 2.4 Primary SHIRPA Scores recorded during Supine Restraint
Score O bserved Behaviour
Body weight Grams
Body length (tip o f  nose to 
base o f  tail)
mm
Skin colour 0 Blanched
(colour o f  plantar surface l Pink
and digits o f  forelimbs) 2 Bright, deep red
Heart rate (felt by 0 Slow, bradycardia
palpation below sternum) 1 Normal
2 Fast, tachycardia
Limb tone 0 No resistance
(resistance to gentle and 1 Slight resistance
finger tip pressure on 2 Moderate resistance
plantar surface o f  left 3 Marked resistance
right hind paw) 4 Extreme resistance
Abdominal tone 0 Flaccid, no return of cavity to normal
(palpation o f  abdomen) 1 Slight resistance
2 Extreme resistance, board-like
Lacrimation 0 None
1 Present
A dowel rod was gently inserted between the teeth at the side o f  the mouse's mouth
Salivation 0 None
(area o f  wetness in 1 Slight margin of sub-maxillary area
sub-maxillary area) 2 Wet zone entire sub-maxillary area
Provoked biting 0
1
Absent
Present
Mouse held by the tail and flicked backwards through the air such that it performs a backward
somersault when released. Landing position was observed.
Righting reflex 0 No impairment
(somersaulted onto 1 Lands on side
table by tail) 2 Lands on back
3 Fails to right when placed on back
Mouse placed into a plastic tube and turned upside down
Contact righting reflex 0
1
Absent
Present
Mouse placed on a grid and raised from horizontal to vertical then observed for 30 seconds.
Negative geotaxis 0 Turns and climbs the grid
(placed on grid which is 1 Turns but then freezes
raised to vertical with 2 Moves but fails to turn
animal facing floor) 3 Does not move within 30 sec
4 Falls off
Fear 1 Freezes during transfer arousal
Irritability 1 Struggles during supine restraint
Aggression 1 Provoked biting or attack
Vocalisation 1 Provoked during handling
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Table 2.5 Secondary SHIRPA screen
Behaviour Summary Protocol
Holeboard Test of Exploratory 
Behaviour
Mouse placed in Holeboard Exploration arena and allowed to explore for 10 
minutes. Exploratory behaviour recorded as the number of infrared beam 
breaks by the mouse (each time it placed its head in a hole). There are 12 
holes in the floor in a regularly spaced but asymmetric pattern.
Rotarod Assessment of 
Sensorimotor Deficits
Mouse was placed on the surface of a rotating drum which accelerates from 
4 to 40 rpm over 5 minutes. Each mouse receives 3 trials.
Spontaneous Locomotor Activity 
(LMA) Test
Mouse was placed in a home cage, lined with sawdust only, which was 
placed in the recording apparatus. LMA recorded as the number of infrared 
beam breaks in 30 minutes.
Hotplate Test of Thermal 
Nociception
Mouse was placed on a hot plate analgesia meter set at S0.0°C and was 
enclosed within an annulus of Perspex. Thermal nociception measured as 
the latency to the first sign of nociception, i.e. fanning or licking of paws.
2.2.4 Determination of LacZ expression by f)-galactosidase assay
Perfusion fixed adult brains from both the human BACE1 Tg overexpressing 
mice and from mice heterozygous for the targeted mutation were dissected, 
equilibrated in 30% sucrose, embedded in OCT cryoprotectant (Agar Scientific) and 
frozen. Cryostat sections (20-25pm) were prepared, mounted onto slides and 
incubated for between 1 hour and overnight at 37°C in X-Gal solution containing 1 
mg/ml X-Gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 0.02% 
NP-40, 0.01% sodium deoxycholate and 2 mM MgCh in PBS. After staining, 
sections were washed twice in PBS for 5 min, counterstained in 1% Orange G, rinsed 
in distilled water, dehydrated through a methanol series (50%, 70%, 100%; 5 mins 
each) and then washed in histoclear twice prior to mounting in DPX mounting 
medium.
2.2.5 Western Blot Analyses
Synaptosomes were prepared from mouse brains using the method of Gray 
and Whittaker (282). Samples from 2 KO, 3 Tg and 2 wt control animals were 
analysed by SDS-PAGE. To visualise full length APP 10% Tris-Glycine 
polyacrylamide gels (Novex) were used. Protein was transferred to a nylon 
membrane (Hybond) and probed with an anti-BACEl mouse monoclonal antibody 
(9B21) and HRP-conjugated detection antibody (Amersham). The carboxyterminal 
fragments were separated on a 12% NuPage BisTris gel (Invitrogen) and probed with 
rabbit polyclonal Ab54 which recognises the extreme carboxyterminus of APP. Actin 
was detected using a mouse monoclonal antibody (ICN). Immunoreactive bands 
were detected using ECL (Amersham) and Biomax film (Kodak).
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2.2.6 Statistical Analysis
Throughout this thesis statistical analyses were conducted using Statistica™ 
(StatSoft, Inc). ANOVA was performed to compare the effects of genotype on each 
of the behavioural variables. The differences between individual means were 
assessed with post hoc simultaneous comparisons using the Sheffe test. Where 
appropriate, non-parametric data were analysed according to the variation in the data 
set. Data with no variation were not analysed with a statistical test, data with 
variation in a binomial response were analysed with Fisher’s Exact test, data with 
variation of more than 2 responses in only 1 group were first grouped to give a 
binomial set o f responses and then tested using Fisher’s Exact test and finally data 
that had multiple responses in both groups were tested with the Mann-Whitney U 
procedure.
2.3 Results
2.3.1 Production of Tg and KO mice
Tg mice were successfully generated from the micro-injection o f the 
expression cassette. Two Tg lines had LacZ expression patterns that represented high 
(Line 4) and low (Line 17) levels of BACE1 expression in the mouse brain. 
Subsequent separate breeding programmes crossing these two lines to wt C57B1/6 
mice generated sufficient mice for experimentation. The B ACT AS mice were 
successfully generated by interbreeding the BACE1 Tg mouse line with a line 
overexpressing human mutant A P P swe protein. The BACTAS mice were 
heterozygous for both transgenes and were bred to a background strain essentially 
isogenic for the C57B1/6J sub strain.
Following successful integration of 12901a/Sv embryonic stem cells injected 
into host C57B1/6 blastocysts, BACE1 KO mice of the founder generation mice 
(those bom from injected blastocysts) were produced. Breeding 5 of these male 
founder mice to C57B1/6J wt mice produced offspring, denoted N1 (from the first 
number generation crossed to an isogenic, C57B1/6, mouse strain). These were 
interbred to produce F1N1 (first Filial and first Number backcrossed generation)
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mice with 25% of the resulting offspring carrying homozygous disruption of the 
endogenous BACE1 locus on a [C57Bl/6xl2901a/Sv] hybrid background.
2.3.2 E xpression p a tte rn s  o f LacZ  in Tg and  KO mice
As both the Tg and KO animals were generated using a reporter construct 
design in which the LacZ gene was incorporated into the mouse genome, staining for 
the expression of LacZ enabled the expression of the human calmodulin kinase 2 
promoter driven transgene or the murine BACE1 promoter driven endogenous gene 
to be followed. In the Tg mice p-galactosidase expression is localised to the 
hippocampus, cortex and olfactory bulb with diffuse expression in the caudate 
striatum (Figure 2.1).
Figure 2.1 p-galactosidase expression in BACE1 mouse models
Parasaggital sections of BACE1 Tg and KO mice. BACE1 KO mouse showing P- 
galactosidase expression concentrated in the hippocampus and distributed in cortical 
lamina A). High magnification image of the hippocampus and cortex of a BACE1 
KO animal B). BACE1 Tg mouse brain showing p-galactosidase expression 
localised to the hippocampus and caudate striatum in a low expressing mouse line C) 
and extending to the cortex and caudate putamen in a higher expressing mouse line 
D). Bars in A), C) and D) = 1.5 mm, B) = 0.5 mm.
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The integration o f the targeting construct into the endogenous murine BACE1 
chromosomal locus places the LacZ gene under the control of the BACE1 promoter, 
which makes it possible to visualise tissue expression from the endogenous murine 
BACE1 promoter by monitoring P-galactosidase enzyme activity or 
immunoreactivity. There is significant expression of P-galactosidase through the 
brain o f BACE1 KO mice though it is concentrated in the hippocampus and cortex 
indicating the endogenous expression pattern o f this gene (Figure 2.1 A). Increased 
magnification allows visualisation of a clear laminated expression pattern in the 
cortex (Figure 2 .IB). In mice heterozygous for the targeted mutation, P-galactosidase 
expression is localised to the hippocampus and caudate striatum in the low 
expressing line 17 (Figure 2.1C) and extends to the cortex, olfactory bulb, medulla 
and fore-brain regions in the high expressing line 4 (Figure 2 .ID). Interestingly, there 
is also significant expression in the cerebellum of the KO mice (Figure 2.1 A) and in 
regions of the periphery. This observation is consistent with previously reported 
findings o f widespread expression of BACE1 mRNA (89;90).
2.3.3 Expression of BACE1 in Tg and KO animals
The fact that human and murine BACE1 protein sequences are highly 
homologous (>96% similar) enabled the generation o f a monoclonal antibody, 9B21, 
which recognizes both proteins (283). Synaptosomal fractions (282) from Tg, KO 
and wt animal brains were prepared and the relative amounts of BACE1 protein 
determined.
Analysis of the synaptosomal fractions from two individual KO homozygous 
mice revealed a complete absence of BACE1. In synaptosomal fractions from wt 
brains endogenous murine BACE1 was readily detectable and co-migrates with 
recombinant BACE1 protein isolated from HEK293 cells expressing the human 
BACE1 cDNA (283). The equivalent fraction from 3 separate BACE1 Tg animals 
indicated clear BACE1 over-expression of the human transgene (Figure 2.2A). 
Quantification of the western blot signal using the P-actin signal as loading control 
(Figure 2.2B) indicated that individual animals show BACE1 protein levels 4-10 fold 
greater than the levels of expression of murine BACE1 in wt animals (Figure 2.3). 
Endogenous BACE1 protein in wt mice and human BACE1 expressed in Tg mice 
appeared to be glycosylated to a similar degree, with both proteins migrating as
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broad bands with an apparent MW of 64 kDa. Analysis of the APP cleavage products 
in these same fractions indicates a clear absence of carboxy-terminal fragments 
generated by BACE1 cleavage (CTFP) in the KO mice and the appearance of CTF5 
(148) and elevated levels of the same fragment in Tg mice (Figure 2.4). These 
findings are consistent with previous reports of similar KO and Tg lines 
(257;265;266).
A) jjjJ; _  &MMM t v  f  f  .4____ BACE1
Figure 2.2 Expression of BACE1 protein in Tg and KO mice
A) BACE1 (9B21) immunoreactivity. B) Actin Immunoreactivity.
Immunoblot analysis blot showing immunoreactivity to BACE1 in brain 
extracts from BACE KO, Tg and wild type (wt) mice using monoclonal antibodies 
specific to BACE1 (9B21 in figure 2.2A) or to the housekeeping protein actin (figure 
2.2B).
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Figure 2.3 Densitometric analysis of BACE1 expression
Densitometric analysis of BACE1 immunoreactivity in Tg and KO mice 
normalised against the P-actin housekeeping control for each animal
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Figure 2.4 Immunobot examining the c-terminal APP fragments
Immunoblot analysis with Ab54 to the c-terminus of APP showing the 
carboxyterminal fragments present in brain extracts from BACE KO, Tg and wt 
mice.
2.3.4 P rim ary  SH IR PA  screening of BACE1 Tg and K O  mice
To evaluate the behavioural phenotype of BACE1 Tg and KO animals they 
were assessed in the SHIRPA battery of behavioural tests (277). Significant 
differences in the measures recorded during the primary SHIRPA behavioural 
characterisation of BACE 1 KO and Tg mice are listed below (for detailed results of 
all the tests see appendices 7.3 and 7.4) .The KO and two Tg mouse lines failed to 
show any significant differences in motor function as measured by either a Rotarod 
test of motor co-ordination or a 30 minute test of locomotor activity. As such, it can 
be concluded that altered motor function was not responsible for the changes 
observed between in the mouse lines.
Measure Units Knockout Transgenic Line 17 Transgenic Line 4
KO wt % Diff. P Tg wt % Diff. P Tg wt % Diff. P
Faeces number 5.9 3.95 49.4% 0.02 3.45 3.05 13.1% 0.42 3.2 3.65 -12.3% 0.42
Arena Activity squarescrossed 16.05 14.35 11.8% 0.56 22.5 22.4 0.4% 0.95 17.9 22.9 -21.8% <0.01
Wire
Manoeuvre righting ability 0.5 (0-1) 2(1-2)
- <0.01 0 (0-0.5) 0(0-1) - 0.3 0(0-1) 0(0-0) - 0.29
Limb Tone resistance 2(1-2). 2 (2-21 - 0.051 2 (2-2) 2(2-2) - 0.82 2 (2-2) 2 (2-2) - 0.79
Provoked
Biting intensity 0(0-0) 0(0-0) - 1 0(0-1) 0 (0-0.5) - 0.28 1 (0-1) 0 (0-0.5) - 0.058
Hoie board 
Exploration
number of 
visits 37.1 58 -36.0% 0.048 42.6 46.7 -8.8% 0.59 78.3 59.8 30.9% 0.052
Table 2.6 Significant differences found during prim ary SHIRPA
Data are represented as mean with percent change from wt control for parametric 
measures or median with interquartile range for non-parametric measures. P-value 
calculated using 1-way ANOVA or Mann-Whitney U test as appropriate. Results are 
collapsed for gender. N = 20.
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2.3.4.1 Faecal Production
While in the viewing jar BACE1 KO mice were recorded as having 
significantly increased faecal pellets production when compared to wt controls 
during the 5 minutes of observation. No such significant differences were seen for 
the BACE1 Tg mouse lines.
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Figure 2.5 Faecal production in BACE1 KO mice
Bars represent mean +/- SEM. * p < 0.05
Analysis of data from the BACE1 KO mice revealed a significant effect of 
gender F(l,36) = 4.54, p = 0.04 and genotype F(l,36) = 6.34, p = 0.02 on faecal 
production with the KO mice producing 49% more faeces than controls mice during 
a 5-minute observation period (Figure 2.5). No significant interaction between 
gender and genotype was observed F(l,36) = 0.94, p = 0.34. No significant effect of 
gender or genotype was seen on this measure for the high (line 4) or low (line 17) 
expression BACE1 Tg mice.
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2.3.4.2 Arena Activity
While in the arena BACE1 Tg line 4 mice crossed fewer squares than wt 
littermates controls during the 30 seconds of observation. No such significant 
differences were seen for the BACE1 Tg line 17 or BACE1 KO mouse lines.
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Figure 2.6 Arena Activity of BACE1 Line 4 Tg mice
Bars represent mean +/- SEM. * p < 0.05
BACE1 Tg line 4 mice were significantly different from wt controls F(l,36) 
= 10.9; p = 0.002 with Tg mice crossing 22% fewer squares in the 30 second 
recording period (Table 2.6). No significant effect of gender or interaction between 
gender and genotype was observed in Tg line 4 and no significant effect of gender or 
genotype was seen for the BACE1 KO or low (line 17) expression BACE1 Tg mouse 
lines.
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2.3.4.3 Wire Manoeuvre
The wire manoeuvre test examines hind limb strength and coordination. 
While observed above arena BACE1 KO mice performed well in this test suggesting 
that they had improved muscle strength and/or co-ordination over wt controls. No 
such significant differences were seen for the either BACE1 Tg mouse line.
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Figure 2.7 BACE1KO mice wire manoeuvre
Key: □ Median □  25%-75% X.Min-Max. * p < 0.05
BACE1 KO mice were significantly different from wt controls p = 0.007 with 
KO mice having a median score of 0.5 compared to a wt littermate control mice a 
median score of 2. This result indicated the BACE1 KO mice had an improved 
righting ability in a wire manoeuvre test (Figure 2.7). No significant effect of gender 
was observed in KO mice and no significant effect of gender or genotype was seen 
for the BACE1 Tg line 17 or line 4 mouse lines.
* *
□
KO WT
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2.3.4.4 Limb Tone
While held in supine restraint above the arena the mice were assessed for 
differences in limb tone. This measure gives an overall indication of the muscle 
strength in a limb. Several of the BACE1 KO had a reduced limb tone compared to 
wt controls suggesting weaker limb muscles in these mice. No such differences were 
seen for the BACE1 Tg line 17 or line 4 mouse lines.
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Figure 2.8 BACE1 KO mice limb tone
Key: □ Median □  25%-75% I  Min-Max
BACE1 KO mice were almost significantly different from wt controls p = 
0.051 with KO mice and wt littermate controls having a median score of 2 but KO 
mice having a lower interquartile range (1-2) than controls (2-2). A score of 2 
indicates moderate resistance to gentle finger tip pressure on a hind paw for both 
lines of mice but the range of responses of the BACE1 KO mice included mice with 
slight as well as moderate resistance (Figure 2.8). No significant effect of gender was 
observed in KO mice and no significant effect of gender or genotype was seen for the 
BACE1 Tg line 17 or line 4 mouse lines.
L r
KO WT
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2.3.4.5 Provoked Biting
While held in supine restraint above the arena the mice were provoked into 
biting the end of a plastic rod by placing the rod close to their mouth. Their response 
to this provocation was recorded and BACE1 Tg line 4 mice were found to bite the 
rod more readily than wt controls indicating that these mice were more ready to 
respond with aggression when provoked. No such significant differences were seen 
for the BACE1 Tg line 17 or BACE1 KO mouse lines.
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Figure 2.9 B A C ElTg line 4 mice provoked biting
Key: □ Median I I 25%-75% X  Min-Max
BACE1 Tg line 4 mice were almost significantly different from wt control 
mice p = 0.058 with Tg mice having a median score of 1 compared to a control score 
of 0. These data indicate that the Tg Line 4 had biting response present when 
provoked whereas the wt controls did not (Figure 2.9). No significant effect of 
gender was observed in Tg line 4 and no significant effect of gender or genotype was 
seen for the BACE1 KO or low (line 17) expression BACE1 Tg mouse lines.
W T TG
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2.3.4.6 Holeboard Exploration
When allowed to explore an arena with holes in the floor placed at irregular 
intervals for 10 minutes, BACE1 KO mice explored significantly fewer holes than wt 
controls and BACE1 Tg Line 4 mice explored more holes than wt controls though 
this measure just failed to reach significance. No such significant differences were 
seen for the BACE1 Tg line 17 mouse line. Differences in exploratory behaviour 
reflect the inquisitive nature of the mice and can be linked to differences in anxiety. 
The holeboard exploration data suggest that BACE1 KO mice are more anxious and 
avoid unknown spaces and BACE1 Tg mice are less anxious, actively investigating 
unknown spaces.
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Figure 2.10 BACE1 KO mouse number of visits during holeboard exploration
Mean +/- SEM * p < 0.05
BACE1 KO mice were significantly different from wt controls F(l,32) = 
4.24, p = 0.048 with the KO mice examining 33% fewer holes during 10 minutes of 
holeboard exploration (Figure 2.10). No significant interaction between gender and 
genotype was observed F(l,32) = 1.37, p = 0.25 and no significant effect of gender 
was seen F(l,32) = 1.76, p = 0.19.
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Figure 2.11 BACE1 Tg line 4 mice holeboard exploration number of hole visits
Mean +/- SEM
BACE1 Tg line 4 mice were different from wt controls with Tg line 4 mice 
visiting 30% more holes in 10 minutes of holeboard exploration although this 
measures just failed to reach statistical significance F(l,36) = 4.05; p = 0.052 (Figure 
2.11). No significant effect of gender F(l,36) = 0.04; p = 0.87 or interaction between 
gender and genotype F(l,36) = 0.23; p = 0.64 was observed in Tg line 4 and no 
significant effect of gender or genotype was seen for the BACE1 Tg line 17.
2.3.4.7 Body Weight
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Figure 2.12 Weight of BACE1 Tg Line 4 mice
Mean +/- SEM * p < 0.05, *** p < 0.001
Analysis of the weight of BACE 1 Line 4 Tg mice revealed a significant effect 
of gender F(l,36) = 115.89; p < 0.001 and genotype F(l,36) = 5.58; p = 0.024 with
68
males weighing approximately 24% more than females as expected and Tg mice 
4.5% less than wt controls (Figure 2.12). No gender x genotype interaction was seen.
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Figure 2.13 Summary of differences in prim ary SHIRPA measures
N = 20. Mean values. Comparison is to respective wild type controls.
A histogram showing percentage differences relative to controls for the 
number of faecal pellets produced, arena activity, hole-board exploration and weight 
of KO, Tg Line 4 (high), Line 17 (Low) Tg mouse lines is shown in figure 2.13. 
Clear and contrasting relationships between the measures of faecal production, arena 
activity and holeboard exploration can be seen in the different mouse lines. The 
faecal production and arena activity are higher in BACE1 KO mice compared to wt 
controls and are lower in BACE1 Tg line 4 mice than respective wt controls. The 
result is reversed for the holeboard exploration measure which is decreased in KO 
mice and elevated in Tg line 4 mice. The low expressing BACE1 line 17 mouse line 
represents an intermediate phenotype between the KO and high expressing line 4 
mouse lines.
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2.3.5 P rim ary  SH IRPA  screening of BACTAS double Tg mice
In order to evaluate the behavioural phenotype of the BACTAS double Tg 
animals they were similarly assessed in the SHIRPA battery of behavioural tests. 
Significant differences in the measures recorded during the primary SHIRPA 
behavioural characterisation of these mice are listed below (for detailed results of all 
the tests see appendix 7.6). The SHIRPA data recorded are representative of 15 dTg 
and 20 wt control animals.
2.3.5.1 Trem or
While in the viewing jar BACTAS double Tg mice were recorded as having 
significantly increased incidence of tremor when compared to wt controls during the 
5 minutes of observation.
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Figure 2.14 Incidence of Trem or in BACTAS mice
Key: □ Median □  25%-75% I  Min-Max. * p < 0.05
Analysis of Tremor in BACTAS mice revealed no significant effect of 
gender, p = 0.12, but did reveal an effect of genotype, p = 0.001 (Figure 2.14) with 
BACTAS double Tg mice having a median score of 1 with an interquartile range of 
(1-1) and wt littermate control mice a median score of 0 with an interquartile range 
of (0-0.5) indicating the Tg mice had a mild tremor but controls did not.
Tg wt
70
2.3.5.2 Arena Activity
While in the arena BACTAS dTg mice were more active than wt littermate 
controls during the 30 seconds of observation.
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Figure 2.15 Arena Activity of BACTAS mice
Mean +/- SEM. * p < 0.05
BACTAS double Tg mice were more active in the arena with a significant 
effect of genotype F(1,31) = 4.82, p = 0.036 but no significant effect of gender 
F(1,31) = 0.66, p = 0.42. BACTAS mice crossing 65% more squares than wt controls 
(Figure 2.15). An interaction between gender and genotype was not seen F(1,31) <
0.001, p =  1.00.
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Provoked Biting
While held in supine restraint above the arena the mice were provoked to bite 
a plastic rod held close to the mouth. The BACTAS dTg mice were found to be less 
likely to bite when provoked when compared to wt controls indicating that the mice 
were less likely to react with aggression when provoked.
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Figure 2.16 Provoked Biting of BACTAS mice
Key: □ Median □  25%-75% I  Min-Max. *** p <0.001
When provoked to bite a plastic rod a significant effect of genotype, p < 
0.001, but no significant effect of gender, p = 0.64 was seen (Figure 2.16). BACTAS 
mice had a median score of 0 with an interquartile range of (0-1) and wt littermate 
control mice a median score of 1 with an interquartile range of (1-1).
* * *
Tg wt
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2.3.5.3 Aggression
While held in supine restraint above the arena B ACT AS double Tg mice had 
a reduced incidence of aggressive responses than wt controls. These data are in 
agreement with the provoked biting data showing an overall reduced aggressive 
phenotype in these mice.
l
w2ou
C/3
0
Figure 2.17 Aggression of BACTAS mice
Key: □ Median IZU 25%-75% I  Min-Max. ** p < 0.01
Analysis of the recorded incidences of spontaneous aggression in revealed no 
significant effect of gender, p = 0.77 but a significant effect of genotype, p < 0.002 
(Figure 2.17) with BACTAS dTg mice having a median score of 0 with an 
interquartile range of (0-1) and wt littermate control mice a median score of 1 with 
an interquartile range of (1-1).
Tg wt
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2.3.5.4 Body weight and length
BACTAS dTg mice were lighter and shorter than wt controls. Interestingly 
no overall difference in weight was seen between male and female mice though 
female BACTAS dTg mice were lighter than female wt controls. No difference was 
seen in the body length of female BACTAS dTg mice compared to female controls.
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Figure 2.18 Weight of BACTAS mice
Mean +/- SEM *** p < 0.001
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Analysis of body weight revealed no significant effect of gender F(l,31) = 
0.83, p = 0.37 but a significant effect of genotype F(l,31) = 13.3, p = 0.001 with the 
Tg mice weighing 15.7% less than wt controls (Figure 2.18). An interaction between 
gender and genotype was observed F(1,31) = 5.45 p = 0.026 and in a planned 
comparison of body weight a significant effect of genotype was seen in the female 
mice F(1,31) = 14.9, p = 0.001 but not the male mice F(l,31) = 1.08, p = 0.31. 
Female BACTAS dTg mice were 29% lighter than female wt control mice.
* * * * * *
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Figure 2.19 Body Length of BACTAS mice
Mean +/- SEM ** p < 0.01
Tg wt
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Analysis of body length revealed a significant effect of gender F(l,31) = 15.7, 
p < 0.001 and genotype F(l,31) = 12.6, p = 0.001 with the BACTAS dTg mice 
measuring an average 3.3mm (3.4%) shorter than wt controls and female mice 
measuring 3.9mm (4.1%) shorter than male mice (Figure 2.19). There was no 
interaction between gender and genotype F(1,31) = 0.77, p = 0.39.
2.4 Discussion
In this chapter data resulting from a basic behavioural characterisation of two 
BACE1 Tg mouse lines, one BACE1 KO mouse line and a double Tg mouse line 
carrying BACE1 and APP transgenes (BACTAS dTg) have been reported. In the 
BACE1 Tg and KO mouse lines a LacZ reporter gene was incorporated into the 
locus (figure 2.1). This enabled the expression pattern o f endogenous BACE1 to be 
assessed and hence the selection of mice expressing the human BACEl-LacZ 
transgene in an expression pattern similar to that driven by the endogenous murine 
BACE1 promoter. This strategy allowed the comparison of the phenotype of these 
animals in the knowledge that transgene expression reflected endogenous murine 
BACE1 gene tissue distribution and relative levels of expression. The possibility that 
the phenotypic changes reported here are related to the expression of the LacZ 
reporter gene can be discounted since both the KO and Tg mouse lines express LacZ 
yet have contrasting phenotypes. Furthermore, other mouse lines expressing the 
LacZ ubiquitously through endogenous murine promoters do not show similar 
phenotypes to those reported here (284;285). The high levels o f transgene expression 
seen in hippocampus and neocortex parallels both the expression of APP in mice and 
the distribution profile of amyloid plaques in the brains o f AD patients (139). Thus 
BACE1 expression in the Tg mice has been successfully targeted to those tissues 
which are closely associated with AD in humans.
In the BACTAS dTg mouse line, expression o f the human A P Pkm 67o/67in l  
mutant transgene is driven by the Thyl promoter. This promoter has an expression 
pattern that overlaps with the distribution profile o f amyloid plaques in the brains of 
AD patients. The combination of the Thyl promoter and calmodulin kinase 2 
promoter used in the BACTAS dTg mouse model allowed expression of human 
BACE1 and APP proteins in the same mouse brain regions as those that develop
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plaques in human AD patients. The TASTPM mouse line previously published has 
both Presenilin 1 ( P S 1m i46v )  and A P P k m 67o/67in l transgenes under control of the 
Thyl promoter. The expression pattern of these transgenes leads to the generation of 
amyloid plaques the brains of these mice that parallels the distribution profile of 
amyloid plaques seen in AD patients (276).
The Tg mouse line overexpressing BACE1 and the KO mouse line lacking 
BACE1 were on different background strains of mice ([C57Bl/6xCBA] hybrid and 
[C57Bl/6xl2901a/Sv] hybrid respectively). Thus a direct comparison between these 
two lines of mice may be confused by differences in background strain. To eliminate 
this possibility in each analysis the genetically modified line was compared with the 
corresponding wt littermate mice as control animals. As littermate animals are of the 
identical respective background strain the effects seen are due to the genetic 
manipulations alone. The BACTAS double Tg mouse line was on a congenic 
C57B1/6J mouse background strain and was also compared to wt littermate control 
mice. The BACE1 mouse lines were tested in the SHIRPA screen at sexual maturity 
and the BACTAS mouse line was tested at a time point when a considerable amount 
o f amyloid plaque deposition was expected to be present as seen in TAS10 single Tg 
mice (275).
Behavioural characterisation of these animals using the battery of tests 
SHIRPA screen revealed that both BACE1 KO and BACE1 Tg mice were generally 
normal with most measures unchanged when compared to wt controls. Five of the 
thirty nine primary SHIRPA test, and one secondary SHIRPA test were significantly 
different from wt controls. One o f the primary SHIRPA differences related to body 
weight, one to arena activity and two related to limb function. The slightly lower 
body weight and reduced activity in the test arena o f the BACE1 Tg mice plus the 
slightly firmer limb tone and improved behaviour of the BACE1 KO mice in the wire 
manoeuvre test did not affect overall locomotion of either line. These behavioural 
differences did not stem from any differences in background strain since the 
behaviour o f controls in each case was clearly distinguishable from, and intermediate 
to, the behaviour observed in the genetically modified animals. Interestingly the 
BACE1 Tg mouse line with a low expression of reporter protein (Line 17) did not 
have any behaviour that was significantly different from its respective wt controls in 
any of the primary and secondary SHIRPA measures recorded. Indeed the mouse line 
represented an intermediate phenotype for many of the significantly altered
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behaviours between the high expressing Tg line and the KO mouse line. Increased 
faecal production, seen in the KO mice, has been reported to correlate with increased 
emotion and anxiety (286). Furthermore, the decreased exploratory activity of the 
BACE1 KO mice in the holeboard test is also suggestive of an anxious behavioural 
phenotype. In contrast to these findings, the Tg BACE1 mice displayed a less 
anxious behaviour in the holeboard test with significantly more exploration. This 
behaviour is typical of that seen following administration o f anxiolytic drugs to wt 
mice (287). Overall, the BACE1 KO and higher expressing BACE1 Tg mice present 
broadly opposite phenotypes with respect to faecal pellet number and holeboard 
activity. These results indicate a bold, more exploratory behaviour in the BACE1 Tg 
animals with a higher level o f BACE1 expression and a timid, less exploratory 
behaviour in the BACE1 KO animals compared to controls.
The BACTAS dTg mice were lighter than wt controls overall and a gender 
specific difference in weight was seen with dTg females being 29% lighter than wt 
females. Interestingly the dTg mice were shorter than wt control mice and females 
were shorter than males though this did not have a significant effect on their weight. 
The increased arena activity and tremor shown by the BACTAS dTg mice is 
indicative of a poor state of health compared to wt control mice. This may also be 
reflected in the reduced likelihood of biting when provoked and the reduced 
aggression shown by the BACTAS mice. These mice were well advanced in plaque 
pathology and it is possible that they had started to exhibit some of the phenotypes of 
increased locomotion (288) and passivity (289) sometimes seen in AD patients.
These data indicate altered levels of anxiety in BACE1 KO and Tg mice, 
hence the behaviour of these mice was investigated in tests sensitive to altered 
anxiety. In addition, as BACE1 is a key enzyme in the development of 
neuropathological lesions that contribute to cognitive decline in AD, the response of 
these lines of mice was investigated in tests sensitive to impaired cognition. The 
results o f these investigations are described in chapter 3.
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3.1 Introduction
The measurements taken during the basic characterisation of these mice were 
all related to physical parameters such as weight, responses to physical stimuli such 
as the hotplate response, or measurements of basic locomotor function such as the 
Rotarod test. The organ affected in Alzheimer’s Disease is the brain, in particular the 
higher level brain functions. This chapter deals with behaviours that include elements 
of higher level CNS processing. These are tests of anxiety and cognition.
3.1.1 Anxiety
Anxiety is an important component of the behaviour of individuals with 
memory deficits and symptoms o f anxiety are commonly exhibited by AD patients 
(290;291). Similarly, altered anxiety can influence the results of cognition in rodents. 
During the basic characterisation of the BACE1 mouse models a number o f results 
indicated altered anxiety. These data suggested that formal testing of anxiety in 
controlled conditions would provide relevant, useful information about the 
phenotype of these mice.
BACE1 transgenic (Tg) and knockout (KO) mouse lines were examined for 
anxiety in the elevated plus maze and the open field Test. These comprise part of the 
tertiary SHIRPA screen.
The open field test is a non conflict model o f emotionality and anxiety and 
was originally described as a test for emotionality in rats (292). Each mouse is placed 
in the centre of a circular arena and the movement recorded using a video tracking 
system. Emotionality is determined by level of activity and the proportion of time 
each mouse spends in the aversive inner zone o f the arena. The Elevated Plus maze is 
a non-conflict animal model of anxiety, which reflects anxiety through the 
manipulation of natural fear and exploratory drive upon exposure to novel stimuli 
(293). The elevated plus maze consists o f an arena with two enclosed arms and two 
open arms. Movement is recorded via a video tracking system. The relative 
movement on open and closed arms is recorded as a measure o f anxiety. Both tests 
are popular procedures in animal psychology (294).
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3.1.2 Cognition
The formation and storage of memory is poorly understood however a 
number of key events and experiments have revealed the central role of the 
hippocampus in the processes underlying memory formation and retention. The first 
o f these arose from an accident when a 27 year old Connecticut epilepsy patient, 
H.M., underwent surgery in 1953 to cure his affliction. During surgery a mistake 
with the surgeon’s knife led to complete bisection of H.M.’s hippocampus. After 
recovery from the surgery H.M. found that while his epilepsy had been improved he 
had also developed temporal retrograde amnesia (295). His condition was not 
dissimilar to that found in Alzheimer patients and this unhappy accident implicated a 
role for the hippocampus in memory. In a recent paper Reidel et al reported on the 
results of an experiment where rats were trained to escape a water filled maze over a 
short period of time. These rats then had their hippocampus inactivated and their 
memory of the escape was retested. Those rats with an inactive hippocampus 
behaved as though they had never seen the water filled maze (296). More recently 
still Day and Morris trained rats repeatedly to find a food reward in a sand maze. 
After an extended period of training the hippocampus o f each rat was inactivated and 
its memory tested. These rats had an intact memory of the location of the food 
reward even without an intact hippocampus (297). These experiments support the 
hypothesis that the hippocampus is required for short-term memory formation but 
that once formed, this memory is consolidated and stored in another location, 
currently thought to be the pre-frontal cortex. These experiments also support the 
observations of memory decline seen in AD patients.
The BACE1 mouse models have changes in the levels of BACE1, an enzyme 
involved in the processing of APP and known to be involved in the formation of fl­
amy loid peptides that are the major component o f the amyloid plaques found in the 
brains of Alzheimer’s Disease patients (265). As AD patients have changes in 
learning and memory performance it was prudent to measure these abilities in the 
BACE1 mouse models. Data from the primary SHIRPA screen indicated altered 
anxiety in the BACE1 mice and so they were tested for cognition in tests that include 
different levels of stress. Animals were first examined in the object recognition test 
as this had the lowest level of stress and were subsequently examined in the fear 
conditioning test as this has a higher stress component. The object recognition (298) 
test is dependent on intact peri-rhinal and post-rhinal cortices (299) whereas the
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neuronal substrates involved in fear conditioning are amygdala (cued memory) and 
hippocampus (contextual memory) (300). In addition the double Tg mouse models 
carrying BACE1 or PS1 with APP transgenes were assessed in the Morris watermaze 
test adapted for mice in order to examine their spatial working memory (301).
3.2 Materials and Methods
3.2.1 Animals
The BACE1 single (Tg) and double transgenic (dTg) mouse models 
described in this chapter were generated as described in chapter 2. The BACE1 KO 
and control mice were generated from independent breeding programmes derived 
from identified homozygous KO and wt littermate control mice then interbreeding 
homozygotes together and wt littermates together to establish 2 lines of mice with 
almost identical genetic background strains but not true littermates (i.e. KO and wt 
mice from the same single generation of breeding).
Anxiety testing was carried out on the same BACE1 KO and Tg mice 
described in chapter 2 at an age of approximately 4 months and with an N = 10 for 
each sex and genotype. BACE1 KO and Tg mice from a subsequent breeding effort 
were tested at an age when differences in cognition have been recorded in mouse 
models o f amyloid deposition (302-304). The object recognition tests were carried 
out when the BACE1 mice were aged approximately 8 - 9  (KO) and 11 - 12 (Tg) 
months and the fear conditioning tests were carried out when the mice were aged 
approximately 1 2 - 1 3  (KO) and 1 5 - 1 6  (Tg) months o f age. For both tests, N = 9 
male, 9 female KO; N = 12 male, 11 female wt controls and N = 11 male, 12 female 
Tg; N = 13 male, 13 female wt controls.
The Amyloid Precursor Protein (APP) is cleaved by 3 enzymes, y-, a - and p- 
secretase. Cleavage by y- and P-secretases lead to the production o f P-amyloid and 
the rate limiting step in this process is thought to be P-secretase cleavage of APP 
(90). In order to compare the effects of increasing P-amyloid production with these 
two enzymes dTg lines that over-express P-secretase with APP (BACTAS) or a 
component of the y-secretase complex (Presenilin 1) with APP (TASTPM) were 
generated by interbreeding the parental mouse strains. The watermaze tests were 
carried out when the BACTAS and TASTPM dTg mice and wt controls were
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approximately 9-10 months of age. For BACTAS dTg mice N = 8 male, 7 female 
dTg; N = 8 male, 7 female wt and for TASTPM dTg mice, N = 7 male, 8 female 
dTg; N = 7 male, 8 female wt.
3.2.2 Anxiety
Anxiety was tested using the open field test of emotionality and the elevated 
plus maze test of anxiety. Each of these tests relies on the innate behaviours o f the 
mouse. The natural inquisitive nature o f the mouse is balanced by a natural fear of 
open, exposed spaces.
3.2.2.1 Open field test of emotionality
This test required the mouse to be placed in the centre of a circular arena 50 
cm in diameter with walls 35 cm high. The arena was made of white Perspex and lit 
from above with white light. This created an environment that can be divided into
two zones, a more aversive inner 
zone, where the mouse is most 
fearful, and a less aversive outer 
zone where the mouse can walk 
near the wall of the arena. Each 
mouse was placed in the centre 
of the arena and allowed to 
explore for 10 minutes. During 
this time the movement o f the 
mice was monitored by a video camera and recorded by a video cassette recorder. 
The camera was linked to a personal computer and all of the movement tracked and 
analysed using a video tracking system. In between each animal the arena was 
cleaned with 70% ethanol.
50 cm
Inner Zone Outer Zone
35 cm
25 cm
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3.2.2.2 Elevated plus maze test of anxiety
The test used an arena made from black Perspex in the shape of a plus. This 
had arms that are 30 cm long and 5 cm wide. Two opposing arms were enclosed with
walls 15 cm high and the other two opposing arms 
were left open. The four arms were raised 50 cm 
above the floor and illuminated with red light. Each 
animal was left to explore the maze for 5 minutes. 
During this test the movement of the mice was 
monitored by a video camera and recorded by a 
video cassette recorder. The camera was linked to a 
personal computer and all of the movement tracked 
and analysed using video tracking software. In between each animal the arena was 
cleaned with 70% alcohol.
3.2.3 Cognition
The Morris watermaze, object recognition and fear conditioning test were 
used to test cognition in the different mouse models. These tests differ in execution 
but, depending on the protocol used, they examine the function of the hippocampus, 
rhinal cortices and amygdala.
3.2.3.1 Object recognition
The object recognition test utilises the natural propensity of rodents to
investigate unfamiliar objects. Mice were allowed to habituate to a plain black
Perspex circular arena, 50 cm in diameter with 35 
cm high walls, with no objects in it for 30 minutes
on day 1. The arena was cleaned with 70% alcohol 
between each habituation. The following day the 
mice were placed, one at a time, into the arena and 
allowed to explore a white, Perspex cylinder, 2.5 
cm in height and 2.5 cm in diameter, designated as 
the familiar object, for 10 minutes. 3 hours later 
the mice were placed into the same arena for 10 
minutes and exposed to the familiar white cylinder and a novel object, a black 
Perspex cube with 1 cm sides. Object investigation was deemed to be when the head
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of the mouse was pointing at the object and the nose was less than 1 cm from the 
object. The time spent investigating each object was recorded and an index of 
novelty preference calculated. Mice that remembered the familiar object after a delay 
of 3 hours were considered to have an unimpaired memory spending significantly 
more time investigating the novel object than the familiar object.
3.2.3.2 Fear conditioning
Mice were exposed to a fear conditioning test chamber (TSE Systems GmbH, 
Germany) approximately 19 cm x 35 cm x 20 cm in height, width and depth. This 
chamber consisted of a clear Perspex box with 4 walls and a lid. The floor of the 
chamber comprised metal bars, 4 mm in diameter and 8.9 mm apart. Surrounding the
box were two levels of 
motion sensors that 
recorded the horizontal 
and vertical movement 
of the mice. In addition 
a sound source and 
light source were on 
the outside of the chamber but inside a wooden box that surrounded the entire unit. 
The metal grid, motion sensors, light and sound sources were all connected to a 
control box which was connected to a PC. The sequence of sound, light, shock and 
pauses were controlled by software on the PC. Using a combination of the 4 
parameters; shock, light, sound and pause; the mice were trained to associate an 
audible cue with the conditioned stimulus of a foot shock. Subsequently their 
response to the unconditioned stimulus of the housing context and conditioned 
stimulus of auditory cue were measured.
The test protocol for the mice began with a 3 minute habituation to the 
chamber, followed by a 30 second delay and then a 30 second period of an audible 
tone ending in a 2 second, 0.7 mA electric shock to the feet delivered through metal 
grids in the floor of the chamber. This tone & shock pairing was repeated a second 
time. 24 hours later the mice were returned to the chamber for 3 minutes, removed 
while the chamber was cleaned with 70% methanol and context changed (by the 
addition of a paper floor covering, a diagonal divider inserted into the chamber and 
brightening the light) then returned to the chamber in its new context for 3 minutes.
84
Following this period the tone was repeated for 30 seconds. The movement of the 
mice was tracked using infra-red beams inside the chamber and analysed by a 
computer.
3.2.3.3 Watermaze
This test was designed for rats but has been adapted for use in mice and relies
on the mouse’s ability to swim combined with its drive to escape the water. The
maze was 100 cm in diameter by 30 cm deep and was arbitrarily orientated to North, 
South, East and West directions. A white partitioning board placed to the West to 
obscure the contents of the rest of the room. Three orientation cues were used in the
test. A red room door with a backed 
^ 5* ^  “ out window to the North, a large
f
black cross made from a black
laminated A4 sheet of paper to the
West on the white partition wall 
and a hollow square again made 
from a black laminated A4 sheet of 
paper was to East. Four 8-inch wide 
black horizontal stripes were added 
to the shower curtain to South. An 
additional wall designed to prevent mice jumping from the maze once they had 
reached the platform was constructed from laminated sheets of A4 paper. The maze 
was filled with 120 litres of tap water made opaque by the addition of latex solution. 
The temperature of the maze was 26°C +/- 1°C controlled by the addition of hot tap 
water.
The watermaze test consisted of an initial phase of visual cue training over 3 
days with 1 session per day and 4 trials per session. This phase of the test was 
designed to examine the visual acuity and swimming ability of the animals as well as 
to habituate them to the pool and train them to escape the water. Training trials were 
massed where each trial immediately followed the preceding trial with an inter-trial 
interval of approximately 90 seconds. After each session mice were dried with a 
towel and returned to their home-cage The visual cues in the room were excluded 
with a white curtain and the mice placed in the watermaze and trained to swim to a 
visual cue attached to the platform during each trial. After a 2 day delay the
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orientation cues to North, South, East and West were revealed and the mice trained 
to escape the water to a hidden platform over 5 days of visual cue training with 1 
session per day and 4 trials per session. During spatial cue training mice were 
allowed up to 60 seconds to find the platform after which time they were guided to 
the platform by hand. On reaching the platform mice were left on it for 20 seconds 
before removal. Seven days after spatial cue training the memory of the mice was 
tested in a single probe trial. During the probe trial the mice were allowed to swim in 
the pool for 60 seconds with no platform present. After 60 seconds the mouse was 
rescued, dried and returned to its home-cage. After this probe trial mice were 
subjected to one of two further tests. They were either tested for changes in synaptic 
plasticity with one session of re-training followed by 5 trials of reversal training 
where the target platform was reversed and the ability of the mice to learn the new 
platform position tested, or they were tested for extended memory retrieval with a 
second probe trial 7 days after the first.
During the watermaze tests the mice were tracked using a closed circuit TV 
system connected to a VCR and PC. The movement of the mice was analysed using 
software designed for tracking animal movement in the watermaze called ‘Water 
2020’ (www.hvsimage.com).
Statistical analyses were conducted using Statistica™ (StatSoft, Inc). 
ANOVA was performed to compare the effects of genotype on each o f the 
behavioural variables. The differences between individual means were assessed with 
post hoc simultaneous comparisons using the Fisher LSD test.
3.3 Results
3.3.1 Anxiety
A number of significant differences were found in the behaviour o f the mice 
when tested in the open field test of emotionality and elevated plus test of anxiety.
BACE1 Tg mice did not differ from controls in open field activity. Overall 
BACE1 KO mice spent 48.1% less time and travelling 39.2% less distance in the 
inner zone o f an open field indicating an anxious phenotype however this behaviour 
was attributable to male and not female KO mice when compared to the same sex wt 
controls. BACE1 KO mice also covered a greater distance than wt controls though 
this measure failed to reach statistical significance. BACE1 Tg mice spent 26% more
86
time and BACE1 KO mice 16% less time on the open arms of an elevated plus maze 
than controls though these measures failed to reach significance. BACE1 Tg also 
demonstrated significantly fewer stretch attend behaviours than controls while in the 
maze and BACE1 KO mice groomed themselves twice as much as control mice. 
These results suggest opposing phenotypes with BACE1 Tg mice less anxious and 
BACE1 KO mice more anxious than respective controls.
3.3.1.1 Open field test of emotionality
No statistically significant effect of gender or genotype was seen on any 
measure when the Tg mice were tested in an open field, however the KO mice 
demonstrated an anxious phenotype.
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Figure 3.1 Percent Time in inner zone for BACE1 Tg mice
Data are presented by gender or genotype for all test animals. Percent Time in the 
inner zone of an open field. The percentage time in the inner zone is an indication of 
the anxiety level of the mice. Mice with elevated anxiety spend less time in the 
relatively aversive environment of the inner zone. The BACE1 Tg spent less time in 
the inner zone though this measure was not significant (p = 0.67). N = 10 of each sex 
and genotype. Mean +/- SEM
No significant effect of gender or genotype was seen for the percent time 
travelled in the inner zone of the open field (Figure 3.1) [gender F(l,36) = 1.16, p = 
0.29; genotype F(l,36) = 0.17, p = 0.67]. Neither was any effect of gender or 
genotype seen for overall distance travelled in the arena [gender F(l,36) = 0.62, p = 
0.43; genotype F(l,36) = 0.01, p = 0.92]. No gender x genotype interaction was seen 
for any of these measures.
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Figure 3.2 Percent Time in inner zone for BACE1 KO mice
Data are presented by gender or genotype for all test animals. Percent Time in the 
inner zone of an open field. The percentage time in the inner zone is an indication of 
the anxiety level of the mice. Mice with elevated anxiety spend less time in the 
relatively aversive environment of the inner zone. The BACE1 KO spent less time in 
the inner zone (p = 0.004). N = 10 of each gender and genotype. Mean +/- SEM. **p
The BACE1 KO mice spent significantly less time in the inner zone of the 
open field than wt controls F(l,36) = 9.56, p = 0.004 and no overall effect of gender 
was seen F(l,36) = 1.08, p = 0.31 (Figure 3.2). A significant interaction of gender 
and genotype was found F(l,36) = 4.84, p = 0.038 and a planned comparison 
revealed a significant difference in males F(l,36) = 13.8, p = 0.001 but not females 
F(l,36) = 0.44, p = 0.55. No significant effect of gender F(l,36) = 0.08, p = 0.782 or 
genotype F(l,36) = 3.31, p = 0.07 on the distance travelled in the arena was seen and 
no gender x genotype interaction was seen for this measure. Overall the male 
BACE1 KO mice covered a similar distance to wt controls and yet spent 65% less 
time and travelled 58% less distance in the inner zone of an open field. These data 
indicate a sex specific anxiety effect of removing endogenous BACE1 expression in 
these mice.
< 0.01
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3.3.1.2 Elevated plus maze test of anxiety
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Figure 3.3 Elevated Plus maze test of anxiety for BACE1 Tg mice
Data are presented by gender or genotype for all test animals. A). Percent Time on 
the open arms. The percentage time on the open arms of an elevated plus maze is an 
indication of the anxiety level of the mice. Mice with elevated anxiety spend less 
time in the relatively aversive environment of the open arms. The BACE1 Tg spent 
more time on the open arms indicating reduced anxiety though this measure failed to 
reach significance, (p = 0.077). B). Stretch Attend behaviours. Tg mice exhibited 
fewer stretch attend behaviours (p = 0.009) indicating reduced anxiety. N = 10 for 
each gender and genotype. Mean +/- SEM. **p < 0.01
The percent time spent in the Open Arms of the elevated plus maze was 
analysed and no significant effect of gender F(l,36) = 0.23, p = 0.63 or genotype 
F(l,36) = 3.32, p = 0.077 was found for the BACE1 Tg mice (Figure 3.3A). One 
significant difference was found for these mice when the number of "stretch attend"
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behaviours was analysed a significant effect of genotype F(l,36) = 7.69, p = 0.009 
but not gender F(l,36) = 2.29, p = 0.14 was found. No significant gender x genotype 
interaction F(l,35) = 0.06, p = 0.80 was seen for this measure. The BACE1 Tg mice 
exhibited 59.5% fewer "stretch attend" behaviours on the elevated plus maze than 
wild-type littermates (Figure 3.3B). Stretch attend behaviours are characterised by a 
stretching and retracting of the body to investigate a novel environment rather than 
walking directly into it. Stretch attends can be indicative of a more cautious 
behaviour and so a reduced number of stretch attend behaviours suggests a reduced 
anxiety phenotype.
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Figure 3.4 Elevated Plus maze test of anxiety for BACE1 KO mice
Data are presented by gender or genotype for all test animals. A). Percent Time on 
the open arms. The percentage time on the open arms of an elevated plus maze is an 
indication of the anxiety level of the mice. Mice with elevated anxiety spend less 
time in the relatively aversive environment of the open arms. The BACE1 KO spent 
less time on the open arms indicating increased anxiety though this measure failed to 
reach significance, (p = 0.38). B). Grooming behaviour. KO mice demonstrated more 
bouts of grooming (p = 0.03) indicating increased anxiety. N = 10 for each gender 
and genotype. Mean +/- SEM. *p < 0.05
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Analysis of the percent time spent in the open arms of the elevated plus maze 
by the BACE1 KO mice revealed no significant effect of gender F(l,35) < 0.001, p = 
0.99 or genotype F(l,35) = 0.77, p = 0.38 (Figure 3.4A). One significant difference 
was found for these mice when the number of ’’grooming" behaviours was examined 
and a significant effect of genotype F(l,35) = 4.84, p = 0.03 but not gender F(l,35) = 
0.01, p = 0.94 was found. The BACE1 KO mice exhibited over twice as many 
"grooming" behaviours on the elevated plus maze than wild-type littermates (Figure 
3.4B).
While there was no significant difference for either genotype in the time 
spent on the open arms of the elevated plus maze, the BACE1 Tg mice spent 26% 
more time there than wt controls and the BACE1 KO mice spent 16% less time than 
wt controls on the open arms. The decreased stretch attend behaviour shown by the 
BACE1 Tg mice and the increased grooming shown by the BACE1 KO mice 
indicate respective bold and timid phenotypes. The overall behavioural phenotype of 
these mice is suggestive of a timid, more anxious phenotype in the BACE1 KO mice 
which is elevated in the male mice and a bold, less anxious phenotype in the BACE1 
Tg mice.
3.3.2 Cognition
Both BACE1 Tg and KO lines of mice had an overall preference for the 
novel object in object recognition test but no memory deficit was seen in either line 
when compared to wt controls. During fear conditioning BACE1 Tg mice showed no 
impairment in hippocampal or amygdala related memory when compared to wt 
controls. The male BACE1 KO mice alone had impairment in the memory function 
of these regions.
Nine month old BACTAS mice had intact learning and memory with no 
difference in synaptic plasticity when compared to wt littermate control mice in the 
watermaze test. At a similar age, the female, but not male, TASTPM mice had 
impaired learning and a poor memory of the accurate position of the escape platform 
in the watermaze.
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3.3.2.1 Object recognition test
In the object recognition (OR) test the preference for a novel object shown by 
the BACE1 mice was assessed when the mice were allowed to explore an arena 
containing an object and subsequently were exposed to the same arena with the now 
familiar object and a new, novel object. The index of time spent investigating the 
novel and familiar objects was taken as an indication of their recall of the familiar 
object and hence their overall memory function.
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Figure 3.5 Object recognition in Tg mice
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A). Overall object preference. B). Time spent on novel or familiar objects for each 
group. Unimpaired mice spend more time on the novel object than familiar object. 
Overall there was no significant difference between Tg and wt mice (p = 0.29) 
indicating memory recall in the KO mice was intact. C). Index of recognition as an 
alternative measure of memory recall. No significant effect of gender or genotype 
was found. Data are presented by gender or genotype for all test animals. N = 11 M 
Tg, 12FT g, 13M w t, 13F w t controls. Mean +/- SEM. *p < 0.05
Data from the OR test of the BACE1 Tg mice were analysed to reveal a 
significant effect of object F(l,28) = 6.54, p = 0.016 with 33.5% more time spent 
investigating the novel object than the familiar object. No significant effect of gender 
F(l,28) = 0.63, p = 0.43 or genotype F(l,28) = 1.17, p = 0.29 was seen on this 
preference. Analysis of the index of recognition revealed no significant effect of 
gender F(l,28) = 0.21, p = 0.65 or genotype F(l,28) = 1.16, p = 0.29 (Figure 3.5). No 
significant gender x genotype interaction was seen for either measure.
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Figure 3.6 Object recognition of KO mice
A). Overall object preference. B). Time spent on novel or familiar objects for each 
group. Unimpaired mice spend more time on the novel object than familiar object. 
Overall there was no significant difference between KO and wt mice (p = 0.071) 
indicating memory recall in the OK mice was intact. C). Index of recognition as an 
alternative measure of memory recall. No effect of gender or genotype was found. 
Data are presented by gender or genotype for all test animals. N = 9 M KO, 9 F KO, 
12 M wt, 11 F wt controls. Mean +/- SEM. ** p < 0.01
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Data from the BACE1 KO mice was analysed to reveal a significant effect of 
object F(l,24) = 8.69, p = 0.007 with 51.9% more time spent investigating the novel 
object than the familiar. No significant effect of gender F(l,24) < 0.001, p = 0.96 or 
genotype F(l,24) = 3.57, p = 0.07 was seen. An analysis of the index of recognition 
revealed no significant effect of gender F(l,24) = 0.85, p = 0.36 or genotype F(l,24) 
= 0.19, p = 0.66 (Figure 3.6). No significant gender x genotype interaction was seen 
for either measure.
3.3.2.2 Fear conditioning
In a standard test of Pavlovian fear conditioning, the BACE1 mice were 
trained to associate an electric foot shock with an audio cue. They were then assessed 
for contextual and cued memory retention.
The data is presented as the % inactivity of the mice in the chamber. Mice 
that remember the aversive stimulus of the electric foot shock will freeze in 
anticipation of a repetition of the aversive event. This freezing is recorded as % 
inactivity. Mice with an intact memory will have a high level of % inactivity 
indicating increased freezing. In addition the difference between the % inactivity in 
old and new contexts was calculated and termed contextual fear as a measure of 
hippocampal function.
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Figure 3.7 Fear conditioning in Tg mice
A). % Inactivity for each phase by genotype. B). % Inactivity for each phase by 
genotype and gender. C). Index of contextual fear. An effect of gender and genotype 
was seen in % inactivity though not contextual fear. N = 11 M Tg, 12 F Tg, 13 M wt, 
13 F wt controls. Mean +/- SEM. * p < 0.05
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Analysis of the BACE1 Tg mouse data revealed a significant effect of gender 
F(l,47) = 9.37, p = 0.004 and genotype F(l,47) = 5.99, p = 0.018 in the measure of 
% inactivity during habituation to the test chamber. A significant effect of gender 
F(l,47) = 4.51, p = 0.039 but not genotype F(l,47) = 2.88, p = 0.09 and gender 
F(l,47) = 4.37, p = 0.04 but not genotype F(l,47) = 3.67, p = 0.06 was seen during 
the old and new context phases respectively. No significant effect of gender F(l,47) 
= 2.03, p = 0.16 or genotype F(l,47) = 0.18, p = 0.67 was seen during the cued phase 
of the test (Figure 3.7A). No significant gender x genotype interaction was seen in 
these 3 phases of the test. A post-hoc Fisher LSD comparison of the inactivity during 
habituation showed that male Tg mice were significantly more inactive than male wt 
littermate control mice (p = 0.019) (Figure 3.7B). Contextual Fear was analysed and 
no significant effect of gender F(l,47) = 0.09, p = 0.76 or genotype F(l,47) < 0.001, 
p = 0.96 was found (Figure 3.7C).
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Figure 3.8 Fear conditioning in BACE1 KO mice
A). % Inactivity for each phase by genotype. B). % Inactivity for each phase by 
genotype and gender. C). Index of contextual fear by gender and genotype. D). Index 
of contextual fear by group. An effect of gender and genotype was seen in % 
inactivity though not contextual fear. N = 9 M KO, 9 F KO, 12 M wt, 11 F wt 
controls. Mean +/- SEM. *** p < 0.05
Analysis of the data generated from the BACE1 KO mouse fear conditioning 
test revealed no significant effect of gender F(l,42) = 0.07, p = 0.79 or genotype 
F(l,42) = 0.09, p = 0.76 in the measure of inactivity during habituation to the test 
chamber. A significant effect of gender F(l,42) = 17.1, p < 0.001 and genotype 
F(l,42) = 24.1, p < 0.001 with a near significant interaction F(l,42) = 3.84, p = 
0.057 was found during the old context phase (Figure 3.8A) where BACE1 KO mice 
were found to be 29.2% less inactive than wt controls. A planned comparison of the 
inactivity during the old context phase revealed a significant effect of genotype for 
male mice F(l,42) = 22.5, p < 0.001 and female mice F(l,42) = 4.56, p = 0.04. Male 
KO mice were 47% less inactive and female mice 17% less inactive than respective
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wt controls. During the new context phase of the test a significant effect of gender 
F(l,42) = 14.6, p < 0.001 but not genotype F(l,42) = 1.21, p = 0.28 was seen (Figure 
3.8A). Analysis of Contextual Fear revealed a significant effect of genotype F(l,42) 
= 20.4, p < 0.001 but not gender F(l,42) = 1.60, p = 0.21 (Figure 3.8C). A 
significant gender x genotype interaction F(l,42) = 4.57, p = 0.038 was found for 
Contextual Fear. When the Contextual Fear data was examined in a planned 
comparison a significant effect of genotype was found for male mice F(l,42) = 21.2, 
p < 0.001 but not female mice F(l,42) = 2.99, p = 0.09. The contextual fear measure 
for male BACE1 KO mice was 68% less and female mice 27% less than respective 
wt controls (Figure 3.8D). A significant effect of gender F(l,42) = 6.72, p < 0.001 
and genotype F(l,42) = 4.29, p = 0.045 was seen during the cued phase of the test. A 
planned comparison of the percent inactivity during the cued phase of the test 
revealed a significant effect of genotype in males F(l,42) = 5.02, p = 0.03 but not 
females F(l,42) = 0.41, p = 0.52. Male BACE1 KO mice were 18% less inactive and 
thanwt controls.
3.3.2.3 Sensitivity to pain
During the fear conditioning mice were exposed to an electrical shock to the 
foot. The response of the mouse may be confounded by differences in sensitivity to 
pain. The regions of the brain thought to be involved in pain perception include the 
primary and secondary somatosensory cortices and the anterior cingulate cortex 
(305). Though these lines of mice did not show differences in pain sensitivity when 
tested during primary SHIRPA, in order to verify the pain sensitivity in these older 
BACE1 mice they were re-tested for thermal nociception using the Hotplate test. The 
mice were placed on a metal plate heated to 50°C and the latency for them to 
withdraw their paw from the heat was recorded. No differences were seen between 
BACE1 Tg or KO mice and respective wt controls.
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Figure 3.9 Thermal Nociception in BACE1 mice
A). Thermal nociception in BACE1 Tg mice. B). Thermal nociception in BACE1 Tg 
mice. No differences were seen in thermal nociception when compared to wt controls 
for each line of mice. For A) N = 11 M Tg, 12 F Tg, 13 M wt, 13 F wt controls. For
B) N = 9 M KO, 9 F KO, 12 M wt, 11 F wt controls. Mean +/- SEM
In a test of thermal nociception, the latency to respond to the heat stimulus 
was recorded for the BACE1 Tg mice (Figure 3.9A). Analysis of this latency 
revealed no significant effect of gender F(1,21) = 0.32, p = 0.58 or genotype F(l,21) 
= 0.03, p = 0.87. BACE1 KO mice were tested in the same way and no significant 
effect of gender F(l,35) < 0.001, p = 0.96 or genotype F(1,35) = 1.64, p = 0.21 was 
seen in latency to respond (Figure 3.9B). No gender x genotype interaction was seen 
for the either line of mice.
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3.3.2.4 Watermaze Test
In a standard test of spatial reference memory the B ACT AS and TASTPM 
dTg mouse lines were trained to escape a water filled pool by swimming to a 
submerged platform. Their ability to learn the location of the platform and 
subsequent recall o f the platform position were used to assess learning and memory. 
Data from the latency to platform, swimspeed and pathlength to platform are 
presented as there may be a difference in swim speed and hence presenting latency 
data alone, the standard measure of performance in the watermaze, may not 
accurately represent cognitive function. This test relied on the motivation of the mice 
to swim to the platform and escape the water. Some animals exhibited learned 
helplessness during the test and refused to swim. In only one case did this occur to 
such an extent (26 of the 32 training trials reached the maximum 60 second latency) 
that the data from this mouse was excluded from the analyses. The B ACT AS dTg 
mice were tested at 9 months of age and the TASTPM dTg mice at 10 months of age. 
Overall B ACT AS dTg mice were unimpaired and TASTPM dTg mice were impaired 
in cognitive function.
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Figure 3.10 Learning in BACTAS dTg mice during watermaze training
A). Latency to platform B). Swimspeed. C). Pathlength to platform. No differences 
were seen between dTg mice and wt controls. Numbers on x-axis indicate training 
day. N = 8 M dTg, 7 F dTg, 8 M wt, 7 F wt controls. Mean +/- SEM
Data from the visual cue phase of the BACTAS mice watermaze test revealed 
a significant effect of day and trial [F(2,52) = 20.3, p < 0.001 and F(3,78) = 7.55, p < 
0.001 respectively] on latency; pathlength [(2,52) = 26.4, p < 0.001 and F(3,78) = 
5.84, p = 0.001 respectively] and on swimspeed [F(2,52) = 3.41, p = 0.040 and
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F(3,78) = 8.44, p < 0.001 respectively]. Genetic status had no significant effect on 
any of these measures. Thus the mice could see and swim well enough to learn to 
escape the water and their learning improved over the 3 days of visual cue training. 
This learning to escape to a visual cue was unaffected by the presence the of the APP 
& BACE1 transgenes.
During the 5 days of spatial cue training no significant effect of day F(4,104) 
= 1.45, p = 0.22 but an effect of trial F(3,78) = 4.88, p = 0.004 was seen for latency. 
The pathlength and swimspeed data analyses revealed a significant effect of day 
[F(4,104) = 11.5, p < 0.001 and F(4,104) = 6.09, p < 0.001 respectively] and trial 
[F(3,78) = 3.39, p = 0.02 and F(3,78) = 3.06, p = 0.03 respectively]. Genetic status 
had no significant effect on any of these measures [latency F(l,26) = 0.89, p = 0.35 
(Figure 3.10A); pathlength F(l,26) = 0.08 (Figure 3.10B), p = 0.78; swimspeed 
F(l,26) = 0.35, p = 0.56 (Figure 3.10C)]. The reduction in escape pathlength over the 
5 days of visual cue training indicates that the mice learned to escape the maze. The 
presence of APP and BACE1 transgenes had no impact on this learning.
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Figure 3.11 BACTAS dTg mouse memory retention in a probe trial
A). Percent time in quadrant B). Number of platform crossings.. No differences were 
seen between dTg mice and wt controls. N = 8 M dTg, 7 F dTg, 8 M wt, 7 F wt 
controls. Mean +/- SEM.
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When tested for memory retention in a probe trial both the BACTAS and wt 
control mice showed a significant preference for training target quadrant [F(l,26) = 
8.98, p = 0.006 and F(l,26) = 14.7, p = 0.001 respectively] showing the mice had 
remembered the position of the platform that they had been trained to find (Figure 
3.11 A). The memory retention of the mice was also measured by the number of 
times the mouse swam over the position in which the platform used to be (platform 
crossings). This measures the ability of the mice to recall the precise position of the 
target platform and represents a more difficult task for the mice. The BACTAS mice 
and wt controls showed a significant preference for the training target platform 
[F(l,26) = 10.9, p = 0.003 and F(l,26) = 10.7, p < 0.001 respectively] showing they 
had retained an accurate memory of position of the platform that they had been 
trained to find (Figure 3.1 IB). Thus, while the mice remembered how to solve the 
task, addition of human APP and BACE1 transgenes had no effect on this memory 
retention.
As the BACTAS mice did not differ from wt controls in their learning and 
memory they were tested for differences in synaptic plasticity. After testing the 
memory retrieval of these mice they were retrained to the escape the maze from the 
original platform position in a single training trial. There was a significant effect of 
trial on the latency to platform F(3,78) = 7.96, p < 0.001, swimspeed F(3,78) = 13.3, 
p < 0.001 and pathlength to platform F(3,78) = 6.25, p = 0.001 during this retraining 
and showing the mice successfully learned to escape the maze again. Genotype had 
no effect on latency F(l,26) = 0.19, p = 0.67, swimspeed F(l,26) = 0.53, p = 0.47 or 
pathlength F(l,26) = 0.08, p = 0.79 during retraining (Figure 3.10A,B,C). 
Subsequently the mice were tested for their ability to forget this learned platform 
position and re-leam a new platform position as a measure of synaptic plasticity. In 
this test the platform position was reversed to the opposite side of the pool. Analysis 
of the reversal training data revealed a significant effect of trial on the latency to 
platform F(4,104) = 9.83, p < 0.001, swimspeed F(4,104) = 10.3, p < 0.001 and 
pathlength to platform F(4,104) = 7.93, p < 0.001 showing the mice successfully 
learned to escape the maze from the new platform position. Genotype had no effect 
on latency F(l,26) = 2.15, p = 0.154, swimspeed F(l,26) = 1.09, p = 0.31 or 
pathlength F(l,26) = 0.07 p = 0.83 during reversal testing (Figure 3.10A,B,C). Thus, 
having learned and remembered the platform position both the BACTAS dTg mice
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and wt controls showed they could re-leam the platform position and then leam to 
escape the water from a completely new platform position.
A)
Visual Cue Spatial Cue WT
40
to 20
1 2 3 1 2 3 4 5
WT
20
1 2 3 1 2 3 4 5
900
WT
800
700
„  600
5  400
300
200
100
1 2 3 1 2 3 54
Figure 3.12 Learning in TASTPM mice during watermaze training
A). Latency to platform, B). Swimspeed. C). Pathlength to platform. No differences 
wee seen between dTg mice and wt controls. Numbers on x-axis indicate training 
day. N = 7 M dTg, 8 F dTg, 7 M wt, 8 F wt controls. Mean +/- SEM
Data from the visual cue phase of the TASTPM mouse watermaze test 
revealed a significant effect of day F(2,52) = 51.2, p < 0.001 and trial F(3,78) = 12.5,
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p < 0.001 on latency and on pathlength [F(2,52) = 50.7, p < 0.001 and F(3,78) = 12.4 
respectively], but not on swimspeed [F(2,52) = 51.2, p < 0.001 and F(3,78) = 12.5 
respectively]. Genetic status had no significant effect on latency F(l,26) = 0.01, p = 
0.92 (Figure 3.12A) or pathlength F(l,26) = 0.53, p = 0.47 (Figure 3.12B) but there 
was an effect on swimspeed F(l,26) = 5.97, p = 0.02 (Figure 3.12C). Thus the mice 
could see and swim well enough to leam to escape the water. This learning to escape 
to a visual cue was unaffected by the presence the o f the human APP and PS1 
transgenes, though the TASTPM dTg mice did appear to have a slower swimspeed 
during the visual cue phase of the watermaze.
Analysis of the spatial cue phase of the TASTPM mouse watermaze test 
revealed no significant effect of day F(4,104) = 1.85, p = 0.12 or trial F(3,78) = 1.04, 
p = 0.38 on latency. A significant effect o f day F(4,104) = 2.65, p = 0.037 but not 
trial F(3,78) = 0.84, p = 0.48 was seen on pathlength. There was no significant effect 
o f day F(4,104) = 0.36, p = 0.84 or trial F(3,78) = 0.67, p = 0.57 on swimspeed. 
Genetic status did have a significant effect on latency F(l,26) = 12.9, p = 0.001 
(Figure 3.12A) and pathlength F(l,26) = 11.8, p = 0.002 (Figure 3.12B) but no 
significant effect on swimspeed F(l,26) = 0.89, p = 0.35 (Figure 3.12C). Thus 
TASTPM dTg and wt control mice could see and swim well enough to leam to 
escape the water and the TASTPM dTg mice were impaired in their ability to leam 
how to escape the water when compared to wt controls.
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Figure 3.13 TASTPM dTg mouse memory retention during first probe trial
A). Percent time in quadrant B). Number of platform crossings. No differences were 
seen between dTg mice and wt controls. N = 8 M dTg, 7 F dTg, 8 M wt, 7 F wt 
controls. Mean +/- SEM.
In a test of memory retention, analysis of the percent time in the target 
quadrant revealed a significant preference for training target quadrant by the 
TASTPM F(l,25) = 4.25, p = 0.05 and wt control mice F(l,25) = 10.2, p = 0.004 
(Figure 3.13 A) showing the mice had remembered the target quadrant of the platform 
that they had been trained to find. Thus, while the mice remembered how to solve the 
task, addition of human APP and PS 1 transgenes had no effect on this memory. 
Interestingly a 2 factor ANOVA of the percent time spent in target quadrant revealed 
a significant gender x genotype interaction F(l,25) = 4.51, p = 0.04. A planned 
comparison of this data revealed that female TASTPM dTg mice did not show a 
preference for the target quadrant F(l,25) = 1.44, p = 0.42 but female wt littermate 
control mice did F(l,25) = 4.87, p = 0.037.
The memory retention of the mice was also measured by the number of 
platform crossings made during the probe trial. The TASTPM mice did not show a 
significant preference for the training target platform F(l,25) = 2.67, p = 0.12 and the
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wt control mice did F(l,25) = 6.48, p = 0.017 showing the wt controls had retained 
an accurate memory of position of the platform that they had been trained to find but 
the TASTPM dTg mice did not (Figure 3.13B).
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Figure 3.14 TASTPM dTg mouse memory retention during second probe trial
A). Percent time in quadrant B). Number of platform crossings. dTg mice were 
impaired in their memory of the platform position. N = 8 M dTg, 7 F dTg, 8 M wt, 7 
F wt controls. Mean +/- SEM
In the second probe trial test 14 days after the training, the TASTPM dTg and 
wt control mice showed a significant preference for training target quadrant [F(l,25) 
= 12.2, p = 0.002 and F(l,25) = 10.9, p = 0.003 respectively, Figure 3.14A] showing 
the TASTPM dTg and wt control mice had remembered the target quadrant of the 
platform that they had been trained to find. As in the first probe trial a planned 
comparison of the percent time in target quadrant data from female mice revealed 
that female TASTPM dTg mice did not show a preference for the target quadrant 
F(,25) = 2.32, p = 0.14 but female wt littermate control mice did F(,25) = 4.31, p = 
0.048.
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When the number of platform crossings during the probe trial was analysed 
the TASTPM dTg mice did not show a significant preference for training target 
platform F(l,25) = 1.36, p = 0.25 and the wt control mice did F(l,25) = 4.49, p = 
0.04 showing the wt control mice had retained an accurate memory of the position 
of the platform that they had been trained to find but the TASTPM dTg mice did not 
(Figure 3.14B). Thus, while the mice remembered how to solve the task, addition of 
human APP and PS1 transgenes made no difference to broader memory recall in 
male TASTPM dTg mice but did impair this recall in female TASTPM dTg mice and 
impaired accurate memory retrieval in both sexes.
3.4 Discussion
Several changes in the levels of anxiety and cognition were seen in the 
BACE1 Tg and KO mice. An intriguing finding related to the two significant 
changes observed in behavioural tests exploring measures of anxiety. Data from the 
primary SHIRPA screen in chapter 2 indicated that removal of the endogenous 
BACE1 gene caused an elevation of anxiety related behaviours while increasing the 
level of BACE1 by expressing human BACE1 in mice caused a reduction in anxiety 
related behaviours. When these mice were examined in the open field test of 
emotionality and elevated plus maze test of anxiety, tests which rely on the
exploratory drive of the mouse when confronted with an aversive environment,
namely the centre of an open field or the open arms of a plus maze (306), the Tg 
mice were found to be not significantly different from wt controls. They did spend 
26% more time in the open arms of the elevated plus mice and had approximately 
60% fewer incidents of ‘stretch attend’ behaviour, an indicator of increased anxiety. 
These results, in combination those from chapter 2, indicate a reduced anxiety 
phenotype for the Tg mice. In identical tests the BACE1 KO mice travelled almost
40% less distance and spent just under 50% less time in the inner zone of an open
field compared to wt controls indicating an anxious phenotype. These mice also 
exhibited almost double the number of grooming bouts and showed a trend for less 
time on the open arms of the elevated plus maze when compared to wt controls. 
Stress-induced self grooming seen on the elevated plus maze has been shown to be a 
stable behavioural trait marker in rats subjected to acute stress (307). However 
chronic mild stress in rats also leads to a decrease in grooming behaviour over a
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number of weeks (308). The BACE1 KO mice were subjected to an acute test of 
anxiety on the elevated plus maze and the increased incidence of grooming observed 
is indicative of increased anxiety in these mice. Taken together these results indicate 
an increased anxiety phenotype in the BACE1 KO mice. The broad phenotype of the 
two different lines of mice is an increased anxiety with reduced exploration in the 
KO mice and a reduced anxiety with increased exploration in the Tg mice. 
Locomotor deficits can confound these results but the data presented in chapter 2 
showed that both lines of mice have unimpaired locomotion as measured by Rotarod 
and locomotor activity boxes.
The object recognition test investigates memory processing that relies on 
intact function of the peri-rhinal and post-rhinal cortices. While there was an overall 
preference for the novel object over the familiar in the object recognition tests for 
BACE1 Tg and KO mouse lines, genotype or gender had no effect on this 
preference. This test was designed to reveal deficits in memory retention of the 
familiar object and the result indicated no impairment in peri-rhinal or post-rhinal 
cortical memory function for BACE1 Tg or KO mice.
The activity of the mice in the fear conditioning test chamber was used to as a 
correlate of the freezing response, a measure of memory recall of a conditioned 
stimulus in the mice. An investigation of the behaviour of these mice in the fear 
conditioning test revealed that the BACE1 Tg mice were less active during 
habituation to the test chambers. Specifically the male BACE1 Tg mice had a 
reduced activity but the female mice did not. This difference in activity carried 
through to the context phase of the test. The difference in habituation activity may 
confound the test if the mice do not habituate uniformly to the test chamber as any 
subsequent differences in activity may not be attributed to a fear response alone. 
However no difference was found in the ratio o f inactivity in the old and new 
contexts, the contextual fear ratio, which removes differences in baseline activity. 
Interestingly no differences were seen in the auditory cue phase of the test. Overall 
the BACE1 Tg mice had no impairment in hippocampal or amygdala function when 
assessed in the fear conditioning test. BACE1 KO mice had no differences in 
habituation to the fear conditioning chambers. They did have reduced inactivity 
when replaced into a test chamber with the same context in which they experienced 
the aversive experience of an electrical foot-shock. However they did not differ in 
activity levels when exposed to the test chamber with a new context. The contextual
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fear ratio showed an impaired response for male but not female KO mice. When 
given an auditory cue that was previously associated with the old context and foot- 
shock, only male BACE1 KO mice showed impairment, females were no different 
from wt controls. This result reflects that seen in the contextual fear ratio with male 
but not female mice having an impaired cued memory recall. Hence male but not 
female BACE1 KO mice demonstrated impaired hippocampal and amygdala 
function in the fear conditioning test. It is interesting that the male BACE1 KO mice 
were found to be more anxious than wt controls and the females were not. No 
differences in memory were seen in the relatively anxiolytic object recognition test 
for this line of mice. It was only the relatively anxiogenic fear conditioning test that 
revealed a difference in memory recall in the male BACE1 KO mice. It may be 
possible that the male BACE1 KO mice showed impairment in the fear conditioning 
test because they are more anxious and more readily froze in response to the memory 
of an electric footshock. Further work in alternative tests of cognition will prove 
useful to explain difference between male BACE1 KO mice and their male wt 
controls.
In order to eliminate the possibility that altering BACE1 expression caused a 
change in sensitivity to the electrical foot shock used in this test the mice were tested 
for nociception in a hotplate test. No differences were seen in this test o f nociception 
for the BACE1 Tg or KO mice when compared to wt controls. In addition the mice 
did not differ in their response to the pain experienced when the middle toe o f a hind 
paw was pinched during the primary SHIRPA detailed in chapter 2.
When compared with wild type controls in a test for spatial reference 
memory, the BACTAS double Tg mice were equally able to navigate to a visual cue 
in the watermaze when the distal room cues were occluded confirming their ability to 
see and swim in the maze. When tested with the room cues revealed a difference in 
swimspeed was seen between the BACTAS Tg and wild type mice and so the 
pathlength measure was used as a measure o f learning. The mice learned to escape 
the maze with a significant daily reduction in pathlength to find the platform. The 
presence of both the BACE1 and A P P km 67o/67inl transgenes had no effect on the 
vision or swimming ability of the mice during visual cue training or on learning 
during the spatial cue training. The transgenes also had no effect on memory 
retention in the mice. Following training the mice had an intact memory of the target 
platform position and were able to re-leam a new target platform position. This
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sparing of synaptic function in the BACTAS mice was not seen in the TASTPM 
mice. These TASTPM mice, carrying A P P km 670/67in l and P S 1m i46L transgenes and of 
a similar age to the BACTAS mice, were also able to navigate to a visual cue 
showing vision and swimming ability were unimpaired. However spatial learning 
was impaired as was the accurate retention of this memory in TASTPM dTg mice 
when compared to wt controls. In the BACTAS mice, human BACE1 is over- 
expressed with mutant human APP and in the TASTPM mice, mutant human PS1 is 
overexpressed in addition to mutant human APP. Studies have suggested that 
BACE1 expression is increased in AD patients (309) and the rate limiting step for 
P-amyloid production is hypothesised to be BACE1 cleavage of APP. One 
consequence o f increased p-amyloid load is decreased cognition in AD patients 
however the impaired cognition seen in the TASTPM mice was not reflected in the 
BACTAS mice suggesting that the decrease in cognitive performance is accelerated 
by increased mutant PS1 expression rather than increased BACE1 expression.
The lack of cognitive impairment seen when human BACE1 expression is 
increased on its own, or in conjunction with human A P P km67o/67in l , in mouse models 
suggests that BACE1 is less important in the progress of cognitive decline than PS1. 
Removing endogenous BACE1 did lead to impaired hippocampal and amygdala 
related memory retention. The amygdala is involved in emotional memory as well as 
anxiety, thus the anxiety phenotype observed when endogenous BACE1 is removed 
may lead to the decrease in memory retention seen in the fear conditioning test. 
Clearly BACE1 has other functions distinct from its activity as P-secretase. These 
data demonstrating impaired cognitive function in BACE1 KO mice is in agreement 
with a recent publication showing impaired cognition in another BACE1 KO mouse 
line (263). Further work is required to define the nature of these deficits and how 
they may be reflected in the human population.
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4.1 Introduction
At approximately the same time that BACE1 was identified, the cloning of 
BACE2 was also reported (92;99;120-122). BACE2 is located on chromosome 21 as 
is the Amyloid Precursor Protein and hence it is overexpressed in Trisomy 21 
(Down's Syndrome) where affected individuals develop amyloid plaques by the age 
of 50. BACE2 is expressed in brain but in relatively low levels compared to BACE1. 
While BACE1 has been shown to be p-secretase and mice lacking BACE1 are 
essentially normal, though with sex specific anxiety (310) and mildly impaired 
cognition, pharmacological inhibition of BACE1 activity alone as a treatment for AD 
may be ineffective if BACE2 activity could substitute for the lack of BACE1. Under 
these circumstances BACE inhibitors would need to inhibit both BACE1 and 
BACE2. Inhibition of p-Secretase is an attractive target for a disease modifying 
therapy in AD. Recent data from cultured cells indicate an antagonistic effect of 
BACE1 and BACE2 in cells that co-express these enzymes (311). If this antagonistic 
effect occurs in vivo pharmacological inhibition o f BACE 1 in vivo would require a 
compound highly selective against BACE2 in order to not to reduce its ability to 
inhibit P-amyloid production.
As pharmacological inhibition o f BACE1 is one potential therapy for AD 
patients, the cognitive function o f mice lacking this enzyme and the closely related 
BACE2 enzyme was assessed. In order to investigate the effect of removing both 
BACE1 and BACE2 enzymes on behaviour, a breeding regime was devised to 
generate a BACE 1/2 double knockout (dKO) mouse line. The dKO and wt littermate 
control mice were tested for anxiety, home cage behaviour, motor function and 
cognition. Subsequently the mice were sacrificed and gross anatomy was examined.
Lines of mice lacking BACE1 or BACE2 endogenous gene expression were 
created on a [C57/B16xl2901a/Sv] hybrid background and then interbred over 2 
generations of breeding to produce homozygous BACE 1/2 dKO mice. These dKO 
mice were analysed for behavioural changes when compared to wild type (wt) 
controls. Male but not female dKO mice showed elevated anxiety and female but not 
male dKO mice showed improved locomotor function and home cage activity when 
compared to same sex wild type controls. Their learning was no different from wild 
type controls however subtle differences were found in memory retrieval in a 
standard reference memory test. The subtle memory deficit and gender specific
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changes in anxiety and locomotion aside, very few differences could be detected 
between the dKO mice and their unmodified controls.
4,2 Materials and Method
4.2.1 Animals
The BACE1 KO mice were generated as previously reported (310). Briefly 
Exon 1 of the BACE1 genomic locus was replaced with a LacZ reporter gene 
(appendix 7.1.2). The BACE2 KO mice were generated by using similar cloning 
technology with a LacZ reporter gene inserted into the BACE2 genomic locus 
(appendix 7.1.3).
The BACE 1/2 dKO mice for experimentation were generated with a specific 
breeding regime. The BACE1 KO mice and BACE2 KO mice lines were generated 
on a [C57Bl/6xl2901a/Sv] hybrid background and independently bred to 
homozygosity. The single homozygous KO mouse lines were then interbred to 
produce double heterozygous KO mice. These mice were subsequently interbred to 
produce a range of genotypes in sufficient numbers for experimental investigation. 
This breeding programme had the great advantage of generating the desired 
BACE 1/2 double homozygous KO mice as well as littermates that were not carrying 
any form of the gene targeted alleles. The background strain was a hybrid mix of 
C57B1/6 and 12901a/Sv mouse strains.
4.2.2 Behavioural analysis
4.2.2.1 Anxiety
The dKO and wt control mice were tested for anxiety using the elevated plus 
maze test of anxiety as described in chapter 3. This test relies on the innate behaviour 
o f the mouse. The natural inquisitive nature of the mouse is balanced by a natural 
fear of open, exposed spaces. The time spent on the open and closed arms o f the 
maze is recorded as a measure o f anxiety.
4.2.2.2 Home Cage Behaviours
A range of behaviours was recorded using the Laboratory Animal Behaviour 
Observation, Registration and Analysis System - LABORAS™ (312), (Metris,
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Hoofdorpp, Netherlands) to establish any effect of removing BACE1 and BACE2 
enzymes on home cage activity. Animals were placed in the test apparatus where the 
vibrations created by their movements were monitored through vibration sensitive 
sensors. These vibrations were converted into electrical signals and processed into 
specific behaviours using validated algorithms. The mice were monitored for 16 
hours during which the mice had access to food and water ad libitum. The duration 
and frequency of climbing, locomotion, drinking, eating, immobility and grooming 
were recorded.
4.2.23 Motor Function
Locomotor co-ordination of the mice was measured using a Rotarod (313). 
This consisted of a rotating drum, 15 cm in diameter that accelerated from 4 to 40 
rpm over 5 minutes. The mice were placed on top o f the drum, separated from each 
other by a divider and the drum started rotating. Each mouse was given 3 trials and 
the mean of these three trials was used in subsequent calculations.
4.2.2.4 Cognition
The mice were assessed for cognition in a test of spatial learning and memory 
based on the Morris Water Maze and adapted for mice. The maze layout was 
identical to that used to test the mice described in chapter 3. Dimensions and cues 
were identical as was the tracking system. The protocol was also identical for the 
visual and spatial cued training phases. The memory retention consisted o f one 60 
second probe trial followed by 4 rewarded spatial cue training trials to the original 
platform position. The following day the mice were given another single training trial 
to the original platform position followed by 4 more trials with the platform in the 
opposite quadrant (reversal), thus testing their ability to re-leam the reversed position 
o f the platform.
4.2.3 Pathology
In order to assess the effect o f removing BACE1 and BACE2 proteins on 
gross anatomy mice were euthanased after behaviour testing and underwent a 
thorough post mortem examination. Organs targeted in this examination included
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lungs, heart, liver, kidneys, spleen, stomach, duodenum, jejunum, ileum, caecum, 
colon, mesenterec lymph nodes, adrenal glands, thymus, testes, epididymides, 
prostate, seminal vesicles, ovaries, uterus, bladder, skin, tongue, larynx, oesophagus, 
thyroid glands, sternum, aorta, salivary gland, cervical lymph nodes, pancreas, 
harderian gland, eyes, spinal cord, femur, nerve, urethra, pituitary gland, 
gastrocnemus & tricep muscle.
4.3 Results
Mice were generated with endogenous BACE1 and BACE2 genes removed 
on a [C57Bl/6xl2901a/Sv] hybrid background strain. The mice appeared to be 
healthy and normal with no problems noted during breeding. The deletion o f both 
BACE1 and BACE2 proteins had no significant effect on the majority o f behaviours 
when compared to wild type controls. There were subtle, gender specific effects of 
genotype on anxiety, home cage behaviour and locomotor function. No effect o f 
genotype was seen on learning or re-leaming ability but an effect was seen on 
memory retention with dKO mice showing impairment in accurate recall o f the 
escape platform position in the watermaze.
4.3.1 Anxiety
Overall dKO mice were not significantly different from wt controls when 
tested in the elevated plus maze of anxiety but a clear trend for increased anxiety in 
the dKO mice was seen. Further analysis revealed that male dKO mice had a 
significant preference for the relatively safe closed arms rather than the exposed open 
arms o f the maze indicating elevated anxiety when compared to wt controls.
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Figure 4.1 BACE1/2 dKO mice behaviour in the elevated plus maze
A) Time spent on the arms of the maze by gender or genotype. B) Time spent on the 
arms of the maze by group. Male dKO mice spent more time on the closed arms than 
open arms. This difference was not seen in any other group. N = 8 M dKO, 9 F dKO, 
5 M wt, 5 F wt controls. Mean +/- SEM. * p<0.05.
Analysis of the time spent in the open and closed arms of the elevated plus 
maze revealed no overall significant preference for open or closed arms by the wt 
control mice F(l,23) = 0.03, p = 0.85 or by the dKO mice F(l,23) = 1.69, p = 0.21 
(Figure 4.1 A). However when the data from individual groups of mice were analysed 
a significant preference for the closed arms was revealed F(l,23) = 5.41, p = 0.029 
for the male dKO mice (Figure 4 .IB) . No preference for either arm was seen for 
male wt F(l,23) = 0.02, p = 0.89 or female dKO F(l,23) = 0.03, p = 0.86 or female 
wt mice F(l,23) = 0.11, p = 0.74. The male dKO mice spent 160% more time on the 
closed arms than the open arms of the maze indicating an anxious phenotype.
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4.3.2 H om e Cage B ehaviours
TW
Home cage behaviours were assessed using the LABORAS system. Most 
of the behaviours assessed using LABORAS showed no significant difference. The 
only significant effect of genotype found in this test was immobility duration. 
Overall dKO mice had a 14% reduction in immobility compared to wt controls, 
however male dKO mice spent only 3% less time immobile while female dKO mice 
spent 29% less time immobile than respective wt controls.
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Figure 4.2 BACE1/2 dKO mouse immobility in the LABORAS™ test
A) Time spent in immobility by gender or genotype. B) Time spent in immobility by 
group. Female dKO mice spent less time immobile then female wt controls. N = 8 M 
dKO, 9 F dKO, 5 M wt, 5 F wt controls. Mean +/- SEM. * p<0.05.
The LABORAS™ apparatus recorded information on 6 behaviours over a 16 
hour period and only one behaviour, immobility, was found to be significantly 
effected by genotype F(l,22) = 5.16, p = 0.033 (Figure 4.2A). No effect of gender 
was found F(l,22) = 2.33, p = 0.14 however there was a near significant gender x 
genotype interaction F(l,22) = 4.03, p = 0.057. A Fisher LSD post hoc test revealed a 
significant effect of genotype on females F(l,22) = 7.48, p = 0.012 but not males
M KO F KOM WT F WT
T
*
T
— r —
M F KO wt
119
F(l,22) = 0.045, p = 0.83 (Figure 4.2B). Female mice were 29% less immobile than 
wt controls.
Interestingly the other behaviours measured in the LABORAS™ apparatus 
showed an effect of removing endogenous BACE proteins. While no significant 
effect of gender or genotype was seen on grooming, analysis of the number of 
grooming bouts of the male mice alone revealed a near significant effect of genotype 
F(l,22) = 3.72, p = 0.06 with male dKO mice spent 32% more time grooming than 
male wt mice. These changes reflect those found when the BACE1 KO mice were 
examined on the elevated plus maze in chapter 3. The female dKO mice had non­
significant increases in the duration and frequency of eating and drinking during the 
test period (appendix 7.16). While not significant these changes are notable as they 
impact on the weight of the mice discussed below.
4.3.3 M otor Function
The Rotarod test was used to assess motor function in the mice. Mice were 
given 3 consecutive trials on a rotating drum. The average of the three trials was used 
in subsequent calculations.
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Figure 4.3 BACE 1/2 dKO mice m otor co-ordination in the Rotarod test
A) Mean latency to fall by gender or genotype. B) Mean latency to fall by group. N = 
8 M dKO, 9 F dKO, 5 M wt, 5 F wt controls. Mean +/- SEM.
Analysis of the performance of the mice in the Rotarod test revealed no 
significant effect of genotype F(l,23) = 0.14, p = 0.71 but a near significant effect of 
gender F(l,23) = 3.47, p = 0.07 (Figure 4.3A). No significant gender x genotype 
interaction F(l,23) = 2.89, p = 0.10 was found. While no significant effect was found 
Figure 4.3B shows that the female dKO mice were able to stay on the Rotarod an 
average of 26% longer than female wt littermate control mice while male dKO mice 
lasted an average of 16% less time than male wt controls.
4.3.4 Cognition
In a standard reference test of memory the mice were trained to spatial cues 
in a watermaze. They were then assessed for memory storage and retention with a
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probe trial and subsequent synaptic plasticity in a reversal test. No effect of removing 
BACE1 and BACE2 genes was seen on learning and synaptic plasticity. A deficit in 
specific memory recall was seen in the dKO mice.
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Figure 4.4 BACE1/2 dKO mouse learning in watermaze training
A). Latency to platform B). Swimspeed. C). Pathlength to platform. No differences 
wee seen between dKO mice and wt controls. Numbers on x-axis indicate training 
day. N = 8 M dKO, 9 F dKO, 5 M wt, 5 F wt controls. Mean +/- SEM
Analysis of performance of the BACE 1/2 dKO during visual cue training 
revealed a significant effect of day and trial [F(2,46) = 29.1, p < 0.001 & F(3,69) =
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4.96, p = 0.004 respectively] on the latency to escape the water (Figure 4.4A) and the 
pathlength to find the platform (Figure 4.4C) [F(2,46) = 23.8, p < 0.001 & F(3,69) = 
4.39, p = 0.007 respectively]. An effect o f day but not trial was seen on swimspeed 
(Figure 4.4B) [F(2,46) = 13.3, p < 0.001 & F(3,69) = 1.45, p = 0.23 respectively]. A 
significant effect of genotype was found on swimspeed F(l,23) = 14.4, p = 0.001 and 
pathlength F(l,23) = 5.95, p = 0.023 but not latency F(l,23) = 0.11, p = 0.73. Thus 
the mice were able to see and swim in the pool and learned to escape the water by 
navigating to the visual cue. No effect o f gender was found in any measure during 
visual cue training.
During spatial cue training a significant effect of day and trial [F(4,92) = 
4.27, p = 0.003 & F(3,69) = 3.56, p = 0.018 respectively] was found on the latency to 
escape the water (Figure 4.4A) and the pathlength to find the platform (Figure 4.4C) 
[F(4,92) = 4.28, p = 0.003 & F(3,69) = 3.59, p = 0.018 respectively]. An effect of 
trial but not day was seen on Swim peed (Figure 4.4B) [F(3,69) = 5.11, p = 0.003 & 
F(4,92) = 0.69, p = 0.60 respectively]. A significant effect o f genotype was found on 
latency F(l,23) = 11.3, p = 0.003 and swimspeed F(l,23) = 10.4, p = 0.004 and but 
not pathlength F(l,23) = 2.88, p = 0.10. No effect o f gender was found in any 
measure during spatial cue training.
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Figure 4.5 BACE1/2 dKO mouse memory retention in a probe trial
A) Percent time in platform quadrant. B) Number of platform crossings. dKO mice 
did not show a significant preference for the target platform. N = 8M  dKO, 9 F 
dKO, 5 M wt, 5 F wt controls. Mean +/- SEM
The time spent in quadrant during the test of memory retention was analysed 
and both the dKO and wt mice showed a significant preference for the training target 
quadrant F(l,23) = 9.09, p = 0.006 and F(l,23) = 20.0, p < 0.001 respectively (Figure 
4.5A). However analysis of the number of platform crossings, a more precise 
measure of memory recall, showed that while wt littermate control mice showed a 
significant preference for the target platform F(l,23) = 18.9, p < 0.001, the dKO 
mice did not F(l,23) = 2.83, p = 0.11 (Figure 4.5B). Gender had no effect on this 
memory retention.
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Figure 4.6 BACE1/2 dKO mouse synaptic plasticity in a reversal test
A). Latency to platform B). Swimspeed. C). Pathlength to platform. No differences 
were seen between dKO mice and wt controls. Numbers on x-axis indicate training 
trial. N = 8 M dKO, 9 F dKO, 5 M wt, 5 F wt controls. Mean +/- SEM
After memory retention was tested the mice were given one retraining trial to 
the original platform position. No effect of genotype was found on latency, 
swimspeed or pathlength. Subsequently the mice were tested for memory plasticity 
with a session of reversal training trials. Analyses of latency, Speed and pathlength 
data revealed an effect of trial in each measure [F(3,69) = 7.83, p < 0.001; F(3,69) =
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11.7, p < 0.001; F(3,69) = 7.63, p < 0.001]. Genotype had no effect on latency 
(Figure 4.6A) F(l,23) = 0.97, p = 0.33 or pathlength (Figure 4.6C) F(l,23) = 0.55, p 
= 0.46 but did have an effect on swimspeed (Figure 4.6B) F(l,23) = 0.55, p = 0.028. 
Gender had no effect on the retraining or reversal training.
The result o f this test of the effect of a dKO genotype on cognition was 
complicated by differences in swimspeed. It is clear from Figure 4.4B that the dKO 
mice had a slower swimspeed than wt controls. As there was a significant effect of 
genotype on swimspeed, the pathlength data is a more accurate indication of 
performance in the maze. The pathlength data from the visual cue training indicate 
that the dKO mice were able to fmd the cued platform more easily than the wt 
littermate control mice, hence their vision and ability to navigate to the platform was 
unimpaired. Similarly during spatial cue training a significant effect of genotype on 
swimspeed was seen, hence pathlength to platform was used as a more accurate 
representation of watermaze performance. Consideration o f the pathlength data 
clearly demonstrated that the mice learned to escape the water, decreasing the 
distance swam from trial to trial within each day and from day to day during the 5 
days o f training (Figure 4.4C). Removing BACE1 and BACE2 gene expression had 
no overall effect on the learning ability o f the mice.
The broad memory retention of the dKO mice was intact as genotype had no 
effect on the time spent in target quadrant during the probe test, however precise 
recall o f the platform position was impaired in the dKO mice. The dKO mice were 
able to re-leam a new platform position without difficulty indicating their synaptic 
plasticity was unchanged from wt controls. Overall removing BACE1 and BACE2 
proteins from these mice had no effect on learning or broad memory recall of 
synaptic plasticity. Effects were seen on the speed at which the mice could swim, 
with dKO mice swimming more slowly, and on the precise memory recall of a 
learned platform position.
4.3.5 Pathology
The post mortem examination was carried out at age 13 months and revealed 
a normal gross anatomy with no gene associated abnormalities detected. Analysis of 
the brain weights revealed no significant effect o f gender or genotype. Interestingly
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the B ACE 1/2 dKO mice were lighter than wt controls at 9 and 13 months of age with 
a greater difference in female mice than male mice.
A) 50
40 
ra 30
05
20
I
10 
0
^  40 
2 30
% 20
0
Figure 4.7 Weight of BACE1/2 dKO mice
A). Weight at age 9 months B). Weight at age 13 months. At 9 months of age dKO 
mice were lighter than wt controls and females were lighter than males. N = 8 M 
dKO, 9 F dKO, 5 M wt, 5 F wt controls. Mean +/- SEM. * p<0.05
When weighed at 9 months of age a significant effect of gender F(l,23) = 
5.37, p = 0.03 and of genotype F(l,23) = 4.72 , p = 0.04 was found on body weight 
(Figure 4.7A). At 13 months a reduced number of animals were measured and the 
effects of gender F(l,5) = 6.07, p = 0.057 and genotype F(l,5) = 4.20, p = 0.09 on 
body weight failed to reach significance (Figure 4.7B). At each age the dKO mice 
were lighter than wt controls (13.9% at 9 months rising to 18.9% at 13 months). As 
expected female mice were lighter than male mice at each age (19.3% at 9 months 
and 29.8% at 13 months). At 9 months of age female dKO mice were 21% lighter 
than female wt controls and male dKO mice were 9.6% lighter than wt controls.
4.4 Discussion
This chapter presented data from an investigation of the consequences of 
removing endogenous BACE1 and BACE2 genes in a single line of dKO mice. Both
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of these proteins cleave APP at the (3-secretase site, an attractive target for 
pharmacological intervention in AD, and so any therapy based on inhibiting BACE 
activity may need to account for inhibition of both proteins’ function or include a 
level of selectivity between them. Additionally while BACE1 has been shown to be 
P-secretase and mice lacking BACE1 are physiologically normal, pharmacological 
inhibition of BACE1 activity alone as a treatment for AD may be ineffective if  
BACE2 activity could substitute for the lack o f BACE 1. Under these circumstances 
BACE inhibitors would need to inhibit both BACE1 and BACE2.
The dKO mice showed subtle, gender specific differences in anxiety and 
motor activity and co-ordination compared to wt controls. The trend for increased 
anxiety seen in the male dKO mice was similar to that seen in male BACE1 KO 
mice. The additional deletion of the BACE2 gene did not appear to increase the 
anxiety in these mice. The gender specific effect is interesting as it implies an 
interaction of the Hypothalamic Pituitary Axis (HPA), a structure known to have an 
altered function in AD (314), with a component o f the BACE1 and/or BACE2 
processing pathway. Learning in the dKO mice was unimpaired as was broad 
memory recall however the memory of a specific target, namely the platform 
location to which the mice were trained, was poorer in dKO mice compared to wt 
controls suggesting impairment in the co-ordinated memory recall function of the 
hippocampus and neo-cortex. Interestingly the dKO mice swam more slowly than 
controls. This may be due to impairment in swimming ability though the motor co­
ordination data suggest this is not the case. When tested in the watermaze the dKO 
mice were 13.9% lighter than wild type littermate control and this difference in 
weight may have contributed to the slower swimspeed. Both male and female dKO 
mice were lighter than respective wt controls. The improved motor co-ordination and 
decreased home cage inactivity shown by female dKO mice demonstrate that though 
they were lighter than controls they had a more robust motor function and were more 
active than wt controls. A more extensive examination of body fat and muscle 
composition may reveal a fuller explanation of this result. No differences in gross 
pathology were seen. Overall very few differences were seen in the BACE 1/2 dKO 
mice, beyond those observed in BACE1 KO mice.
While inhibition o f BACE1 in humans is an attractive target for disease 
modifying therapy in Alzheimer Disease, in keeping with data contained in chapters 
2 and 3 of this thesis and with previously published work (310), the data might
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suggest that inhibition of both BACE1 and BACE2 would lead to anxiety related 
behaviour in treated patients. However, one key difference is that here mice have 
been generated which completely lack BACE1 and BACE2 proteins while the 
administration of a BACE inhibitor as a therapeutic would not change protein levels, 
at least in the short term, only inhibit the enzyme activity. These data do suggest that 
in searching for a novel P-secretase inhibiting therapy, pharmacologists need not be 
overly concerned with high compound selectivity against BACE2. The anxiety 
phenotype seen in these mice raises the intriguing question as to an as yet 
undiscovered function of BACE 1 and/or BACE2 in the serotonergic system and how 
this may relate to Alzheimer’s Disease.
129
Chapter 5 - <BJLCE1 hpochgut 
micefaiC to put on weight at 
the same rate as wiCd type 
controC mice
130
5.1 Introduction
AD patients have a number o f secondary behavioural indications associated 
with the disease including anxiety, aggression and depression. In addition weight loss 
has been observed in AD patients (315) and may be predictive of AD onset (316). 
While these symptoms can be attributed to a number o f separate causes, in 
combination these peripheral symptoms may be explained by impaired functioning 
of the hormonal control by the Hypothalamic-Pituitary-Axis (HPA) (196; 197). The 
hypothalamus and pituitary glands are located at the base of the brain in the sella 
turcica, a pit o f the sphenoid bone. The pituitary gland secretes a number of 
hormones vital to various organs including growth hormone controlling, among other 
things, fat, bone and muscle growth. Thyroid stimulating hormone is also secreted by 
the pituitary gland. This has an effect on the thyroid gland and thyroxine secretion, 
which has a range of influences on growth. Hypothalamic regulatory hormones 
regulate the pituitary secretions. Both the pituitary and hypothalamic glands 
hormonal secretions are highly vascular and are regulated with a feedback control 
system via the blood stream.
BACE1 has been identified as (3-secretase however the mature BACE1 
protein has numerous binding domains (see 1.3.2) and splice variants have been 
localised to the pancreas (95). These features, combined with the fact that APP is 
described as a poor substrate for BACE1 (317), suggest additional functions for 
BACE1. It is highly likely therefore, that BACE1 has a function independent o f APP 
processing. As described in the introduction to this thesis, recent publications have 
proposed alternative substrates for BACE1 including P-selectin glycoprotein ligand- 
1, the sialyl-transferase ST6Gall, amyloid precursor like protein 2 (APLP2), 
lipoprotein receptor-related protein (LRP) and a voltage gated sodium channel (3- 
subunit (SCN2P) with the potential for other substrates yet to be discovered.
This chapter reports the findings of an investigation o f the metabolic changes 
found in the BACE1 Tg and KO mouse lines. During the behavioural phenotyping of 
the mice, weight measurements were routinely taken. It was noted that a difference in 
weight was apparent between the BACE1 Tg and KO mouse lines and respective 
wild type controls. At post mortem tissues were harvested and various measurements 
taken to attempt to explain the differences in observed body weight.
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5.2 Materials and Methods
5.2.1 Animals
The animals used to measure body weights, provide material for the tissue 
weights and temperatures measurements were those reported in chapter 3 and were 
sacrificed at approximately 15 to 18 months of age. Animals used to provide tissues 
for the neurochemistry and blood biochemistry analyses were those described in 
chapter 2, aged approximately 4 to 5 months.
5.2.2 Body Weights
The total body weight o f the mice was measured using a standard animal 
balance and weighing bowl. BACE1 KO mice were weighed at averages age of 8, 13 
and 15 months. The BACE1 Tg mice were weighed at average ages o f 12, 16 and 18 
months. Some o f the mice died over the study period and half of the BACE1 Tg mice 
from each group were sacrificed prior to the final body weight measurements.
5.23 Tissue Weights
At post mortem the peri-genital fat pads and the interscapular brown adipose 
fat pads were dissected away from surrounding tissues, cleaned of contaminating 
viscera and weighed. These tissues were chosen as, besides being relatively easy to 
identify as discrete deposits and isolate, they are indicators o f fat storage and fat 
metabolism.
5.2.4 Temperature
Temperature measurements were taken using a transponder microchip 
incorporating a temperature sensor that was implanted in the posterior upper left 
flank of each animal. The microchip was inserted and allowed to remain in place for 
2 days prior to temperature readings. These measurements were taken one week prior 
to culling the animals.
132
5.2.5 Neurochemistry
Upon completion o f the behavioural testing, brains from 4 to 5 month old 
BACE1 mice were harvested and the following regions were dissected and snap 
frozen and stored at -80°C until assay: dorsal striatum, nucleus accumbens, 
hippocampus, hypothalamus, cerebellum and frontal cortex (left and right 
hemispheres pooled). Details of the method used to examine neurochemical changes 
in these brains are in appendix 7.3.1. Briefly, samples were probe sonicated in buffer 
(10 pl/mg tissue) and centrifuged at 10,000 rpm and 4°C for 10 minutes. Supernatant 
fractions were analysed using HPLC with electrochemical detection and quantified 
by comparison with calibration curves run previously for 3,4-dihydroxyphenylacetic 
acid (DOPAC), dopamine (DA), 5-hydroxy indole-3-acetic acid (5-HIAA), 
homo vanillic acid (HVA), 5-hydroxytryptophan (5-HTP) and 5-hydroxytryptamine 
(5-HT). Turnover rates were assessed by calculating the following ratios: 
DOPAC/DA, HVA/DA, DOPAC/HVA and 5-HIAA/5-HT. The ex vivo 
neurochemical phenotype o f the animals was analysed by an analysis o f variance 
(ANOVA). Differences between individual means were assessed with the post-hoc 
Fisher's test.
5.2.6 Blood Biochemistry
The mice were analysed for changes in blood biochemistry following the 
behavioural testing. Blood from the mice was collected under terminal anaesthesia. 
The whole blood was collected into EDTA coated tubes and spun at 13,000 rpm for 2 
minutes to isolate the blood serum. This was removed and frozen at -80°C until use. 
The serum was analysed using published methods (318).
5.3 Results
5.3.1 Animal Ages and Survival
Throughout the period of study a number of mice died. The number o f mice 
weighed at each time point is shown for BACE1 KO mice in Table 5.1 A and BACE1 
Tg in Table 5 .IB. The dates o f death of the mice were not recorded and so an 
accurate survival analysis was not possible however from a starting cohort of 24 KO 
and 24 wt control mice (12 of each gender), 15 KO and 21 wt control mice survived
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to 15 months of age. From a starting cohort of 26 Tg and 26 wt control mice (13 of 
each gender), 23 Tg and 26 wt control mice survived to 16 months o f age (not all of 
the mice were included in the final measurements for the Tg mice). These data 
represent a survival o f 62.5% for the KO mice compared to 87.5% for the wt control 
mice and 88.5% for the Tg mice compared to 100% for the wt controls.
Age (months) M KO M wt F KO F wt KO W t M F
8 9 12 9 11 18 23 21 20
13 9 12 9 11 18 23 21 20
15 7 12 8 9 15 21 19 17
Age (months) M Tg M wt F Tg F wt Tg wt M F
12 11 13 12 13 23 26 24 25
16 11 13 12 13 23 26 24 25
18 5 7 6 7 11 14 12 13
Table 5.1 N um ber and age of BACE1 mice
A) KO mice. B) Tg mice
Small differences in the average ages of the mice were apparent as a 
consequence of the breeding regimes used to generate the experimental cohorts of 
mice. While the range of birth dates for the BACE1 Tg mice was 1.7 months, a 2 
factor ANOVA of the age o f these mice revealed no significant differences between 
the genders F(l,45) = 0.15, p = 0.70 or genotypes F(l,45) = 0.12, p = 0.73 
investigated. No gender x genotype interaction was seen. However as a result o f the 
independent breeding regime used for the BACE1 KO mice the dates o f birth ranged 
over 3 months and while no significant difference between the age of the genders 
F(l,37) = 0.07, p = 0.79 was seen, the mean age o f the different genotypes F(l,37) = 
13.9, p = 0.001 did significantly differ between the KO and wt mice. No gender x 
genotype interaction was seen. Consequently a direct comparison between the 
weights o f the KO and wt control mice was not feasible as the weight o f the mice 
changed with age, however as the interval between weighing had been constant a 
comparison of the change in weight over time was possible. The actual weights of 
the BACE1 KO (Figure 5.1) and BACE1 Tg mice (Figure 5.2) are shown below in 
order to give a clear representation of the effect o f genotype on weight. In
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calculations of statistical differences the change in weight of the KO (Figure 5.1C) 
and Tg (Figure 5.2C) mouse lines are used.
5.3.2 Body Weights
Overall the BACE1 KO mice were lighter than wt control mice and put on 
less weight as they aged. This failure to put on weight was more prevalent in female 
KO mice than male KO mice. The male but not female BACE1 Tg mice were 
heavier and put on more weight then wt controls.
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Figure 5.1 Weights of BACE1 KO mice aged 7 - 1 6  months
A) Male mice. B) Female mice. C) Change in weight over time. KO mice failed to 
put on weight at the same rate as wt controls. Starting N = 9 M KO, 9 F KO, 12 M 
wt, 12 F wt controls. Mean +/- SEM
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Analysis of the change in weight of the BACE1 KO mice from an average of 
8 months to an average of 13 months revealed a significant effect of gender F(l,37) = 
5.91, p = 0.02 and genotype F(l,37) = 23.4, p < 0.001 with no gender x genotype 
interaction F(l,37) = 0.08, p = 0.77. When male and female were considered 
independently male KO mice put on significantly less weight than male wt controls 
F(l,37) = 13.4, p = 0.001 and female KO mice put on significantly less weight than 
female wt controls F(l,37) = 10.2, p = 0.003 (Figure 5.1C). Considering the change 
in weight from an average of 13 months to an average of 15 months this failure to put 
on weight was did not quite reach significance in male KO mice compared to male 
wt controls F(l,32) = 3.42, p = 0.07 but was still present in female KO mice 
compared to wt controls F(l,32) = 11.3, p = 0.002 (Figure 5.1C). It is clear that both 
male and female KO mice were lighter and failed to put on weight at the same rate as 
wt control mice.
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Figure 5.2 Weight of BACE1 Tg mice aged 12 -  18 months
138
A) Male mice. B) Female mice. C) Change in weight over time. Tg M mice put on 
more weight than wt controls from ages 12-16 months. Starting N = l l M T g ,  12F 
Tg, 13 M wt, 13 F wt controls. Mean +/- SEM
The change in weight shown by BACE1 Tg mice from an average of 12 
months to an average of 16 months was unaffected by gender F(l,45) = 1.74, p = 
0.19 or genotype F(l,45) = 0.85, p = 0.36 but a gender x genotype interaction was 
found F(l,45) = 4.59, p = 0.037. When male and female mice were considered 
independently male Tg mice put on significantly more weight than male wt controls 
F(l,45) = 4.59, p = 0.037 and female Tg mice did not differ from female wt controls 
F(l,45) = 0.76, p = 0.39 (Figure 5.2C). Considering the change in weight from an 
average of 16 months to an average of 18 months this difference in the rate at which 
the mice put on weight was absent in male Tg mice compared to male wt controls 
F(l,21) = 0.18, p = 0.67 as it was in female Tg mice compared to wt controls F(l,21) 
= 0.54, p = 0.47 (Figure 5.2C). It is clear that between the ages of 12 and 18 months 
male Tg mice were heavier than wt controls and female Tg mice were initially 
heavier and put on less weight with age, ending lighter than wt controls.
5.3.3 Tissue W eights
Though there was a significant difference in age between the KO and wt 
control mice the tissues that were harvested at post mortem were analysed together in 
order to gain a feel for the reasons behind the changes in body weight. Tg mice did 
not significantly differ in age from wt controls and hence a direct comparison was 
possible.
Both male and female KO mice had significantly less peri-genital fat than 
respective wt controls. The peri-genital fat weights from Tg mice were not 
significantly different from wt controls.
No significant effect of genotype was seen on brown adipose tissue weights, 
though overall BACE1 KO mice had 28% less and BACE1 Tg mice 27% more 
brown adipose tissue than respective wt controls. There was an obvious gender 
difference with males having 62% (KO mouse line) or 110% (Tg mouse line) more 
brown adipose tissue than females.
The weights of the brains from BACE1 Tg mice were no different from those 
of wt controls.
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Figure 5.3 BACE1 Peri-Genital Fat weights
A) KO mice. B) Tg mice. N = 7 M KO, 8 F KO, 12 M wt, 9 F wt controls. N = 5 M 
Tg, 6FTg ,  7 Mwt ,  7 F w t  controls. Data are represented by gender or by genotype. 
Mean +/- SEM. *** p<0.001
Analysis of the Peri-Genital Fat (PGF) weight of BACE1 KO mice revealed 
no significant effect of gender F(l,32) = 1.17, p = 0.29 but an effect of genotype 
F(l,32) = 32.1, p < 0.001 (Figure 5.3A). In a planned comparison of PGF weight, 
male and female KO mice had significantly lighter PGF weight than respective wt 
controls [F(l,32) = 20.8, p < 0.001 and F(l,32) = 11.9, p = 0.002 respectively]. 
BACE1 Tg mice had PGF weights that were not significantly affected by genotype 
F(l,21) = 0.08, p = 0.29 but almost significantly affected by gender F(l,21) = 3.91, p
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= 0.06 (Figure 5.3B). No gender x genotype interaction was seen for either line of 
mice. The BACE1 KO mice had 63% less and BACE1 Tg mice 5% less PGF than 
respective wt controls.
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Figure 5.4 BACE1 Brown Adipose Tissue Weight
A) KO mice. B) Tg mice. N = 7 M KO, 8 F KO, 12 M wt, 9 F wt controls. N = 5 M 
Tg, 6FTg ,  7Mwt ,  7 F w t  controls. Data are represented by gender or by genotype. 
Mean +/- SEM. * p<0.05. ** p<0.01
Analysis of the Brown Adipose Tissue (BAT) weight of BACE1 KO mice 
revealed a significant effect of gender F(l,12) = 6.46, p = 0.026 but no effect of 
genotype F(l,12) = 3.13, p = 0.10 (Figure 5.4A). Analysis of the BACE1 Tg mouse 
BAT weight revealed a significant effect of gender F(l,12) = 11.5, p = 0.005 but no
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effect of genotype F(l,12) = 1.30, p = 0.28 (Figure 5.4B). No gender x genotype 
interaction was seen for either line of mice. The BACE1 KO mice had 28% less and 
BACE1 Tg mice 27% more BAT than respective wt controls. Regardless of 
genotype, males from the BACE1 KO line of mice had 62% more BAT than females. 
Similarly males from the BACE1 Tg line of mice had 110% more BAT than females.
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Figure 5.5 BACE1 Tg mice Brain Weight
N = 5 M Tg, 6FTg ,  7Mwt ,  7 F w t  controls. Data are represented by gender or by 
genotype. Mean +/- SEM.
Analysis of the Brain weight of the BACE1 Tg mice revealed no significant 
effect of gender F(l,12) = 0.041, p = 0.84 or genotype F(l,12) = 0.003, p = 0.96. No 
gender x genotype interaction was seen (Figure 5.5). The BACE1 Tg mouse brains 
were 0.1% heavier than wt controls.
5.3.4 Body T em p era tu re
No significant effect of genotype on temperature was found however an 
effect of gender was seen. Males were 3% (KO mouse line) or 1% (Tg mouse line) 
cooler than females.
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Figure 5.6 BACE1 Body Temperatures
A) KO mice. B) Tg mice. N = 7 M KO, 8 F KO, 12 M wt, 9 F wt controls. N = 5 M 
Tg, 6 FT g ,  7 Mwt ,  7 F w t  controls. Data are represented by gender or by genotype. 
Mean +/- SEM. ***p<0.001.
Analysis of the Body Temperature of the BACE1 KO mice revealed a 
significant effect of gender F(l,32) = 14.6, p < 0.001 but no effect of genotype 
F(l,32) = 1.09, p = 0.31 (Figure 5.6A). A planned comparison of temperature 
revealed no significant difference between male KO and male wt controls F(l,32) = 
0.25, p = 0.62 or between female KO and female wt controls F(l,32) = 0.94, p = 
0.34. Analysis of the BACE1 Tg mice Body Temperature revealed a near significant 
effect of gender F(l,16) = 3.58, p = 0.07 but no effect of genotype F(1,16) = 0.33, p 
= 0.57 (Figure 5.6B). No gender x genotype interaction was seen for either line of 
mice. Males from the BACE1 KO line of mice were 1.1°C (3%) cooler than females. 
Males from the BACE1 Tg line of mice were 0.35°C (1%) cooler than females.
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5.3.5 Neurochemistry
When compared to wt controls numerous changes in the brain amines were 
found in the BACE1 Tg mice contrasting sharply with the very limited changes seen 
in the BACE1 KO mice. The BACE1 Tg mice showed a significant increase in 5- 
HIAA levels in several brain regions with some indication of a decrease in the levels 
of 5-HT. This corresponds to a significant increase in the overall turnover o f 5-HT 
(5-HIAA/5-HT). The BACE1 KO mice exhibited small changes in the serotonergic 
system, with reduced 5-HT levels seen in the hippocampus.
A)
Amine
Brain Region
Cerebellum FC HiPP Hypo NAC Striatum
Tg WT Tg WT Tg WT Tg WT Tg WT Tg WT
3MT 0.518 ± 0.268
0.947 ± 
0.292
13.07 ± 
3.683
6.237 ± 
1.150
1.343 ± 
0.192
1.355 ± 
0.405
52.13 ± 
0.762
2.537 ± 
1.214
330.2 ± 
38.17
395.5 ± 
33.96
1151.6± 870.6 ± 
89.5972.21
5HIAA 82.23 ± 57.87 ± 5.739
179.3 ± 
10.05
176.2 ± 
41.66
508.5 ± 408.6 ± 
24.28
481.5 + 
66.72
311.8 ± 
42.11
395.0 ± 274.6 ± 
17.10
157.5 ± 108.9 ± 
6.6367.152 38.97 19.28 16.05
5HT 111.1 ± 101.0 ± 10.05
538.9 ± 
11.84
597.7 ± 
51.89
627.2 ± 705.1 ± 
36.34
781.2 ± 
70.71
778.5 + 
53.06
793.2 ± 
12.38
743.0 ± 
25.48
262.1 ± 
22.50
263.1 ± 
22.696.783 20.69
5HTP 0.637 ± 0.328
0.782 ± 
0.269
3.992 ± 
1.255
4 .128 ± 
1.441
1.922 ± 
0.532
2.120 ± 
0.626
5.453 ± 
1.530
7.753 ± 
3.906
1.285 ± 
0.409
1.510 ± 
0.294
25.30 ± 9.990 ± 
3.3596.079
DA 1.008 ± 0.689
1.249 ± 
0.372
136.1 ± 
57.92
125.7 ± 
92.90
7 .267 ± 
1.546
20.27 ± 
8.363
354.5 ± 500.6 ± 
54.72
1021.8 ± 1077.9 ± 
9.583
9820.8 ± 
87.85
9812.6 ± 
93.3337.21 17.91
Dopac 27.56 ± 4.333
14.40 ± 
7.133
1.280 ± 4.312 ± 
0.532
50.83 ± 
5.401
51.07 ± 
7.360
694.8 ± 
15.54
711.2 ± 
12.37
1600.6 ± 1149.7 + 
76.000.363 83.86
HVA 5.330 ± 1.327
4.505 ± 
0.888
136.8 ± 76.34 ± 
9.612
25.05 ± 
1.397
26.76 ± 
2.341
100.2 ± 
14.12
84.04 ± 
5.60
912.4 ± 
68.09
787.3 ± 
76.86
1974.5 ± 1461.5 ± 
174.36.967 116.6
5-HIAA
/5-HT
0.745 ± 
0.059
0.576 ± 
0.025
0.332 ± 
0.014
0.282 ± 
0.036
0.819 ± 0.590 ± 
0.055
0.602 ± 0.393 ± 
0.036
0.498 ± 0.372 ± 
0.028
0.620 ± 0.423 ± 
0.0290.081 0.035 0.024 0.073
Dopac
/DA
0.370 ± 
0.097
0.205 ± 
0.065
0.212 ± 
0.074
0.338 ± 
0.080
0.144 ± 0.103 ± 
0.011
0.680 ± 0.660 ± 
0.008
0.163 ± 0.117 ± 
0.0070.007 0.006 0.008
HVA
IDA
35.90 ± 
24.37
4.647 ± 
0.934
2.157 ± 
0.605
1.890 ± 
0.449
4.505 ± 
1.300
2.443 ± 
0.709
0.282 ± 0.175 ± 
0.009
0.889 ± 
0.053
0.730 ± 
0.070
0.201 ± 0.148 ± 
0.0170.031 0.011
Dopac
/HVA
0.198 ± 
0.024
0 .170 ± 
0.068
0.053 ± 0.165 ± 
0.025
0.534 ± 
0.054
0.586 ± 
0.050
0.777 ± 
0.042
0.956 ± 
0.111
0.815 ± 
0.030
0.856 ± 
0.1210.017
s i
Amine
Brain Region
Cerebellum FC HiPP Hypo NAC Striatum
KO WT KO WT KO WT KO WT KO WT KO WT
3MT 3.330 ± 0.645
5.334 ± 
3.434
3.870 ± 
1.235
1.146 ± 
0.364
0.973 ± 
0.423
0.928 ± 
0.556
4.012 ± 
1.225
4.307 ± 
1.703
103.1 ± 
28.09
247.0 ± 
84.52
789.4 ± 
76.59
868.0 ± 
60.85
5HIAA 64.73 ± 7.537
71.14 ± 
4.875
149.8 ± 
10.66
156.0 ± 
7.468
327.1 ± 
14.88
368.8 ± 
26.51
397.1 ± 
14.01
401.8 ± 
17.48
247.9 ± 
43.88
279.7 ± 
30.41
179.5 ± 
10.52
169.2 ± 
28.56
5HT 115.8 ± 18.07
127.4 ± 
10.97
622.6 ± 
51.61
640.2 ± 
29.78
524.4 ± 
25.16
607.8 ± 
25.15
873.7 ± 
13.70
863.9 ± 
14.28
780.8 ± 
43.90
762.6 ± 
62.08
300.6 ± 
24.35
354.7 ± 
32.09
5HTP 1.910 ± 0.587
2.830 ± 
1.539
0.363 ± 
0.101
0.527 ± 
0.194
2.965 ± 
0.907
3 .898 ± 
1.100
11.59 ± 
1.328
11.08 ± 
3.576
6.588 ± 
3.511
4.103 ± 
1.438
DA 25.58 ± 3.401
33.33 ± 
4.52
8.419 ± 
3.366
7.981 ± 
0.861
469.0 ± 
39.67
459.9 ± 
50.85
6875.2 ± 
419.2
7623.1 ± 
479.9
9569.8 ± 
67.9
9953.2 ± 
52.6
Dopac 24.35 ± 3.324
24.66 ± 
3.049
2.715 ± 
0.508
4.693 ± 
1.138
73.61 ± 
5.826
72.37 ± 
5.065
626.1 ± 
41.22
793.1 ± 
101.6
972.7 ± 
58.97
1162.6 ± 
115.0
HVA 79.46 ± 11.52
79.86 ± 
6.672
28.75 ± 
3.353
26.34 ± 
2.785
143.4 ± 
6.849
124.1 ± 
12.19
931.4 ± 
65.87
917.5 ± 
61.12
1616.3 ± 
92.33
1628.9 ± 
114.8
5-HIAA
/5-HT
0.573 ± 
0.038
0.568 ± 
0.041
0.244 ± 
0.012
0.245 ± 
0.012
0.626 ± 
0.019
0.606 ± 
0.032
0.455 ± 
0.019
0.466 ± 
0.022
0.309 ± 
0.045
0.375 ± 
0.049
0.616 ± 
0.054
0.488 ± 
0.078
Dopac
IDA
1.075 ± 
0.222
0.781 ± 
0.129
0.630 ± 
0.225
0.601 ± 
0.134
0.162 ± 
0.018
0.161 ± 
0.01
0.092 ± 
0.006
0.104 ± 
0.01
0.101 ± 
0.005
0.117 ± 
0.011
HVA
IDA
3.533 ± 
0.787
2.558 ± 
0.365
6.574 ± 
1.964
3.404 ± 
0.324
0.324 ± 
0.046
0.287 ± 
0.044
0.138 ± 
0.012
0.121 ± 
0.005
0.169 ± 
0.01
0.164 ± 
0.011
Dopac
/HVA
0.310 ± 
0.015
0.308 ± 
0.028
0.093 ± 
0.011
0.173 ± 
0.028
0.522 ± 
0.057
0.615 ± 
0.077
0.683 ± 
0.054
0.866 ± 
0.089
0.612 ± 
0.051
0.723 ± 
0.070
Table 5.2 BACE1 Neurochemistry
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A) Tg mice B) KO mice. Significant differences are in bold and underlined. Measures 
are in ng/g of wet tissue.
BACE1 Tg mice (Table 5.2B) showed a significant increase in 5-HT turnover 
in cerebellum F(l,10) = 6.87; p = 0.02, hippocampus F(l,10) = 5.45; p = 0.04, 
hypothalamus F(l,9) = 13.6; p = 0.005, nucleus accumbens F(l,10) = 12.0; p = 0.006 
and caudate striatum F(l,10) = 6.31; p = 0.03 compared to wt controls. Concurrently, 
this corresponded to a significant increase in the level of 5-HIAA in cerebellum 
F(l,10) = 7.06; p = 0.02 , hippocampus F(l,10) = 4.74; p = 0.054), nucleus 
accumbens F(l,10) = 21.9; p < 0.001 and striatum F(l,10) = 7.82; p = 0.019. In 
addition, a significant decrease was observed in the level of dopamine in the 
hypothalamus F(l,9) = 5.16; p = 0.05 and nucleus accumbens F(l,10) = 7.61; p = 
0.02. HVA levels were significantly increased in the frontal cortex F(l,10) = 25.9; p 
< 0.001 and striatum F(l,10) = 5.98; p = 0.034 of Tg mice, with a significant 
decrease of DOPAC observed in the hippocampus F(l,10) = 22.2; p < 0.001 and a 
significant increase in DOPAC in the striatum F(l,10) = 15.9; p = 0.003. These 
changes resulted in an overall significant increase in dopamine turnover (assessed by 
calculating DOPAC/DA ratios) in the hypothalamus F(l,9) = 10.4; p = 0.01 and 
striatum F(l,10) = 17.9; p = 0.002, with a trend towards an increase in the nucleus 
accumbens F(l,10) = 3.92; p =0.076. Furthermore, a significant increase in dopamine 
turnover (HVA/DA) was observed in the hypothalamus F(l,9) = 9.04; p = 0.015 and 
striatum F(l,10) = 6.57; p = 0.028 and a significant decrease in dopamine turnover 
(DOPAC/HVA) in the hippocampus F(l,10) = 14.2; p = 0.004.
Analysis of data from the BACE1 KO mice (Table 5.2A) revealed three 
significant changes in neurochemistry. These were a decrease in 5-HT levels in the 
hippocampus F(l,10) = 5.49, p = 0.04, a decrease in dopamine turnover 
(DOPAC/HVA) in the hippocampus F(l,10) = 6.88, p = 0.026 and a decrease in total 
dopamine content in the striatum F(l,10) = 19.9; p = 0.001 when compared to wt 
controls.
5.3.6 Blood Biochemistry
BACE1 KO mice had significantly elevated levels of circulating High 
Density Lipoprotein (HDL) Cholesterol and Triglycerides while BACE1 Tg mice 
had significantly lowered circulating Triglyceride levels.
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Figure 5.7 BACE1 Blood lipids
Percent difference compared to wt controls. N=10 for each gender and genotype. 
*p<0.05, **p<0.01.
Analysis of the Blood Biochemistry of the young mice revealed a significant 
increase in HDL Cholesterol F(1,19) = 4.66, p = 0.044 and Triglycerides F(l,22) = 
7.98, p = 0.01 in BACE1 KO mice when compared to controls. A significant 
decrease in Triglycerides F(l,33) = 4.18, p = 0.049 was seen in the BACE1 Tg mice 
when compared to wt controls. A small, non-significant decrease in HDL Cholesterol 
was also seen in the BACE1 Tg mice F(l,33) = 0.37, p = 0.54. HDL Cholesterol was 
1.2% less (Tg) and 21% more (KO) than respective controls and Triglycerides were 
19% less (Tg) and 42% more (KO) than respective wt controls.
5.4 Discussion
The young BACE1 Tg mice showed a significant increase in 5-HIAA levels 
in several brain regions with some indication of a decrease in the levels of 5-HT 
when compared to wt controls. This corresponds to a significant increase in the 
overall turnover of 5-HT (5-HIAA/5-HT), which is generally thought to be indicative 
of an increase in 5-HT release. The young BACE1 KO mice also exhibited small 
changes in the serotonergic system, with reduced 5-HT levels seen in the 
hippocampus. These findings correlate with the observed anxiolytic phenotype in the 
BACE1 Tg animals since 5-HT has been implicated in anxiety (319) and drugs 
which elevate synaptic 5-HT, such as serotonin specific reuptake inhibitors (SSRI) 
are clinically effect as anxiolytics (320). Although it is difficult to draw definitive
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conclusions from these findings, a link has been demonstrated between disturbances 
in the 5-HT system, ageing and the neuropathology of AD (321;322). There is 
increasing evidence that a combination of disturbances in cholinergic and 
serotonergic function play a role in cognitive impairment in AD, with serotonergic 
dysfunction potentially responsible for a significant portion of the behavioural 
aspects o f the disease (323).
This detailed neurochemical analysis is in agreement with the anxiety 
behaviours reported in chapter 3. Mice over-expressing BACE1 exhibited an increase 
in 5-HT turnover and were less anxious and more exploratory in their behaviour, 
consistent with the known correlation between anxiety and decreased 5-HT turnover 
(324). In contrast, mice lacking BACE1 displayed an anxious and less exploratory 
phenotype.
In addition to the effects of BACE1 overexpression on the serotonergic 
system, there also appear to be some changes to the dopaminergic system in these 
animals (e.g. the decreased dopamine in hypothalamus and nucleus accumbens, 
increased HVA in frontal cortex and striatum). Changes in dopaminergic 
neurotransmitter systems have also been observed in a number of post-mortem 
studies of AD brain (322;325).
While the male BACE1 Tg mice put on more weight and were heavier than 
male wt controls they did not have more peri-genital fat (PGF) but did have more 
brown adipose tissue (BAT). BAT has a high density of mitochondria and is integral 
to lipid metabolism and thermogenesis (326). The reduced body weight and inability 
to put on weight shown by both male and female BACE1 KO mice was reflected in 
the reduced weight o f PGF and trend towards a reduction of BAT in these mice.
This correlation between body weight and the presence or absence of the 
BACE1 gene indicates a role for BACE1 in metabolism. There is also a gender 
specific difference indicating a hormonal component to this effect. Changes in 
BACE1 expression have been reported in AD patients. These reports are associated 
with increased BACE1 enzyme levels in human post mortem AD brains (309;327) as 
well as in aged monkey, mouse and non-demented human brains (328). Additionally 
BACE1 expression in sporadic AD patients was shown to be increased with elevated 
(3-amyloid peptide load (329). The suggested mechanism for this increase in BACE1 
expression is that an unknown process stabilises BACE1 mRNA long enough for 
additional enzyme production. This elevation of BACE 1 expression may be expected
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in AD patients as, if the expression is translated into enzyme activity, increased 
cleavage of APP at the P-secretase cleavage sites will result in elevated production of 
the P-amyloid found in AD patients. Decreased BACE1 expression has not been 
investigated in the same way as, once BACE1 was identified as p-secretase, the main 
thrust o f research centred on the activity of BACE1 as P-secretase and its 
involvement in P-amyloid production.
The reduction in weight shown by the BACE1 KO mice may be accounted 
for by reduced adipose tissue deposition, which does not result from increased 
physical activity or heat production. One explanation for the reduced adipose tissue 
is a reduction in food intake. Appetite is controlled in part by the neuroendocrine 
system of the Hypothalamic Pituitary Axis (HPA) (for a review see (330). One 
potent anorectic agent in this system of control is a-Melanocyte Secreting Hormone 
(a-MSH). a-MSH is secreted from the Arcuate Nucleus of the hypothalamus in the 
CNS (for a review see (331). In addition to this function a-MSH has is involved in 
skin pigmentation and has been shown to have a role in energy homeostasis and 
other physiological functions (332). Soluble APPa (sAPPa) has an identical effect 
on melanocytes as a-MSH in the periphery, stimulating melanin production and 
pseudopodial extension in melanocytes (333). When P-secretase activity is removed 
in BACE1 KO mice the amount of APP substrate available for a-secretase cleavage 
is increased. If an interaction between sAPPa and a-M SH can be established then 
the effect of removing BACE1 expression on weight may be explained.
The weight loss shown by the BACE1 KO mice is positively correlated with 
the decreased levels of serotonin seen in the hippocampus o f these mice. A number 
of studies have shown that serotonin appears to be involved in the Neuropeptide Y 
network of food intake regulation (334-336), pointing towards a potential link 
between the decreased levels o f serotonin and the weight loss seen in the BACE1 KO 
mice. In humans, anorexia is seen during aging at the time of life when decreased 
serotonin signalling is also observed (337). AD patients show weight loss during the 
disease progression (338) and the serotoninergic system is known to be disturbed in 
these patients with a variable decrease in the serotonin content of several brain 
regions (339).
Young BACE1 KO mice have elevated circulating HDL Cholesterol and 
Triglyceride levels while young BACE1 Tg mice have depleted circulating
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Triglyceride levels. These changes in blood serum biochemistry may result from 
altered lipid metabolism with decreased insulin production leading fat breakdown 
(lipolysis) and elevated serum triglyceride levels in KO mice and increased insulin 
production and fat storage (lipogenesis) and triglyceride levels in Tg mice. This 
could explain the reduction in adipose tissue in KO mice and increased adipose tissue 
seen in male Tg mice.
The presence o f a copper binding site in the BACE1 protein may indicate a 
role for BACE1 as a mediator of weight via copper binding (104) as rats deprived o f 
dietary copper lose weight (340). In addition other explanations for this decrease in 
weight shown by BACE1 KO mice may be revealed with further studies targeted at 
dietary and metabolic effects of BACE1 removal.
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Chapter 6 - (Discussion and 
Conclusions
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The results from chapter 1 indicate that both BACE1 Tg and BACE1 KO 
mouse lines were essentially unchanged from wild type littermate controls with some 
subtle differences in behaviour. The slightly lower body weight and reduced activity 
in the test arena o f the BACE1 Tg mice plus the slightly firmer limb tone and 
improved behaviour of the BACE1 KO mice in the wire manoeuvre test, did not 
affect overall locomotion o f either line. The increased faecal production, seen in the 
KO mice, has been reported to correlate with increased emotion and anxiety (286). 
Furthermore, the decreased exploratory activity of the BACE1 KO mice in the 
holeboard test is also suggestive of an anxious behavioural phenotype. In contrast to 
these findings, the BACE1 Tg mice displayed a less anxious behaviour in the 
holeboard test with significantly more exploration. This behaviour is typical o f that 
seen following administration of anxiolytic drugs to wild type mice (287). Overall, 
the BACE1 KO and higher expressing BACE1 Tg mice present broadly opposite 
phenotypes with respect to faecal pellet number and holeboard activity. The lower 
expressing BACE1 Tg mouse line represented an intermediate phenotype between 
these two mouse lines. These results indicate a bold, more exploratory behaviour in 
the BACE1 Tg animals with a higher level of BACE1 expression and a timid, less 
exploratory behaviour in the BACE1 KO animals compared to controls.
The B ACT AS double Tg mice had a gender specific difference in weight 
with double Tg females being 29% lighter than wild type females. Interestingly 
B ACT AS mice were shorter than control mice and females were shorter than males 
though this did not have a significant effect on their weight. The increased arena 
activity and tremor shown by the B ACT AS mice may be indicative of a poor state of 
health compared to wild type control mice. This may also be reflected in the reduced 
likelihood o f biting when provoked and the reduced aggression shown by the 
B ACT AS mice. These mice were well advanced in plaque pathology (data not 
shown) and it is possible that they had started to exhibit some of the phenotypes of 
increased locomotion (288) and passivity (289) sometimes seen in AD patients.
Analysis of anxiety and cognition of the BACE1 Tg and KO mice revealed 
several differences compared to wild type controls. When BACE1 Tg mice were 
examined in classic tests for anxiety, the open field test and elevated plus maze test, 
they were not found to be significantly different from wild type controls. They did 
spend 26% more time in the open arms of the elevated plus mice and had 
approximately 60% fewer incidents of ‘stretch attend’ behaviour, an indicator of
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increased anxiety. These results, in combination those from chapter 2, indicate a 
reduced anxiety phenotype for the Tg mice. In identical tests the BACE1 KO mice 
travelled almost 40% less distance and spent just under 50% less time in the inner 
zone o f an open field compared to controls indicating an anxious phenotype. These 
mice also exhibited almost double the number of grooming bouts and showed a trend 
for less time on the open arms of the elevated plus maze when compared to wild type 
controls. Taken together these results indicate an increased anxiety phenotype in the 
BACE1 KO mice. The broad phenotype o f the two different lines of BACE1 mice is 
an increased anxiety in the KO mice and a reduced anxiety in the Tg mice.
When tested for differences in peri-rhinal cortex dependent cognitive function 
in the object recognition test no impairment was seen for BACE1 Tg or KO mice 
compared to wild type controls. The fear conditioning test examined hippocampus 
and amygdala dependent cognitive function. BACE1 Tg mice were unimpaired in 
hippocampal or amygdala related function in this test. Conversely BACE1 KO mice 
showed a gender specific impairment with male KO mice having impaired 
hippocampal and amygdala function while female KO mice were only impaired in 
hippocampal function when measured in this test.
BACE1 cleavage of APP is hypothesised to be the rate limiting step in the 
production of P-amyloid peptide. Thus elevating human BACE1 rather than 
P S lMi46v expression, in conjunction with human A P P k m 67o/67in l  in mouse models 
might be expected to accelerate the cognitive impairment known to be associated 
with increased P-amyloid production (263). The spatial learning and memory of two 
double Tg lines of mice, B ACT AS and TASTPM, were examined in the watermaze 
test. The B ACT AS mice were unimpaired in learning and memory or in synaptic 
plasticity in this test. However this sparing of synaptic function in the B ACT AS mice 
was not seen in the TASTPM mice. These mice had impairment in learning and in 
the accurate retention of a learned platform position when compared to wild type. 
The impaired cognition seen in the TASTPM mice was not reflected in the B ACT AS 
mice suggesting that increased mutant PS1 expression rather than increased BACE1 
expression accelerates the decrease in cognitive performance.
Recently Rockenstein et al (341) have demonstrated that high levels of 
BACE1 activity are sufficient to elicit neurodegeneration and neurological decline in 
vivo. The authors present data to show impaired watermaze performance in hBACEl 
Tg, mutant hAPP751 Tg and mutant hAPP751 x hBACEl dTg mouse lines. These
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mice were on a mixed background strain and were tested at 6 months o f age. This 
data is not in agreement with data presented in this thesis on the B ACT AS dTg 
mouse line. Differences in background mouse strains (congenic v hybrid), the levels 
of BACE1 Tg expression (reported to be high in the paper) and promoter used (Thyl 
for both lines in the publication v Cam Kinase II-BACE1 & T hyl-A PPK M 67o/67iN L  in 
this thesis) may account for this discrepancy. The authors do state that they saw 
decreased levels of Api_x and Af3i_42 in the hBACEl/hAPP mice in agreement with 
one publication but in disagreement with several others.
The lack of cognitive impairment seen when human BACE1 expression is 
increased on its own, or in conjunction with human A P P k m 67o/67in l  in the mouse 
models described in this thesis, suggests that BACE1 is less important than PS1 in 
the progress of cognitive decline. Removing endogenous BACE1 led to a sex 
specific impairment in hippocampal and amygdala related memory function. The 
amygdala is involved in emotional memory as well as anxiety, thus the anxious 
phenotype observed when endogenous BACE1 is removed may relate to the 
impaired memory function seen in the fear conditioning test. Clearly BACE1 has 
other functions distinct from its activity as P-secretase. These data demonstrating 
subtly impaired cognitive function in BACE1 KO mice is in agreement with a recent 
publication demonstrating impaired cognition in another line of BACE1 KO mice 
(263). Further work is required to explore the nature of these behavioural phenotypes 
and how they may be reflected in the human population.
Specific anxiety and cognitive related effects have been found with the 
removal of endogenous BACE1. While any therapeutic agent would only reduce 
BACE1 enzyme activity and not remove the protein entirely, the high homology 
between BACE1 and BACE2 may mean that a reduction in BACE2 activity as a 
consequence of BACE1 inhibition must also be considered. To address this issue a 
single line of mice was produced with both BACE1 and BACE2 endogenous gene 
function removed. Additionally while BACE1 has been shown to be P-secretase and 
mice lacking BACE1 are physiologically normal, pharmacological inhibition of 
BACE1 activity alone as a treatment for AD may be ineffective if BACE2 activity 
could substitute for the lack of BACE1. Under these circumstances BACE inhibitors 
would need to inhibit both BACE1 and BACE2.
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The BACE 1/2 double KO mice showed subtle, gender specific differences in 
anxiety and motor activity and co-ordination compared to wild type controls. The 
trend for increased anxiety seen in the male BACE 1/2 double KO mice was similar 
to that seen in male BACE1 KO mice. The additional deletion of the BACE2 gene 
did not appear to increase the anxiety in these mice. Learning in these double KO 
mice was unimpaired however memory of a specific target, namely the platform 
location to which the mice were trained, was poorer in double KO mice compared to 
wild type controls. Interestingly this impairment in memory was not sex specific but 
was present in the same neuronal substrate, the hippocampus, as that found in the 
BACE1 KO mice in the fear conditioning test.
Both male and female BACE 1/2 double KO mice were lighter than respective 
wild type controls. The improved motor co-ordination and decreased home cage 
inactivity shown by female double KO mice when compared to wild type controls 
demonstrate that though they were lighter than controls they had a more robust motor 
function and were more active. A more extensive examination of body fat and 
muscle composition may reveal a fuller explanation of this result. No differences in 
gross pathology were seen. Overall very few differences were seen in the BACE 1/2 
double KO mice compared to controls beyond those observed in BACE1 KO mice.
In keeping with data reported in chapters 2 and 3 of this thesis and with 
previously published work (310), these results might suggest that inhibition o f both 
BACE1 and BACE2 would lead to anxiety related behaviour in treated patients. 
However, one key difference is that here mice have been generated which completely 
lack BACE1 and BACE2 proteins while the administration of a BACE inhibitor as a 
therapeutic would not change protein levels, at least in the short term, only inhibit the 
enzyme activity.
Young BACE1 Tg mice showed an increase in 5-HT turnover. Young 
BACE1 KO mice also exhibited small changes in the serotonergic system, with 
reduced 5-HT levels seen in the hippocampus. There is increasing evidence that a 
combination of disturbances in cholinergic and serotonergic function play a role in 
cognitive impairment in AD, with serotonergic dysfunction potentially responsible 
for a significant portion o f the behavioural aspects o f the disease (323). This detailed 
neurochemical analysis in chapter 5 is in agreement with the anxiety behaviours 
reported in chapter 3. Mice over-expressing BACE1 exhibited an increase in 5-HT 
turnover and were less anxious and more exploratory in their behaviour, consistent
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with the known correlation between anxiety and decreased 5-HT turnover (324). In 
contrast, mice lacking BACE1 displayed an anxious and less exploratory phenotype. 
In addition to the effects of BACE 1 overexpression on the serotonergic system, there 
also appeared to be some changes to the dopaminergic system in these animals. 
Changes in dopaminergic neurotransmitter systems have been observed in a number 
of post-mortem studies of AD brain (322;325). These results extend our current 
knowledge of BACE1 mouse models and reveal an unexpected link between 
BACE1, serotonergic neurotransmission and behaviour.
Male BACE1 Tg mice put on more weight and were heavier than male wild 
type controls having more brown adipose tissue (BAT). The reduced body weight 
and inability to put on weight shown by both male and female BACE1 KO mice was 
reflected in the reduced weight of peri-genital fat (PGF) and trend towards a 
reduction o f BAT in these mice. This correlation between body weight and the 
presence or absence o f the BACE1 gene indicates a role for BACE1 in metabolism. 
The reduction in weight shown by the BACE1 KO mice is accounted for by reduced 
adipose tissue deposition that does not result from increased heat production or 
differences in motor ability. One explanation for the reduced adipose tissue may be a 
reduction in food intake. Appetite is controlled in part by the neuroendocrine system 
of the Hypothalamic Pituitary Axis (HPA) and several potent anorectic agents in this 
system could be altered in BACE1 KO mice. a-Melanocyte Secreting Hormone (a- 
MSH) has been shown to have a role in energy homeostasis and other physiological 
functions and has the same effect as soluble APPa (sAPPa) on melanocytes as a- 
MSH in the periphery. When P-secretase activity is removed in BACE1 KO mice the 
amount o f APP substrate available for a-secretase cleavage is increased. If an 
interaction between sAPPa and a-M SH can be established then the effect of 
removing BACE1 expression on weight may be explained. Another hormone found 
that may explain the phenotype of the BACE1 KO mice is corticotrophin releasing 
hormone (CRH). This hormone acts with argenine vasopressin (AVP) to stimulate 
the release o f adrenocorticotrophic hormone (ACTH) from the pituitary. CRH is 
known to be elevated in corticotrophin releasing hormone binding protein (CRH-BP) 
KO mice and this increase in ‘free’ CRH is the most likely explanation for the 
anorectic and anxiogenic phenotype seen in these mice (342), a phenotype very 
similar to that seen in the BACE1 KO mice.
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Young BACE1 KO mice have elevated circulating HDL Cholesterol and 
Triglyceride levels while young BACE1 Tg mice have depleted circulating 
Triglyceride levels. If lipolysis and lipogenesis do account for these changes then 
insulin metabolism may also be changed in these mice. Interestingly while no direct 
correlation between insulin and BACE1 have been shown, BACE1 is expressed in 
the same cellular type as insulin in the pancreas, the p-cells, though the protein is not 
expressed as an active enzyme. If an interaction between these proteins can be 
identified a potential link between BACE1 expression and weight control, possibly 
via insulin and leptin regulation, may be found. In a recent paper Steen et al (343) 
suggested that the disparate symptoms and cellular pathologies of sporadic AD may 
have a common cause in the reduced glucose utilisation and deficient energy 
metabolism seen in the early phase of the disease. The paper describes extensive 
abnormalities in insulin and insulin-like growth factor signalling mechanisms in the 
brains of AD patients. The authors then goes on to suggest that these findings 
indicate a role for impaired insulin signalling in the pathogenesis of AD and propose 
the term “Type 3 Diabetes” to describe AD. The findings described in this thesis also 
implicate BACE1 in fat metabolism and show that BACE1 KO mice have altered 
cholesterol and triglyceride levels.
The presence o f a copper binding site in the BACE1 protein may indicate a 
role for BACE1 as a mediator of weight via copper binding as rats deprived of 
dietary copper lose weight. In addition other explanations for this decrease in weight 
shown by BACE1 KO mice may be revealed with further studies targeted at dietary 
and metabolic effects of BACE 1 removal.
There are numerous potential reasons to explain the key findings in this thesis 
and I present an hypothesis in an attempt to bring together the various potential 
explanations for these results.
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A BACE-less Hypothesis
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A BACE-less hypothesis must incorporate the removal of BACE1 causing 
increased anxiety and reduced weight in KO mice. Changes in the serotonergic 
system are known to influence anxiety, hence decreased serotonin at the synapse may 
account for the anxiogenic phenotype. While the impaired hippocampal function 
seen in the fear conditioning test by BACE1 KO mice and in the watermaze by the 
BACE 1/2 double KO mice indicates a cognitive role for BACE in the hippocampus 
this may interact with the anxiogenic phenotype of the KO mice as the cognitive 
paradigms where an effect was seen all include an element of stress in the test. An 
explanation of the reduced weight loss does not appear to lie in differences activity 
or thermogenesis, suggesting appetite may play a role. Differences in appetite may 
be linked to non - p-secretase activity of BACE1 either in binding copper, HPA
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activation via CRH or aMSH, or by influencing fat metabolism through leptin or 
insulin regulation.
The data reported in this thesis raises several questions about the role of 
BACE1 in anxiety and fat metabolism. Future experiments to address these questions 
should include:
• Monitor the feeding and defecation of the BACE1 KO mice.
•  Investigate obesity resistance in the mice by altering the diet to increase fat 
intake.
•  Examine the levels of copper, CRH, Leptin, Insulin and associated proteins in 
appropriate target tissues (brain, pancreas and adipose fat).
•  Assess the effect o f BACE1 inhibitors in APP Tg mice on anxiety, fat 
metabolism and cognition.
• Investigate biology of BACE 1 /APP interaction.
This thesis has presented data from studies investigating the effect of altered 
levels of the Beta-site Amyloid Precursor Cleaving Enzyme (BACE), a key protein 
in the development of the p-amyloid lesions found in the brains Alzheimer’s Disease 
patients. Levels of BACE have been changed using genetic manipulation to increase 
or remove the expression of BACE in different mouse models. While inhibition of 
BACE in humans is an attractive target for disease modifying therapy in Alzheimer’s 
Disease, differences in anxiety, cognition and metabolism have been found in 
BACE1 KO mice. Importantly BACE1 inhibition in humans will only seek to reduce 
the level of enzyme activity to mediate P-amyloid production, whereas in BACE1 
KO mice the protein is completely removed. What is clear from the data is the 
identification of a potential novel role for BACE1 in neurotransmission, behaviour 
and fat metabolism. In conclusion, although it is presently unclear how BACE1 over- 
or under-expression results in such changes in neurotransmitter levels and turnover, 
these neurotransmitter systems are affected in the dementia patients and as such point 
to an unexpected and interesting role for BACE1 that warrants further investigation. 
It is hoped that future work will help determine whether these changes are related to 
the activity of BACE1 as an APP processing enzyme or are in fact indicative of a 
currently unknown function for this protein.
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Chapter 7 - Appendices
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7.1 Generating Transgenic and Knockout mice
7.1.1 Expression cassette cloning strategy
The manipulated DNA must have certain elements in order to be expressed 
successfully in the host genome. At the very basic level a transgene requires a gene 
of interest and polyadenylation signal driven by a suitable promoter. In order to 
follow the expression pattern of the transgene at a gross tissue level a reporter gene 
can be included, separated from the transgene by an IRES (Internal Ribosomal Entry 
Sequence Element). This allows two gene products to be produced from one 
promoter thus ensuring that the reporter gene will accurately report where the 
transgene has been expressed (see figure below).
huBACEl Beta-galactosidase __ SY40 pACalmodulin Kinase 2 IRES
Bicistronic mRJN A i i i
Transgenic mice were generated using an over-expression cassette consisting of the 
promoter of the a  subunit of the Ca2+-calmodulin-dependent protein kinase II gene 
(CaMKIIa) driving expression of the human BACE1 cDNA linked to a LacZ 
reporter gene via an IRES element. The CaMKIIa promoter has been shown to drive 
neuronal specific expression of transgenes predominantly in the cortex and 
hippocampus with additional expression in forebrain, amygdala and striatum. The 
gene construct was microinjected into isogenic C57B1/6 single celled mouse oocytes. 
Positive founder mice were identified by PCR using primers specific to the human 
BACE1 cDNA sequence (5' primer: 5'-GGCT ACT ACGT GG AG AT G ACCGT GGG- 
3'; 3’ primer: 5'-CCT GGGT GT AGGGC AC AT AC AC ACCC-3'; thirty cycles of 94°C 
(30s), 65°C (30s), and 72°C (60s) giving a product size of 190 bp) and numbers were 
expanded over two generations to produce experimental animals.
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7.1.2 BACE1 K nockout T argeting  Strategy
When engineering the target gene the most important consideration is 
ensuring the expression of the endogenous gene is completely removed. If even part 
of a gene is transcribed the resulting partial gene product may be translated into a 
functional protein and have unknown effects possible entirely unrelated to its original 
function. In order to avoid this situation the endogenous locus of the gene of interest 
must be genetically engineered to prevent any transcription. This achieved by 
manipulating the endogenous locus as close to the transcription initiation site (ATG) 
as possible. This manipulation should remove at least the first exon of the locus and 
replace it with a reporter gene, LacZ for example. More of the locus can be removed 
so as to ensure no functional gene product is transcribed.
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Structure of a region of the BACE1 genomic locus. A) Only the first two 
exons (red boxes) and intron 1 are shown, the rest of the locus remains intact after 
homologous recombination. The position of the ~300bp Avrll/Xbal and ~400bp 
Nhel/Apal restriction fragment probes used to identify homologous recombination 
events at the 5' and 3' ends respectively are indicated as black boxes. B) Structure of 
the targeting construct. The 5' and 3' arms of homology are ~2kb SfoI/Eco47III and 
~4kb Sacl/Xbal restriction fragments respectively. The Eco47III site is 8bp 
downstream of the BACE1 translation initiation codon. Components of the IRES- 
LacZ cassette and the PGK-Neo selection cassette are indicated. C) Structure of the 
targeted locus. Homologous recombination replaces most of exon 1 and ~lkb of 
intron 1 with the IRES-LacZ cassette and the PGK-Neo selection cassette. 
Restriction sites: R, EcoRV; Sf, Sfol; E, Eco47III; Sa, SacI; X, Xbal.
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Gene targeting was performed in E l4.1 embryonic stem (ES) cells, replacing 
most of the first coding exon of the mouse BACE1 locus with an IRES- LacZ 
expression cassette and a positive selection cassette containing the neomycin 
phosphotransferase gene driven by the PGK promoter. 5' and 3' homology arms 
(~2.0kb SfoI/Eco47III and ~4.0kb Sacl/Xbal restriction fragments respectively), 
were cloned from a 129SVJ genomic BAC library and placed either side of the 
IRES-LacZ expression cassette and positive selection cassette to generate the 
targeting construct. Homologous recombination in neomycin resistant ES cells was 
confirmed by Southern blot of EcoRV digested genomic DNA using a ~300bp 
Avrll/Xbal restriction fragment as 5' external probe (which detects >15kb and lO.Okb 
bands at the wild type and targeted locus respectively). Approximately 1 in 100 
G418 resistant clones had undergone homologous recombination. Homologous 
recombination at the 3' end was confirmed in these ES cell clones by Southern blot 
of EcoRV digested genomic DNA using a ~400bp Nhel/Apal restriction fragment as 
3' external probe (which detects >15kb and 6.5 kb bands at the wild type and targeted 
locus respectively). Three targeted clones were injected into C57B16/J-derived 
blastocysts. Male chimeras were crossed with C57B16/J females to produce N1F0 
offspring, which were subsequently inter-crossed to generate [C57B16/J x 
12901a/Sv] N1F1 generation used in subsequent testing. Genotyping of N1F0 and 
N1F1 offspring was confirmed by the above Southern blot procedures, genotype 
analysis of mice for the generation of the N1F1 study population was performed by 
PCR of tail DNA. Primers were designed to generate PCR products specific to the 
wild-type locus (A-5' primer exon 1 specific: 5'-
CGCTGCACTGGCTCCTGCTATGGG-3’; A-3' primer exon 1 specific: 5'- 
T CT CC AC AT AGT AGCCCT GGCCGG- 3'; thirty cycles of 94°C (30s), 60°C (30s), 
and 72°C (60s) were used giving a product size of 220 bp) or targeted locus (N-5', 
neo gene specific 5' primer: 5'- CCGGCCGCTTGGGTGGAGAGG-3' and N-3', neo 
gene specific 3' primer: 5'-TCGGCAGGAGCAAGGTGAGATGACA-3'; thirty 
cycles of 94°C (30s), 68°C (30s), and 72°C (30s) were used giving a product of 
299bp).
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7.1.3 BACE2 K nockout T argeting  S trategy
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7.1.4 Colony Expansion
7.1.4.1 Initial Breeding Strategy for Transgenic Mice.
After identification of the desired mouse line from screening the first, 
founder, generation of mice screening the colony will need to be expanded in order 
to generate animals for further characterisation and breeding. Initial breeding regimes 
will be determined by the properties of the gene of interest, for example sex 
specificity or copy number (in the case of Tg animals). The rapid expansion of the 
colony is best achieved by breeding founder male mice to two wild type females. 
This 'trio' of mice is left in the cage to produce litter after litter until enough FI 
generation mice are produced. Gestation in mice is approximately 19-21 days and, 
when left in the same cage as the male, the female will mate within 12-24 hours of 
parturition (a post-partum mating) and give birth in another 19-21 days later. This 
cycle can be repeated successfully up to 6 times before breeding performance is 
affected.
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7.1.4.2 Independently Segregating Transgenes
When a transgene is directed injected into an embryo multiple copies of the 
transgene can randomly integrate into the host genome in a concatenation at one 
integration site or at multiple integration sites. When the mice breed homologous 
recombination may separate the transgenes at multiple integration sites leading to 
segregation of the transgene. This can results in FI offspring having different copies 
of the transgene and hence different protein expression levels. A Southern blot 
analysis is required to assess the transgene copy number of different FI litters and 
check for this segregation event. After the FI generation transgene segregation, while 
not impossible, is far less likely.
7.1.4.3 Initial Breeding Strategy for Knockout Mice
After founder identification from the percentage coat colour contribution to 
the Founder KO mouse are selected on the basis of the percent contribution of the 
injected ES cell to the coat colour. If the host strain of mouse used is C57B1/6 then 
the coat colour of the host will be black. If 129 ES Cells are used then the donor coat 
colour is a light brown. Thus one can assess the percent contribution of the donor ES 
Cells, and hence the proportion carrying the targeted locus, by looking at coat colour. 
100% black mouse will not have incorporated many ES Cells but will breed 
vigorously whereas a 100% light brown mouse will have incorporated many ES 
Cells but will not breed well. Five founder mice with more than 50% of their coat 
colour as light brown should be chosen for breeding onto the FI generation. The 
resulting FI generation mice need to be genotyped to assess whether the targeted 
locus has transmitted through the germ line successfully. FI mice carrying the 
targeted mutation can be interbred at this point to generate mice homozygous for the 
targeted locus. Assuming they are viable, these mice can be analysed to discover if 
the locus has been targeted correctly and the protein is indeed knocked out.
7.1.4.4 Background Strain.
The background strain can have an enormous influence on the phenotype of 
Tg and KO mice. If isogenic donor single celled embryos are used then over­
expression Tg mouse lines will be isogenic from birth. However KO mouse lines will
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usually be a mix of C57B1/6 and 129 strains. In cases where the FI generation mice 
is a hybrid mix of strains then more reliable phenotypic data will be obtained from 
the mouse line being back-crossed to produce an isogenic background. This decision 
to backcross is made by considering the reasons for making the mouse line. If just 
one protein is to be investigated in the mouse line then other proteins from the 
different strains are less likely to have an impact on the data. However if many 
interacting proteins are to be investigated or behavioural observations made then an 
isogenic background will produce more reproducible data.
7.2 Materials and Methods -  SHIRPA test
7.2.1 Primary SHIRPA test
Initially the weight of the animals is recorded. Subsequently a number of 
measures are recorded for each animal when it is placed in a viewing jar, then when 
it is placed in, on or above an arena and finally during supine restraint.
7.2.1.1 Behaviour Recorded in the Viewing Jar.
• The animal is placed in the viewing jar for 5 min. This is located on top o f a 
grid which is suspended above a piece of white paper. The behaviours listed 
in Table 2.1 are recorded without disturbing the animal and the amount of 
urination or defaecation is monitored at the end of the observation period. 
Incidents of bizarre or stereotyped behaviour and convulsions are recorded 
separately.
7.2.1.2 Behaviour Recorded in the Arena.
• A metal plate is inserted under the viewing jar and the animal transferred and 
briskly dropped onto the centre of the floor of the arena without being 
handled. The stop watch is started and the immediate reaction to the new 
environment is recorded along with the measures detailed in Table 2.2.
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7.2.1.3 Behaviour Recorded on or Above the Arena.
• After removing the animal from the arena, grip the tail between thumb and 
forefinger and record the observations listed in Table 2.3.
7.2.1.4 Behaviour Recorded During Supine Restraint
• Firmly scruff the animal and record the measures listed in Table 2.4. Record 
the final behaviours as absent, 0 or present, 1 throughout the procedure.
7.3 Materials and Methods -  Neurochemical Analysis
7.3.1 BACE1 KO and Tg mice
Upon completion of behavioural testing, brains from BACE1 mice were 
harvested and the following regions were dissected and snap frozen and stored at - 
80°C until assay: dorsal striatum, nucleus accumbens, hippocampus, hypothalamus, 
cerebellum and frontal cortex (left and right hemispheres pooled). All reagents used 
were analytical grade and were purchased from Sigma Chemicals (Poole, UK). All 
solvents were HPLC grade and were purchased from Fisher Scientific 
(Loughborough, UK). Samples were probe sonicated in 0.1% w/v Na2S205, 0.01% - 
w/v EDTA, 0.1% w/v L-cysteine, 0.4M perchloric acid (10 pl/mg tissue) and 
centrifuged at 10,000 rpm, 4°C for 10 minutes. Supernatant fractions were analysed 
using HPLC with electrochemical detection. The mobile phase consisted of 0.07M 
KH2P04, ImM octane sulphonic acid and O.lmM Na2EDTA made up in 10% 
methanol, 0.5% propan-2-ol. Analytes were separated using 2 x 100 x 4.6mm i.d. 
C18 Speed Rod columns connected in series. Calibration curves were generated for 
3,4-dihydroxyphenylacetic acid (DOPAC), dopamine (DA), 5-hydroxyindole-3- 
acetic acid (5-HIAA), homo vanillic acid (HVA), 5-hydroxy tryptophan (5-HTP) and 
5-hydroxytryptamine (5-HT). Turnover rates were assessed by calculating the 
following ratios: DOPAC/DA, HVA/DA, DOPAC/HVA and 5-HIAA/5-HT.
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7.3.2 BACE 1/2 double KO mice
Brain regions were dissected from: 2 male and 2 female BACE 1/2 KO and 
wild type mice, snap frozen on dry ice and stored at -80°C. Brain samples were 
weighed and homogenised in homogenising buffer (Perchloric acid, Na 
metabisulphate, EDTA. Na2, cysteine, deionised water) in the ratio of lOOul 
homogenising buffer per mg of tissue. This resulted in a tissue concentration of 
O.Olg/ml. The samples were then centrifuged at 10000 x g at 4°C for 10 minutes. The 
supernatant was removed and stored at -80°C. 20pl of the resulting supernatant was 
transferred into a micro volume glass vial for HPLC-ECD (Electrochemical 
Detection) analysis. HPLC Mobile Phase: 0.07M KH2P 0 4, 1.5mM OSA.Na, O.lmM
EDTA.Na2, 12% MeOH, 88% H20 , 0.5% THF. lOul of each sample was injected at
a flow rate o f 2.5ml/min onto the columns (Chromolith Speedrod 50 x 4.6mm & 2 x 
100 x 4.6mm) and compared with a previously run calibration to identify and 
quantify components (DOPA, DOPAC, Dopamine, 5-HIAA, 5HTP, HVA, 3-MT, 5- 
HT). This is measured using a Decade electochemical detector, voltage set at +0.65 
with reference.
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7.4 BACE1 KO SHIRPA Results
Wild type (+/+) Knockout (KO/KO)
Stats
test
P-
Values
Median
(Interquartile range)
Median
(Interquartile range)
Body Position NV - 3 (3-3) 3(3-3)
Spontaneous Activity U 0.79 1(1-1) 1(1-1)
Respiration NV - 2 (2-2) 2 (2-2)
Tremor NV - 0 (0-0) 0 (0-0)
Transfer Arousal U 0.48 3 (3-4) 4(3-4)
Arena Activity AN 0.56 14.35 ± 1.84 16.05 ±2 .16
Palprebral Closure NV - 0 (0-0) 0 (0-0)
Piloerection NV - 0 (0-0) 0 (0-0)
Startle Response U 0.42 1.5 (1-2) 2(1-2)
Gait NV - 0 (0-0) 0 (0-0)
Pelvic Elevation U 1.00 2 (2-2) 2 (2-2)
Tail Elevation NV - 1(1-1) 1(1-1)
Touch Escape U 0.99 2(1-2) 2(1-2)
Positional Passivity NV - 1(1-1) 1(1-1)
Abnormal Behaviour F 0.50 0 (0-0) 0 (0-0)
Visual Placing U 0.79 3 (3-3) 3 (2.5-3)
Grip Strength U 0.73 2 (2-2) 2 (2-3)
Body Tone NV - 1(1-1) 1(1-1)
Toe Pinch U 0.27 3 (2-3) 3 (2.5-3)
Wire Manoeuvre u 0.007 2 (1-2) 0.5 (0-1)
Pinna NV - 1(1-1) 1(1-1)
Cornea NV - 1(1-1) 1(1-1)
Heart Rate NV - 1(1-1) 1(1-1)
Limb Tone U 0.05 2 (2-2) 2 (1-2)
Abdominal Tone NV - 1(1-1) 1 (1-1)
Lacrimation NV - 0 (0-0) 0 (0-0)
Salivation F 0.50 1(1-1) 1(1-1)
Provoked Biting U 1.00 0 (0-0) 0 (0-0)
Right Reflex NV - 0 (0-0) 0 (0-0)
Contact Righting NV - 1(1-1) 1(1-1)
Negative Geotaxis U 0.63 0 (0-0) 0 (0-0.5)
Fear NV - 0 (0-0) 0 (0-0)
Irritability U 0.42 0(0-1) 0 (0-0)
Aggression F 0.50 0 (0-0) 0 (0-0)
Vocalisation U 0.28 1 (0-1) 0(0-1)
Faeces AN 0.02 3.95 ± 0.51 5.90 ± 0.63
Urination AN 0.33 0.55 ±0 .15 0.75 ±0 .16
Body Weight AN 0.45 28.25 ± 0.93 27.42 ±  1.27
Body Length AN 0.31 96.65 ± 1.19 95.20± 1.45
Summary of Primary Screening Results Grouped by genotype. Data are shown as 
median with quartile range in parentheses except where data are expressed as mean ± 
SEM. Significant measures are in bold type. AN = ANOVA, U = Mann Whitney U 
test, F = Fishers Exact Test, NV = No Variability.
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7.5 BACE1 Line 17SHIRPA Results
Wild type (+/+) Transgenic (Tg/±)
Stats
test
P-
Values
Median
(Interquartile range)
Median
(Interquartile range)
Body Position NV - 3 (3-3) 3 (3-3)
Spontaneous Activity U 0.79 1(1-1) 1(1-1)
Respiration NV - 2  ( 2 -2 ) 2  ( 2 -2 )
Tremor NV - 0 (0-0) 0 (0-0)
Transfer Arousal U 0.68 3 (3-4) 3(3-4)
Arena Activity AN 0.95 24.4 ± 1.13 24.5 ± 0.99
Palprebral Closure NV - 0 (0-0) 0 (0-0)
Piloerection NV - 0 (0-0) 0 (0-0)
Startle Response U 0.59 2  (2 -2 ) 2  ( 2 -2 )
Gait NV - 0 (0-0) 0 (0-0)
Pelvic Elevation NV - 2  (2 -2 ) 2  (2 -2 )
Tail Elevation U 1.00 1(1-1) 1(1-1)
Touch Escape u 0.62 2  (2 -2 ) 2  (2 -2 )
Positional Passivity NV - 1(1-1) 1(1-1)
Abnormal Behaviour NV - 0 (0-0) 0 (0-0)
Visual Placing F 0.24 3 (3-3) 3 (3-3)
Grip Strength U 0.84 2 (2-3) 2 (2-2.5)
Body Tone NV - 1(1-1) K l - l )
Toe Pinch U 0.79 3 (3-3) 3 (3-3)
Wire Manoeuvre u 0.30 0(0-1) 0 (0-0.5)
Pinna NV - 1(1-1) 1(1-1)
Cornea NV - 1(1-1) K l - l )
Heart Rate NV - 1(1-1) 1(1-1)
Limb Tone U 0.82 2 ( 2 -2 ) 2  (2 -2 )
Abdominal Tone NV - 1(1-1) 1(1-1)
Lacrimation NV - 0 (0-0) 0 (0-0)
Salivation NV - 1(1-1) 1(1-1)
Provoked Biting U 0.28 0 (0-0.5) 0(0-1)
Right Reflex NV - 0 (0-0) 0 (0-0)
Contact Righting NV - 1(1-1) 1(1-1)
Negative Geotaxis F 0.50 0 (0-0) 0 (0-0)
Fear NV - 0 (0-0) 0 (0-0)
Irritability U 0.42 0(0-1) 0(0-1)
Aggression NV - 0 (0-0) 0 (0-0)
Vocalisation U 1.00 1 (0-1) 1 (0-1)
Faeces AN 0.42 3.05 ± 0.41 3.45 ±0 .27
Urination AN 0.55 0.25 ±0 .10 0.35 ± 0.27
Body Weight AN 0.46 22.46 ± 0.55 22.13 ±0 .54
Body Length AN 0.22 84.60 ± 0.94 83.25 ± 0.97
Summary of Primary Screening Results Grouped by genotype. Data are shown as 
median with quartile range in parentheses except where data are expressed as mean ± 
SEM. Significant measures are in bold type. AN = ANOVA, U = Mann Whitney U 
test, F = Fishers Exact Test, NV = No Variability.
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7.6 BACE1 Line 4 Tg SHIRPA Results
Wild type (+/+) Transgenic (Tg/±)
Stats
test
P-
Values
Median
(Interquartile range)
Median
(Interquartile range)
Body Position NV - 3 (3-3) 3 (3-3)
Spontaneous Activity U 0.79 1(1-1) 1(1-1)
Respiration NV - 2  ( 2 -2 ) 2  ( 2 -2 )
Tremor NV - 0 (0-0) 0 (0-0)
Transfer Arousal U 0.13 4(3-4) 3 (3-4)
Arena Activity AN 0.002 22.95 ± 0.96 17.90 ± 1.15
Palprebral Closure NV - 0 (0-0) 0 (0-0)
Piloerection NV - 0 (0-0) 0 (0-0)
Startle Response U 0.70 2  (2 -2 ) 2 (1.5-2)
Gait F 0.50 0 (0-0) 0 (0-0)
Pelvic Elevation U 0.79 2  ( 2 -2 ) 2  (2 -2 )
Tail Elevation F 0.24 1(1-1) 1(1-1)
Touch Escape U 0.42 2 (2-3) 2 (2-2.5)
Positional Passivity NV - 1(1-1) 1 (1-1)
Abnormal Behaviour NV - 0 (0-0) 0 (0-0)
Visual Placing U 0.42 3 (2.5-3) 3 (3-3)
Grip Strength u 0.31 2 (2-3) 2  (2 -2 )
Body Tone NV - 1(1-1) 1(1-1)
Toe Pinch u 0.87 3 (2-3) 3 (2-3)
Wire Manoeuvre u 0.29 0 (0-0) 0(0-1)
Pinna NV - 1(1-1) 1(1-1)
Cornea NV - 1(1-1) K l - l )
Heart Rate F 0.50 1(1-1) 1(1-1)
Limb Tone U 1.00 2 ( 2 -2 ) 2  (2 -2 )
Abdominal Tone F 0.50 1(1-1) 1(1-1)
Lacrimation NV - 0 (0-0) 0 (0-0)
Salivation NV - 1(1-1) 1(1-1)
Provoked Biting U 0.06 0 (0-0.5) 1 (0-1)
Right Reflex NV - 0 (0-0) 0 (0-0)
Contact Righting NV - 1(1-1) 1(1-1)
Negative Geotaxis F 0.50 0 (0-0) 0 (0-0)
Fear NV - 0 (0-0) 0 (0-0)
Irritability U 0.59 0 (0-1) 0(0-1)
Aggression u 1.00 0 (0-0) 0 (0-0)
Vocalisation u 0.42 1 (0-1) 1 (0.5-1)
Faeces AN 0.42 3.65 ±0.32 3.20 ± 0.44
Urination AN 0.18 0.10 ±0.07 0.30 ±0.13
Body Weight AN 0.02 22.17 ±0.58 21.15 ±0.63
Body Length AN 0.11 85.75 ±0.92 84.15 ±0.82
Summary of Primary Screening Results Grouped by genotype. Data are shown as 
median with quartile range in parentheses except where data are expressed as mean ± 
SEM. Significant measures are in bold type. AN = ANOVA, U = Mann Whitney U 
test, F = Fishers Exact Test, NV = No Variability.
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7.7 BACTAS dTg SHIRPA Results
Wild type (+/+) Transgenic (dTg/-)
Stats
test
P-
Values
Median
(Interquartile range)
Median
(Interquartile range)
Body Position U 0.86 3 (3-3) 3 (3-3)
Spontaneous Activity U 1.00 1(1-1) 1(1-1)
Respiration NV - 2 (2-2) 2 (2-2)
Tremor U 0.001 0 (0-0.5) 1 (1-1)
Transfer Arousal u 0.34 3 (2-3) 3 (2-3)
Arena Activity AN 0.036 5.1 ± 0.8 8.3 ± 1.4
Palprebral Closure NV - 0 (0-0) 0 (0-0)
Piloerection U 0.17 0(0-1) 1 (0-1)
Gait u 0.65 0 (0-0) 0(0-1)
Pelvic Elevation u 0.76 2 (2-2) 2 (2-2)
Tail Elevation u 1.00 1(1-1) 1(1-1)
Touch Escape u 0.40 2 (2-2) 2(1-2)
Positional Passivity F 0.17 1(1-1) 1(1-1)
Abnormal Behaviour NV - 0 (0-0) 0 (0-0)
Visual Placing NV - 3 (3-3) 3(3-3)
Grip Strength U 0.76 2 (2-2) 2 (2-2)
Body Tone u 0.83 1 (0-1) 1 (0-1)
Wire Manoeuvre u 0.15 3 (3-3.5) 3 (2-3)
Heart Rate NV - 1(1-1) 1(1-1)
Limb Tone u 0.09 1(1-1) 1(1-1)
Abdominal Tone F 0.07 1(1-1) 1(1-1)
Lacrimation NV - 0 (0-0) 0 (0-0)
Salivation NV - 0 (0-0) 0 (0-0)
Provoked Biting F <0.001 1 (1-1) 0 (0-1)
Right Reflex NV - 0 (0-0) 0 (0-0)
Contact Righting NV - 1(1-1) 1(1-1)
Negative Geotaxis U 1.00 1 (0-2.5) 4 (0-4)
Fear u 0.83 0 (0-0) 0 (0-0)
Irritability NV - 0 (0-0) 0 (0-0)
Aggression AN 0.002 0 (0-0) 0(0-1)
Vocalisation NV - 0 (0-0) 0 (0-0)
Faeces AN 0.21 1.7 ±0.4 2.6 ±0.5
Urination AN 0.41 0.1 ±0.1 0.0 ± 0 .0
Body Weight (g) AN 0.001 40.6 ±1.3 34.3 ± 1.6
Body Length (mm) AN 0.001 97.0 ±- 0.9 93.7 ± 1.0
Summary of Primary Screening Results Grouped by genotype. Data are shown as 
median with quartile range in parentheses except where data are expressed as mean ± 
SEM. Significant measures are in bold type. AN = ANOVA, U = Mann Whitney U 
test, F = Fishers Exact Test, NV = No Variability.
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7.10 BACE1 Tg Line 4 mice Rotarod Results
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7.14 BACE1 KO mice Hotplate Results
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7.17 On line data sources
OMIM web sites:
Alzheimer’s Disease: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= 104300
BACE1: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=604252
BACE2: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=605668
PS1: http://www.ncbi.nhn.nih.gov/entrez/dispomim.cgi7icN104311
PS2: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600759
APP: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id= 104760
ADAM 17 (TACE): http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=603639
ADAM 10: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602192
CDR Assessment: http://www.adrc.wustl.edU/cdrScale.html#scale 
MMSE: http://www.minimental.com/
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